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ABSTRACT 
 
SYNTHESIS OF NOVEL 6-SUBSTITUTED AND 5-SUBSTITUTED PYRROLO[2,3-d] 
PYRIMIDINE ANTIFOLATES AS TARGETED ANTICANCER THERAPIES 
 
 
 
By 
Xinxin Li 
December 2018 
 
Dissertation supervised by Professor Aleem Gangjee, Ph. D.  
 The dissertation will give an introduction, background and current research progress in the 
areas of antifolates and chemotherapy of anticancer. The design and synthesis of classical 6- 
substituted pyrrolo[2,3-d]pyrimidines and 5-substituted pyrrolo[2,3-d]pyrimidines as potential 
antifolates have been described. The design variations include: methylated thiophene regioisomers, 
fluorinated phenyl regioisomers, thionyl regioisomers on the side chain of pyrrolo[2,3-
d]pyrimidines. As a part of this study, a series of new compounds have been synthesized and 
characterized. Of these, ten final compounds were submitted for biological evaluation. 
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BIOCHEMICAL REVIEW 
 
 
Figure 1 Structure of folic acid illustrating the three principle moieties of the molecule. 
Folic acid (FA) (Figure 1), a water-soluble vitamin of the B-complex group, was first 
isolated by Mitchell and coworkers1 from spinach leaves in 1941. The structure of FA consists of 
three principle moieties: a hetero-bicyclic pteridine (scaffold), a p-aminobenzoic acid (PABA) and 
a glutamic acid (Figure 1). The FA structure probably does not occur in nature as such, but it can 
be considered as the parent compound of a group of naturally occurring folates, which belong to 
the B9 family. Folate refers to the various reduced derivatives of folic acid which is naturally found 
in food. There are several differences between FA and folates: 1) The reduction states of the 
pteridine ring (oxidized, 7,8-H2, and 5,6,7,8-H4) could occur in folates. 2) In folate, one carbon 
unite can be attached to N5 or N10 or both. 3) Glutamate residues (poly-γ-glutamates) of folates may 
be attached to the glutamate moiety by γ-peptide bonds to give folate polyglutamates.  
Folates are anionic hydrophilic molecules at physiologic pH and because of that they can 
not cross biological membranes by diffusion.2 As a result, mammalian cells have evolved several 
sophisticated membrane transport systems for facilitating cellular uptake of folate cofactors.  There 
are three major uptake systems for the membrane transport of folates and antifolates across 
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biological membranes.These include the reduced folate carrier (RFC),2 the folate receptors (FRs) 
α and β,3and the proton-coupled folate transporter (PCFT).2-4 RFC is expressed ubiquitously and 
is recognized to be the major transport system for folates in mammalian cells and tissues at 
physiologic pH.2-4 FRs α and β are glycosylphosphatidylinositol-anchored proteins that transport 
folates by receptor-mediated endocytosis.5-6 Finally, PCFT is a proton-folate symporter that 
functions optimally at acidic pH by coupling the flow of protons down an electrochemical 
concentration gradient to the uptake of folates into cells.7-9 The reduced form of folic acid including 
5-methyltetrahydrofolate (N5-CH3-FH4) and10-formyl tetrahydrofolate (N10-CHO-FH4) are 
actively taken up into the cell via the RFC system. However, folic acid has a higher affinity for 
FRs, which has a higher affinity for the oxidized form of the folate cofactor than the reduced form.    
Folic acid plays an important role in one-carbon transfers system, so it is essential for 
deoxyribonucleic acid (DNA) synthesis, repair and cell replication.2,3,10 Folate antagonist or 
antifolates with structures similar to folic acid are considered cytotoxic drugs. These drugs inhibit 
one or more biosynthetic steps that required folate coenzymes. Antifolates represent an important 
class of antimetabolites and are used as chemotherapeutic agents for cancer.11-15  
1. FOLATE METABOLISM  
The mammalian folic acid cycle is a highly complex and crucial process for transferring 
one-carbon unite to amino acids, nucleotides and other biomolecules. In mammals, folic acid 
cannot be synthesized and must be obtained through the diet, primarily fruits and vegetables.1 Folic 
acid is the starting material for tetrahydrofolic acid (tetrahydrofolate, THF), which is the 
fundamental molecule in folic acid cycle. Folic acid exists in several oxidative states, each of them 
is critical for the entire biosynthesis of nucleic acid precursors and amino acids. Intracellular 
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reduction of the pteridine ring in folic acid is enzymatically reduced by nicotinamide adenine 
dinucleotide phosphate (NADPH) - specific dihydrofolate reductase (DHFR) and leads to the 
formation of 7,8-dihydrofolate (FH2) followed by 5,6,7,8-tetrahydrofolate (FH4) (Figure 2).7 FH4 
functions as the coenzyme in the utilization of single-carbon units and is the central component of 
folate metabolism. Tetrahydrofolate is subsequently processed through a variety of oxidative 
enzymatic modifications that function as one-carbon donors. It is one of the critical components 
in the synthesis of amino acids (glycine, serine, methionine, and histidine), nucleic acid (purine 
nucleotide and the 5-methyl group of thymine) and the formation of formylmethionyl-tRNA. 
(Figure 2). FH4 can carry various single carbon units, including methyl, methylene, and formyl 
groups. These single carbon units can be oxidized to methanol, formaldehyde, and formic acid, 
respectively. Subsequently these one-carbon units can be attached to the N5- and/or N10- positions 
of FH4 to form 5-methyltetrahydrofolate (N5-CH3-FH4), 5,10-methylenetetrahydrofolate (N5,N10-
CH2-FH4), 5-formyltetrahydro-folate (N5-CHO-FH4),10-formyltetrahydrofolate (N10-CHO-FH4), 
and 5-formiminotetra-hydrofolate (N5-CH=NH-FH4) respectively (Figure 2).  
There are numbers of enzymes involve in folate-dependent reactions, using different 
derivatives of FH4 in one-carbon transfer reactions. Such as: (i) 5,10-methylene tetrahydrofolate 
(N5,N10-CH2-FH4) provides a carbon for the synthesis of thymidylate from deoxyuridylate 
mediated by thymidylate synthase (TS), an initial step in the synthesis of precursors for DNA. (ii) 
N10-CHO-FH4 could provide two carbons for the synthesis of the purine ring in reactions mediated 
by glycinamideribonucleotide formyl transferase (GARFTase) and amino-imidazole-
carboxamideribonuleotide formyl transferase (AICARFTase). (iii) N5-CH3-FH4 provides the 
methyl group for the vitamin B12 dependent synthesis of methionine from homocysteine mediated 
by methionine synthetase, which is followed by the synthesis of S-adenosylmethionine (Figure 2). 
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Figure 2 Folates and their roles in the biosynthesis of nucleic acid precursors and amino acids. 
Note: TS: Thymidylate Synthase; DHFR: Dihydrofolate Reductase; SHMT: Serine 
Hydroxymethyltransferase; MTHFD: Methylenetetrahydrofolate Dehydrogenase; MTHFR: 
Methylenetetrahydrofolate Reductase; GARFTase: Glycinamide-ribonucleotide Formyl 
Transferase; AICARFTase: Amino-imidazole-carboxamide-ribonuleotide Formyl Transferase; 
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AICAR: Aminoimidazole-4-carboxamide ribosyl-5-phosphate; dTMP: 2’-Deoxythymidylate 5’-
monophosphate; dUMP: 2’-Deoxyuridylate-5’-monophosphate; dTMP: 2’-Deoxythymidylate 5’-
triphosphate; GAR: Glycinamide Ribosyl-5-phosphate; DNA: Deoxyribonucleotide; IMP: Inositol 
monophosphate.
 
TS can utilize the FH4 cofactor N5, N10-CH2- FH4, that acts as the source of the methyl group 
as well as the reductant by concerted transfer of its methylene moiety and the 6-hydrogen atom in 
the form of hydride to form the 5-methyl group of dTMP (Figure 3). This transformation represents 
 
Figure 3 TS catalyzed biosynthesis of dTMP from dUMP. 
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the only de novo source of dTMP in dividing cells; hence, inhibition of TS, in the absence of 
salvage, could lead to “thymineless death”.16 
“Thymineless death” is observed in mammalian cells when severe deoxythymidine-
triphosphate (dTTP) depletion takes place due to methotrexate (MTX) or 5-fluorouracil (5-FU) 
treatment.17 The dTTP depleted mammalian cells irreversible lose colony forming ability and 
undergo cell death.16 The phenomenon of thymineless death is underlied in the mechanism of 
several antibacterial, antimalarial and anticancer agents, such as sulfamethoxazole, trimethoprim, 
methotrexate and fluorouracil16, 18-20. In 1954, Barner and Cohen21,22 discovered this phenomenon 
that thymine requiring mutants of the E. coli bacterium lost viability when grown in a medium 
lacking thymine but containing other essential nutrients. Subsequently, this discovery led to the 
development of theories to explain the mechanism of action of several pyrimidine analogs that 
targeted thymine metabolism in bacteria and tumor cells.23 The phenomenon was commonly 
attributed to "unbalanced growth" wherein cells continued fundamental processes of RNA 
transcription, protein synthesis and metabolism in the absence of DNA replication.22 This effect is 
unusual in that the deprivation of many other nutritional requirements such as amino acids or 
vitamins has a biostatic, but not lethal effect.24-25 Studies on numerous tumor cells have indicated 
that thymine starvation has both direct and indirect effects. The direct effects involve both single- 
and double-strand DNA breaks.17 Single-stand DNA breaks may be repaired effectively, but 
double-strand DNA break will lead to cell death.  Depletion of dTTP in mammalian cells induces 
apoptosis, although the mechanism underlying this process remains to be elucidated.26-28 
Methotrexate and 5-FU cause a decrease in dTTP levels and a concomitant increase in dUTP, 
which is incorporated into DNA. This leads to extensive DNA damage as a result of the active 
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process of excision repair at the many uracil-containing sites in DNA, and thus triggers a DNA-
damage-induced apoptosis.17  
During the TS catalyzed reaction, N5,N10-CH2-FH4 is oxidized to FH2 and converted back 
to FH4 by dihydrofolate reductase (DHFR) which maintains the intracellular reduced folate pool. 
Thus, inhibition of DHFR leads to a partial depletion of the intracellular reduced folate pool which 
consequently limits cell growth.29 Both human TS and human DHFR are essential enzymes for 
cell growth and hence both continue to represent attractive targets for chemotherapeutic agents.30,31  
β-Glycinamide-ribonucleotide transformylase(GARFTase) and aminoimidazole-
carboxamide ribosyl-5-phosphate formyl transferase (AICARFTase) are the other two enssential 
folate related enzymes in the de novo biosynthesis of purine nucleotides (Figure 4). These two 
enzymes utilize the cofactor, N10-CHO-FH4 to transfer one carbon units.32 The C-8 carbon and C-
2 carbon of purine nucleotides are comprised of these “one carbon units”.  GARFTase catalyzes 
the third in the series of ten reactions required for purine synthesis (Figure 4), the conversion of 
glycinamide ribosyl-5-phosphate (GAR) to formyl-glycinamide ribosyl-5-phosphate (fGAR), 
utilizing N10-formyl-FH4. In mammals, GARFTase occurs as one enzyme in a trifunctional protein, 
which catalyzes the second and the fifth steps of this pathway in addition to the third step. Or 
fGAR formed is converted further to aminoimidazolecarboxamide ribosyl-5-phosphate (AICAR). 
AICARFTase is responsible for the catalysis of the last two steps in de novo biosynthesis of purine. 
AICARFTase utilizes N10-CHO-FH4 and converts AICAR to formyl-aminoimidazolecarboxamide 
ribosyl-5-phosphate (fAICAR). The fAICAR continues along the purine biosynthetic pathway and 
leads to the formation of inosine-5’-monophosphate (IMP), the precursor of adenosine-5’-
triphosphate (ATP) and guanosine-5’-triphosphate (GTP) necessary for ribonucleic acid (RNA) 
synthesis and of 2’-deoxyadenosine-5’-triphosphate (dATP) and 2’-deoxyguanosine-5’-
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triphosphate (dGTP) necessary for DNA synthesis and 2’-deoxyguanosine-5’-triphosphate (dGTP) 
necessary for DNA synthesis.30 
 
Figure 4 De novo synthesis of Purines. 
As mentioned above, mammalian cells have three main folate transport system. Once 
transported inside the cell, the cofactors are converted to the poly-γ-glutamyl species by the 
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enzyme folylpoly-γ-glutamate synthetase (FPGS), which adds glutamic acid residues to the 
gamma carboxylic acid via amide bonds. Usually 4-8 glutamate residues are added to the γ-
carboxylic acid group of the cofactor or reduced folate. The polyglutamylated folates usually have 
higher binding affinity to some folate dependent enzymes (e.g. TS) and have increased intracellular 
retention time, because of their polyanionic nature.33,34 
Due to the crucial role in the biosynthesis of nucleic acid precursors, folates and their 
metabolism have been recognized as attractive targets for cancer chemotherapy.35-41 Based on the 
transport mechanism and the ability to undergo polyglutamylation, antifolates are classified into 
two types: classical antifolates and nonclassical antifolate.42 Classical antifolates contain an intact 
L-glutamate side chain, while nonclassical antifolates contain a lipophilic side chain.43,44As shown 
in Figure 5, representatives of classical antifolates include methotrexate (MTX), aminopterin, 
edatrexate, PDDF (N10-propargyl-5,8-dideazafolate), raltitrexed (RTX, ZD1694, Tomudex), 
pemetrexed (PMX, LY231514, Alimta), GW1843U89 and plevitrexed (ZD9331). These analogs 
closely resemble the structure of endogenous folates and its metabolites. They are actively taken 
up into cells by RFC, FR and/or PCFT systems present on the cell surface.33,38 The nonclassical 
antifolates are represented by structures shown in Figure 6:  
nolatrexed, (thymitaq),  pyrimethamine, trimethoprim (TMP), piritrexim (PTX) and trimetrexate 
(TMQ). Nonclassical antifolates are not taken up by the folate active transport systems (RFC, FR 
and PCFT) and are presumably taken up by passive and/or facilitated diffusion.33,38 
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Figure 5 Representative examples of classical antifolates and their principal target enzyme. 
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Figure 6 Representative examples of nonclassical antifolates and their principal target. 
2. MEMBRANE TRANSPORT OF FOLATES 
As mentioned above, due to the lack of de novo biosynthetic enzymes in mammals for 
folates, folate cofactors must be obtained from dietary resources. Because folates are hydrophilic 
anionic molecules and cannot passive diffuse across biological membranes, several sophisticated 
membrane transport systems have evolved to facilitate membrane translocation of these essential 
cofactors. The three main transport systems include RFC, FR, and PCFT. Each of these plays a 
unique role in mediating folate transport across epithelia and into tissues.’ 
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2.1. The Reduced Folate Carrier (RFC) 
RFC is the major transport system of folates in mammalian cells. It is ubiquitously 
expressed in mammalian cells and tissues. In addition, RFC is the major transporter of antifolate 
drugs used for cancer chemotherapy such as MTX, PMX, and RTX (Figure 5), and that the 
effectiveness of these agents is closely linked to levels and activity of this transport system in both 
tumors and normal tissues.45-47 
2.1.1. Structure of RFC 
In 1968, the functional properties of RFC were first report in murine leukemia cells by 
Goldman and coworkers48. RFC (SLC19A1) belongs to the major facilitator superfamily (MFS) 
of transporters. It is characterized by its anion exchange property. Human RFC (hRFC) is 
comprised of 591 amino acids and is 64-66% conserved with rodent RFCs. RFC is an integral 
membrane protein characterized by 12 transmembrane domains (TMDs) and cytoplasmic-oriented 
N- and C-termini.49-52 hRFC is N-glycosylated at an N-glycosylation consensus site (Asn58) in the 
first extracellular loop (EL) connecting TMD1 and TMD2.53A large loop domain that connects 
TMD6 and TMD7 is poorly conserved between species and can be replaced altogether by a 
nonhomologous segment from the SLC19A2 carrier.54 When separate TMD1-TMD6 and TMD7-
TMD12 RFC half-molecules are co-expressed in human RFC-null cells, they are targeted to the 
cell plasma membrane surface and restore RFC transport activity.  
2.1.2. RFC distribution 
RFC is the primary transport system for folates cofactors in mammalian cells and tissues. 
It can transport folates into cells of peripheral tissues from blood.55 In human tissues, the highest 
level of hRFC transcript were detected in liver and placenta.56 The appreciable levels of hRFC 
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were recorded in kidney, leukocytes, lung, bone marrow, intestine, and portions of the central 
nervous system (CNS) and brain.56 In other tissues such as the basolateral membrane of the renal 
tubule epithelium, the apical brush border membrane of the small intestine and colon, hepatocyte 
membranes, the apical surface of the choroid plexus, hRFC were also detected. RFC is essential 
for tissue development since targeting both RFC alleles is embryonic lethal.57 In addition, at least 
in some tissues (e.g., small intestine), mouse RFC is responsive to dietary folates supply such that 
increased RFC transcripts and proteins were detected under conditions of dietary folate 
deficiency.58  
2.1.3. Transport mechanism of RFC 
RFC, a bidirectional anion transporter, can transport reduced folates via counter-transport 
with organic anions.3 5-methyl THF is the physiologic substrate of RFC.As an integral 
transmembrane protein, RFC has a high affinity (~50-100-fold) for reduced folates (Ki ~1-5 µM) 
and a low affinity for FA (Ki ~200 µM). Transport by RFC is characterized by a neutral pH 
optimum and significantly decreased transport activity in acidic environment when pH is below 
7.3,4,8. 
RFC can generate small transmembrane chemical gradient. However, due to two glutamate 
carboxyl groups of folates that are fully ionized at physiological pH, folates are negatively charged. 
If considered with the within the context of the membrane potential, RFC produces a substantial 
electrochemical potential difference for folates across cell membranes.49 The energy source for 
this uphill process is unique. RFC function is not directly linked to ATP hydrolysis and it is neither 
Na+ nor H+ dependent.59,60  Instead, RFC-mediated transport is highly sensitive to the 
transmembrane anion gradient, especially, the organic phosphate gradient.59,60 Organic phosphates 
are highly concentrated in cells where they are synthesized by ATP-dependent reactions and are 
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largely retained. Their resulting asymmetrical distribution across cell membranes provides the 
driving force for RFC-mediated uphill transport of folates into cells.60 
2.1.4. RFC in antifolate chemotherapy 
MTX, RTX, and PMX, classical antifolates (Figure 5), are all actively transported into 
mammalian cells by RFC as the major transporter.47,61 Membrane transport of antifolates such as 
MTX is critical to antitumor activity since this provides sufficient intracellular drug concentration 
to sustain maximal inhibition of enzyme targets (e.g. DHFR and TS) and for synthesis of 
polyglutamate derivatives required for high affinity binding to some intracellular 
enzymes and for sustained drug effects as plasma antifolate level decline. However, the loss of 
active transport of MTX in drug resistance has been documented as early as 1962 in MTX resistant 
L5178 murine leukemia cells.62 Since that time, impaired transport has emerged as one of the 
dominant modes of tumor resistance to classical antifolate inhibitors such as MTX.63,64 
Impaired transport that results in a loss of sensitivity to standard doses of antifolate should 
be circumvented to some extent by increasing extracellular concentrations of drug. This increase 
forces the drug into tumor cells expressing mutated or low levels of RFC, and involves alternate 
uptake routes or passive diffusion, to a sufficient extent to inhibit intracellular enzymes and/or to 
support polyglutamate synthesis. However, RFC is ubiquitously expressed in mammalian cells. 
Therefore, the elevated extracellular antifolate concentration always results in dose-limiting 
toxicity due to the lack of selectivity of uptake into the tumor cells compared to normal cells.  
2.2  The folate receptors (FRs) 
The FRs is a family of proteins with high affinity folate binding and represents another 
mode of folate uptake into mammalian cells. They bind folic acid, reduced folates, many anti- 
folates conjugates with high (low nanomolar) affinities.  
 - 15 - 
 2.2.1. Structure of FRs 
The FRs are encoded by three distinct genes, designated α, β and γ localized to 
chromosome 11q13.3-q13.5.65 FRs α, β and γ are highly homologous proteins (68-79% identical 
amino acid sequence) and contain from 229 to 236 amino acids with two (β, γ) or three (α) N-
glycosylation sites.66 In contrast to RFC, FRα and FRβ are anchored in plasma membranes 
via a glycosyl phosphatidylinositol (GPI) anchor, while FRγ is a secretory protein of unknown 
function due to the lack of a signal sequence for GPI anchor attachment.6  
Recently, Melcher and co-workers66reported the first crystal structure of FRα with folic 
acid at 2.8 Å resolution. FRα has a globular structure stabilized by eight disulpfide bonds and 
contains a deep open folate-binding pocket comprised of residues that are conserved in all receptor 
subtypes. The pteroate moiety of folate is buried inside the receptor, while its glutamate moiety is 
solvent-exposed and sticks out of the pocket entrance, allowing it to be conjugated to drugs without 
adversely affecting FRα binding.67 (Figure7, 8). 
 
 
 
 
 
 Figure 7. hFRα- folate scaffold buried inside and glutamic acid is solvent exposed. (MOE 2014, PDB ID 
4LRH).67 
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Figure 8. hFRα- interaction of folic acid with ligand-binding-pocket residues. (MOE 2014, PDB 
ID 4LRH).67 
2.2.2. FRs distribution  
FRα is predominantly expressed on the apical (luminal) surface of polarized mammalian 
epithelial cells, particularly in the proximal tubule cells of the kidney choroid plexus, retina, uterus 
and placenta.68,69 Because FRα is predominantly expressed on the apical surface, it is not in contact 
with the circulating folate. The unusual polarized expression of FRα appears to protect normal 
tissues from FR-targeted cytotoxic agents in the circulation.70 FRβ is expressed in placenta, spleen, 
thymus and in CD34+ monocytes and hematopoeitic cells.71-73 In normal bone marrow and 
peripheral blood cells, expression of FRβ is restricted to myelomonocytic lineage (e.g. mature 
neutrophils) and was reported to be nonfunctional.74 hFRγ is secreted at low levels from lymphoid 
cells in the spleen, thymus, and bone marrow.74 
FRα has been reported to be overexpress in malignant tissues, such as non-mucinous 
adenocarcinomas of the ovary, uterus and cervix, and ependymal brain tumors.6 FRα levels 
positively correlate with tumor stages and grades.75 FRβ malignant expression has been reported 
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to involve a substantial fraction of chronic myelogenous leukemia (CML) and acute myelogenous 
leukemia (AML) cells, but not Acute Lymphoblastic Leukemia (ALL).75-77 Both FRα and FRβ in 
malignant tissues seem to be functional, prompting the use of folic acid and pteroyl moieties for 
tumor targeting of toxins, liposomes, imaging and cytotoxic agents.70,77,78 
2.2.3. Transport mechanism of FRs 
 
 
 
 
 
 
 
 
 
Figure 9. Endocytosis of FRs. 
Folate internalization by membrane-associated FRs involves receptor-mediated 
endocytosis.3,4,6,8 The process of internalization by FRs is initiated when a folate molecule binds 
to a folate receptor on the cell surface. This is followed by invagination of the plasma membrane 
at that site and the formation of vesicle (endosome) that migrates along microtubules in the 
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cytoplasm to the perinuclear endosomal compartment where it is acidified to a pH of 6.0-6.5. The 
decrease in pH results in a conformational change of the complex which leads to dissociation of 
the folate from folate receptor complex.79 The folate ligand is then exported into the cytoplasm by 
a process requiring a trans-endosomal pH gradient.80-83 The endosome then migrates to the cell 
surface and is fused with the cell membrane, the same FRs recycle. (Figure 9) 
2.2.4. FRs and antifolate chemotherapy 
Many reports have shown that FRα is overexpressed in solid tumors such as ovarian, lung 
and breast carcinomas, including up to 90% of ovarian cancers.76 In addition, FRα expression has 
been associated with higher stage, grade and differentiation status of ovarian tumors. However, in 
normal tissues, FRα is reported to be inaccessible to the circulation.5 FRβ is expressed in a wide 
range of myeloid leukemia cells, but FRβ is unable to bind folate, when it is in normal 
hematopoetic cells.75 Thus, the high affinity FRs offer a potential means of selective tumor 
targeting, given their restricted pattern of tissue expression and function. Folate-conjugated 
cytotoxins, liposomes, radionuclides, or cytotoxic antifolates have all been used to target 
FRs.5,33,84,85 However, for most folate-based therapeutics such as classical antifolates (including 
MTX, RTX and PMX), tumor selectivity is lost, since substrates are shared between FRs and the 
ubiquitously expressed RFC.  
2.3. The proton-coupled folate transporter (PCFT) 
In 2006, PCFT a new folate carrier (SLC46A1) and two other members of this family 
(SLC46A2 and SLC46A3) were discovered.86,87 PCFT belongs to the superfamily of solute 
transporter family. The gene that encodes human PCFT (SLC46A1) is located on chromosome 
17q11.2. PCFT as a high-affinity folate transporter is a proton-folate symporter that functions 
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optimally at acidic pH 5.5 by coupling the flow of protons down an electrochemical concentration 
gradient to the uptake of folates into cells.49,87 PCFT is a high-affinity folate transporter with a low 
acidic pH optimum. Its primary role appears to be intestinal absorption of dietary folates and plays 
a major role in in vivo folate homeostasis.88-89 
2.3.1. Structure of PCFT 
Hydropathy analyses predict PCFT is comprised of 459 amino acids with a molecular mass 
of 49.8 kDa. It is predicted to include 12 TMDs with N- and C-termini oriented to the cytoplasm 
(Figure 10). This structure has been validated by immunofluorescence analysis of hemagglutin 
(HA)-tagged hPCFT molecules.90,91 The loop domain between the first and second TMDs must be 
extracellular because the two putative N-glycosylation consensus sites in this region are 
glycosylated. N-glycosylation does not appear to be required for either PCFT trafficking or 
function.92 
 
Figure 10  Human PCFT structure.48 
2.3.2. PCFT expression patterns in human tissue 
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PCFT is expressed in many normal tissues including small intestine, colon, liver, kidney, 
placenta, retina and brain. Within the intestine, high PCFT levels are found in the in apical brush-
border membranes in the proximal jejunum and duodenum. In addition, PCFT is also found in the 
choroid plexus.92 
2.3.3. Transport mechanism of PCFT 
Folate transport mediated by human, mouse and rat PCFTs is electrogenic,  
indicating that there is a net translocation of positive charges as each folate molecule is 
transported.7,93-95 PCFT functions as a folate-proton symporter: the downhill flow of 
protons via PCFT is coupled with the uphill flow of folates into cells. A trans vesicular pH 
gradient results in increased unidirectional folate transport and substantial transmembrane 
folate concentration gradients from the low-pH to the high-pH compartment, which is 
consistent with a proton-coupled process.96 Acidic pH optimum is a distinguishing characteristic 
of PCFT. For PCFT, transport is maximal at pH 5-5.5. As the pH increases above pH 5.5, transport 
decreases dramatically; above pH 7, activity is not detectable.4,8 This leads to an important cancer 
chemotherapy hypothesis that selective transport via PCFT could afford targeted therapy access of 
solid tumors expressing PCFT. The pH of solid tumors is often acidic,94,97 which favors PCFT 
transport. However, the role of hPCFT in antifolate activity and tumor selectivity is still under 
investigation, transport of classical antifolates by PCFT has been described previously.95 
2.3.4. PCFT and antifolate chemotherapy 
The expression of RFC in both normal and tumor cells presents a potential obstacle to 
antitumor selectivity. Further, loss of RFC results in resistance to MTX and RTX, yet PTX 
cytotoxic activity can be preserved or even increased if PCFT is present.98 For agents such as PMX 
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that are transported by both RFC and PCFT, loss of tumor selectivity could be due to RFC transport 
in normal tissues. Thus, there is a compelling rationale for developing cytotoxic antifolates that 
are substrates for transporters other than RFC with limited expression and/or transport in normal 
tissues compared with tumors. This rationale provided the impetus to develop targeted agents that 
are selectively transported into tumors by FRs and PCFT over RFC, with potent intracellular 
targets inhibition.48 Recently, Gangjee and coworkers99-101reported novel 6-substituted classical 
pyrrolo[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine as cytotoxic antifolates with varying 
lengths of the carbon bridge region that are characterized by selective FR and/or PCFT transport 
over RFC transport. 
3. Glycinamide-ribonucleotide transformylase (GARTFase) 
Glycinamide ribonucleotide transformylase (GARTFase) is one of the most important 
trifunctional enzymes involved in purine synthesis.  GARFTase (EC 2.1.2.2) was first discovered 
and partially characterized from pigeon liver in pioneering investigations by Warren and 
Buchanan.102 GARFTase catalyzes the transfer of the formyl group from N10-CHO-FH4 to the 
primary, side-chain amino group of glycinamide ribonucleotide (GAR) to yield 
formylglycinamide ribonucleotide (FGAR) and tetrahydrofolate (Figure 4), ultimately resulting in 
the incorporation of C-8 into inosinic acid (IMP). This reaction is the third step and the first of two 
folate-dependent formyl transfers in the de novo purine biosynthetic pathway. Purine nucleotides 
play a critical role as precursors to RNA and DNA. Therefore, inhibition of de novo purine 
biosynthesis might be a viable approach for cancer chemotherapy.103,104 This suggestion was 
confirmed when it was demonstrated that 5,10-dideazatetrahydrofolate, a potent experimental 
antitumor agent, has, as its mechanism of action, the inhibition of GARFTase and, consequently, 
of de novo purine biosynthesis.105 GARFTase is of mechanistic interest for the ease with which it 
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catalyzes the formyl transfer,106,107of biological interest for its role in the synthesis of DNA 
precursor purines.108 it is also structural interest for the delineation of key mechanistic features of 
its catalytic reaction,109-112 and of medicinal interest as an important target for chemotherapeutic 
drug design.113-123 
3.1. Structure of GARFTase 
Recently, The structure of the Escherichia coli (E. coli) GARFTase has been solved at pH 
3.5 (1.8 Å),124 pH 6.75 (2.8 and 3.0 Å),125and pH 7.5 (1.9 Å)124 and at neutral pH in complexes 
with GAR and 5-deazatetrahydrofolate (2.5 Å),110 GAR and 10-formyl-5,8,10- trideazafolic acid 
(2.1 Å),111 and two multi-substrate adduct inhibitors (1.96 and 1.6 Å).109 The hGARFTase domain 
is now readily available through cloning and overexpression.126,127 The hGARFTase is located at 
the C-terminus of a trifunctional enzyme with a molecular mass of more than 110 kDa, which is 
also responsible for catalyzing the second (glycinamide ribonucleotide synthetase) and fifth 
(aminoimidazole ribonucleotide synthetase) reactions of de novo purine biosynthesis.128 The 
crystal structure of hGARFTase has been reported at pH 4.2 (1.7 Å), at pH 8.5 (2 Å), at pH 8.5 in 
the binary complex with the substrate β-GAR (2.2 Å)112 and at pH 7 in a binary complex with the 
co-substrate analog inhibitor 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8- tetrahydrofolic acid 
(10-CF3CO-DDACTHF) (2 Å)129 and a series of other folate inhibitors.119 
3.2. Catalytic Mechanism of GARFTase 
Kinetic studies of the E. coli enzyme106, the human enzyme126 and the murine 
enzyme130 suggest a sequential mechanism in which the formyl group is transferred by a direct 
nucleophilic attack of the GAR amino group on the formyl carbon of the co-substrate, leading to 
the formation of a tetrahedral intermediate. Formation of this intermediate and its collapse to 
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product require proton transfers. It has been proposed that a “fixed” water molecule, rather than 
the invariant amino acids in the active site,131 mediates the required proton transfer between the 
substrate and cofactor, but this has not been verified experimentally.  
 
Figure 11 Proposed mechanism for GARFTase.132 
A proposed mechanism for GARFTase is shown in Figure 11.132 As the cofactor 
binds to the active site, Asp144 forms a salt bridge to the imidazolium of His108 and the 
formyl group is positioned to form hydrogen bonds to Asn106 and the protonated 
imidazolium group of His108. The free base form of the amino group of GAR then attacks the 
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activated formyl group to form a tetrahedral intermediate. A proton transfer from GAR to the N10 
of folate is mediated by a catalytic water molecule, followed by breakdown of the tetrahedral 
intermediate to form products. The positioning of this water molecule may be assisted by a 
hydrogen bond to the carboxylate of Asp144. (For clarity, Asp144 is shown twice in Figure 11; it 
spans the N1 of His108 to the bound H2O molecule.)  
3.3. Binding of Inhibitors 
Zhang et al.129 reported a 1.98 Å X-ray crystal structure (Figure 12) of hGARTFase in a 
binary complex with the co-substrate analog inhibitor 10-CF3CO-DDACTHF (Table 2) at pH 7 
(PDB entry 1NJS). The cofactor binding pocket of GARTFase is located at the interface between 
the N-terminal mononucleotide binding domain and the C-terminal half of the structure. The 
binding site for the folate cofactor moiety consists of three parts:  the pteridine binding cleft, the 
benzoylglutamate region, and the formyl transfer region. 
 
Figure 12 Crystal structure (MOE 2014) of hGARTase in a binary complex with inhibitor 10-
CF3CO-DDACTHF at pH 7 (PDB ID 1NJS). 
Pteridine Binding Cleft. The diaminopyrimidinone ring is deeply buried in the active site 
cleft and occupies the same location as the quinazoline ring of 10-formyl-5,8,10-trideazafolic acid 
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(10-formyl-TDAF) in the E. coli GARFTase complex (PDB entry 1C2T). The connecting stem 
from the diaminopyrimidinone ring, composed of single carbon bonds, is longer than its 
counterpart in 10-formyl-TDAF, due to the removal of the fused benzene ring, which makes it 
more flexible when adapting to the binding site to optimize the gem-diol interactions with the 
protein. The diaminopyrimidinone ring of 10-CF3CO-DDACTHF is tilted about 15° relative to the 
quinazoline ring of 10-formyl-TDAF, which places N2 within hydrogen bonding range 
(3.1 Å) of the backbone carbonyl oxygen of Glu141. The diaminopyrimidinone ring conserves all 
of the key interactions that were previously observed with the quinazoline ring of 10-formyl-TDAF 
and provides additional key hydrogen bonds with the enzyme. Several hydrophobic residues 
encircle a deep cavity holding the heterocycle. The hydrophobic pocket consists of Leu85, Ile91, 
Leu92, Phe96, and Val97 lining one end and the folate-binding loop of residues 141-146 at the 
other. The diaminopyrimidinone ring makes six hydrogen bonds to the main chain amides and 
carbonyls of Arg90, Leu92, Ala140, Glu141, and Asp144, and two hydrogen bonds to ordered 
waters (W18 and W70). In the quinazoline ring of 10-formyl-TDAF, N8 of the folate pteridine 
ring is replaced with a carbon. This nitrogen has been proposed to play a key role in the recognition 
and interaction with folate-binding enzymes and forms one end of an H-bond 
donor-acceptor-donor array. While its replacement with carbon does not preclude the 
binding to GARFTase, its presence appears to contribute to substrate recognition by the 
folate transport system and/or FPGS. The diaminopyrimidinone ring of 10-CF3CO- DDACTHF, 
however, preserves this nitrogen (N8).  
Glutamate Tail. In the 10-CF3CO-DDACTHF complex, the p-aminobenzoate 
moiety locates in a hydrophobic pocket sandwiched between the side chains of Ile91 
and Ser118.  The electron density of the carbonyl group is well-defined and in the same 
 - 26 - 
plane as the phenyl ring. The glutamate tail is oriented almost perpendicular to the p-
aminobenzoate plane and parallel to the aliphatic stem of the diaminopyrimidinone ring. In the 
complex structure of 10-CF3CO-DDACTHF with human GARFTase, the glutamate moiety is 
solvent-exposed, but exhibits a remarkably well-ordered structure, in contrast to its flexibility in 
E. coli GARFTase complex structures. A salt bridge (2.7 Å) is formed between the glutamate α-
carboxylate and Arg64 so that the γ-carboxylate points to the solvent. An additional interaction 
observed here includes a hydrogen bond between the Ile91 backbone amide and the α-glutamate 
carboxylate (2.8 Å). 
Formyl Transfer Region and the Gem-Diol Structure. Key interactions for tight binding of 
inhibitor 10-CF3CO-DDACTHF to GARFTase are found in the formyl transfer region. Strong 
density next to the ketone oxygen indicates that the ketone is hydrated to a gem-diol, similar to the 
10-formyl-TDAF and β-GAR complex with the E.coli GARFTase (PDB ID 1C2T). The gem-diol 
forms extensive interactions with the formyl transfer region, especially with Asp144 and His108, 
two essential residues in the formyl transfer reaction. The Asp144 carboxylate hydrogen bonds 
bind (2.5 and 2.7 Å) to each of the hydroxyl groups of the gem-diol. N3 in the imidazole ring of 
His108 also forms hydrogen bonds with both hydroxyls of the gem-diol [OA1 (2.7 Å) and OA2 
(3.1 Å)]. Moreover, OA2 also makes a potential hydrogen bond (3.0 Å) with the backbone 
carbonyl oxygen of Gly117.  
Recently X-ray crystal structure of hGARTFase with pemetrexed and 6-substituted 
pyrrolo[2,3-d] pyrimidine antifolate (Figure 13) and β-GAR substrate were determined.133 Based 
on the crystallographic models antifolates form six hydrogen bond interactions with hGARFTase 
peptide backbone atoms via the pyrrolo[2,3-d] pyrimidine moiety. In addition, two hydrogen bonds 
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with the peptide backbone, a bidentate polar interaction with Arg871, and three long distance 
charge–charge interactions with Arg897 and Lys844 are mediated via the glutamyl tail.  
 
Figure 13 Crystal structure of hGARTFase. (PDB: 4ZZ1)133 
3.4. GARFTase Inhibitors 
Three types of GARFTase inhibitors are reviewed. These are listed in Table 1, Table 2 and 
Table 3 below:   
3.4.1. 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydropyrimido[5,4-
b][1,4]thiazines (Table 1) 
3.4.2. Pyrimidines (Table 2)  
3.4.3. Pyrrolo[2,3-d]pyrimidines and thieno[2,3-d]pyrimidines (Table 3) 
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3.4.1. 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydropyrimido[5,4-
b][1,4]thiazines (Table 1) 
Lometrexol. In 1985 Taylor and coworker139 synthesized the first GARFTase inhibitor to 
enter clinical trials, the 6-(R)-isomer of 5, 10-dideazatetrahydrofolic acid (DDATHF), termed 
lometrexol (LMTX, Table 1). This discovery established GARFTase and the purine de novo 
biosynthetic pathway as viable targets for antineoplastic intervention. LMTX is a poor inhibitor of 
both DHFR and TS, but a potent inhibitor of GARFTase (Ki = 6 nM) and a substrate for FPGS.140 
The diastereomers were separated and found to be equipotent as inhibitors of cell growth and as 
substrates for FPGS.134 The (6R)-diastereomer, which corresponds to the configuration found in 
natural tetrahydrofolates, was chosen for further development. Patients treated with LMTX in 
Structure Compound Biological 
Activity 
Ref. 
 
 
 
Lometrexol 
(DDATHF) 
hGARFTase (Ki) 
6 nM 
 
134 
 
LY-222306 
(6-R,S) 
hGARFTase (Ki) 
0.77 nM 
CCRF-CEM 
(IC50) 27 nM 
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LY-254155 
(6-R,S) 
LY-309887 
(6-R) 
hGARFTase (Ki) 
2.1 nM 
CCRF-CEM 
(IC50) 27 nM 
 
136 
 
AG-2034  
hGARFTase (Ki) 
28 nM 
CCRF-CEM 
(IC50) 2.9 nM 
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AG-2037 
(pelitrexol) 
 
hGARFTase (Ki) 
0.5 nM 
 
 
 
138 
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phase I clinical trials developed severe and cumulative myelosuppression and mucositis. The 
cumulative toxicity of LMTX is thought to be due in part to its ability to be 
transported by both the RFC and FRs, resulting in increased cellular levels and a lack of selectivity 
for tumor cells.141,142  
(2S)-2-[[5-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-
yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid (LY309887). Unexpected observations of 
delayed cumulative toxicity with LMTX led to a search for a second-generation antimetabolite 
with a more favorable toxicological, biochemical and pharmacological profile. In 1994, Habeck et 
al.135 reported a novel class of classical antifolates that replaced the 1’,4’-phenyl group of LMTX 
with a 2’,5’-furan (LY222306) and a 2’,5’-thiophene (LY254155) (Table 2). Both LY222306 and 
LY254155 (mixtures of diastereomers) were found to be potent inhibitors of CCRF-CEM cell 
growth (IC50 = 27 and 2.3 nM, respectively) and tight binders of human GARFTase (Ki = 0.77 and 
2.1 nM, respectively). Further evaluation of LY254155 was restarted in 1996 after the compound 
was resolved into its two diastereomers.136,143 LY309887 (6R-2’,5’-thienyl-5,10-
dideazatetrahydrofolic acid, Table 1) was more potent than LMTX at inhibiting tumor growth in 
the murine C3H mammary tumor model and several tumor xenografts. LY309887 displayed a 9-
fold greater inhibitory potency against GARFTase compared to LMTX. In preclinical models, 
LY309887 was more active than LMTX against two pancreatic xenografts and in the human LX-
1 lung carcinoma model. In two preliminary reports of phase I studies with LY309887, all patients 
received concurrent folic acid but still suffered from cumulative toxicity, suggesting that, like 
LMTX, cumulative toxicity remains a property of LY309887.144,145  
AG-2034 and AG-2037. AG-2034 (Table 1) was designed from the X-ray structure of the 
GARFTase domain of the human trifunctional enzyme. The only difference between AG-2034 and 
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LY-309887 is the 5-sulfur in the pteridine ring. AG-2034 inhibits hGARFTase (Ki = 28 nM) and 
is a substrate for rat liver FPGS, with similar efficacy as LMTX, while AG-2034 is a more effective 
ligand for FRs than LMTX. AG-2034 inhibited cell growth (IC50 = 4.0 and 2.9 nM, respectively, 
against L1210 and CCRF-CEM cells) and exhibited in vivo antitumor activity against lung 
carcinomas, lymphosarcomas, mammary and colon adenocarcinomas and melanoma. In phase I 
clinical studies, AG-2034 displayed much less cumulative myelosuppression than LMTX, but like 
LMTX did result in mucositis and diarrhea.146 AG-2037 (pelitrexol) is currently in phase I clinical 
development (Table 1).147 The configuration at C-6 is reversed compared to LMTX and the 
thiophene is methylated at the 4-position of AG-2037. AG-2037 is a potent inhibitor of GARFTase 
(Ki = 0.5 nM) and exhibits significant antiproliferative effects against tumor cells in vitro and in 
vivo.148 Several phase I studies have been completed that indicate that AG-2037 is well tolerated 
and its maximum tolerated dose and schedule for phase II studies have been determined.149,150  
4.2. Pyrimidines (Table 2)  
Structure Compound Biological Activity Ref. 
 
 
7-DM-
DDATHF 
X = CH2 
 
5-DACTHF 
X = NH 
CCRF-CEM (IC50) 
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hog     liver 
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2.6 µM 
 
 
 
151 
 
 
 
152 
Structure Compound Biological Activity Ref. 
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1 X = CH 
 
 
 
2 X = N 
 
hog    liver 
GARTFase (IC50) 
2.06 µM 
hog    liver 
GARTFase (IC50) 
0.14 µM 
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154 
 
10-CHO-
DDACTHF 
R = H 
 
 
10-CF3CO-
DDACTHF 
R = CF3 
hGARTFase (Ki) 
14 nM 
CCRF-CEM (IC50) 
60 nM 
 
rhGARTFase (Ki) 
15 nM 
CCRF-CEM (IC50) 
16 nM 
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(10R)-CH3S-
DDACTHF 
 
 
 
(10S)-CH3S-
DDACTHF 
 
rhGARTFase (Ki) 
210 nM 
CCRF-CEM (IC50) 
80 nM 
 
rhGARFTase (Ki) 
180 nM 
CCRF-CEM (IC50) 
50 nM 
155 
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α-CH2-10-
CF3CO-
DDACTHF 
R1=COONH2 
R2=COOH 
 
γ-CH2-10-
CF3CO-
DDACTHF 
R1=COOH 
R2=COONH2 
 
γ -Tetrazole-
10-CF3CO-
DDACTHF 
R1=COOH 
R2=tetrazole 
hGARFTase (Ki) 
4.8 µM 
CCRF-CEM (IC50) 
inactive 
 
 
hGARFTase (Ki) 
56 nM 
CCRF-CEM (IC50) 
300 nM 
 
 
hGARFTase (Ki) 
130 nM 
CCRF-CEM (IC50) 
40 nM 
156 
 
 
 
 
 
156 
 
 
 
 
 
157 
7-DM-DDATHF. During the development and evaluation of LMTX, open-chain 
analogs of LMTX were synthesized and evaluated.151,152 These analogs did not possess a 
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stereocenter and were therefore less challenging to synthesize. 7-DesmethyleneDDATHF (7-DM-
DDATHF) (Table 2) is approximately 8-fold less potent than LMTX 
against human leukemia CCRF-CEM cells (IC50 = 130 nM vs. 16 nM) and only 3-fold 
less active against GARFTase isolated from murine leukemia L1210 cells. 7-DMDDATHF is also 
a substrate for FPGS and its polyglutamated conjugates are more potent 
inhibitors of GARFTase than the parent compound. Removal of the annulated 
tetrahydropyridine ring of LMTX had minimal effect on binding to GARFTase. A similar 
compound 5-DACTHF (Table 2) was reported by Kelley and coworkers152 in 1990. 5- 
DACTHF showed an IC50 of 2.6 μM against GARFTase isolated from hog liver, and 
slight inhibition of AICARFTase (IC50 = 200 μM in L1210 cells). Further SAR studies 
afforded the thienyl and thiazolyl analogs of 5-DACTHF.153 The thiophene analog 1 (Table 2) was 
equal in activity to 5-DACTHF in controlling MCF7 breast cancer cell growth, while thiazole 2 
(Table 2) was 9-fold more active than 5-DACTHF and 4-times more active than LMTX. 
Compound 2 and LMTX have very similar activity against hog liver GARFTase. 
10-CF3CO-DDACTHF. Boger and coworkers122 reported the synthesis and 
evaluation of 10-formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-CHODDACTHF, 
Table 2), an acyclic analog of LMTX bearing a nontransferable C-10 formyl 
group. 10-CHO-DDACTHF inhibited cell growth (IC50 = 60 nM, CCRF-CEM) and 
hGARFTase (Ki = 14 nM), but suffered from instability due to a facile oxidative 
deformylation. Continued development of such GARFTase inhibitors was accomplished 
by combining the 2,4-diaminopyrimidone core of 10-CHO-DDACTHF with a more 
stable trifluoromethyl ketone moiety.13010-(Trifluoroacetyl)-5,10-dideaza-acyclic- 
5,6,7,8-tetrahydrofolic acid (10-CF3CO-DDACTHF, Table 3) is a potent inhibitor of 
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tumor cell proliferation, with an IC50 of 16 nM against CCRF-CEM cells, which 
represents a 10-fold improvement over LMTX. 10-CF3CO-DDACTHF specifically 
inhibits recombinant hGARFTase (Ki = 15 nM), and is stable, displaying no competitive 
oxidative deacylation. 
10-CH3S-DDACTHF. Further exploration of analogs containing alternative tetrahedral 
intermediate mimics continued with the synthesis and evaluation of 10-CH3SDDACTHF (Table 
2).158 10-CH3S-DDACTHF proved to be potent, exhibiting an IC50 of 100 nM against CCRF-CEM 
cells. A follow-up asymmetric synthesis of (10R)- and (10S)- diastereomers of 10-CH3S-
DDACTHF was recently reported in 2008.158 Both diastereomers are potent and selective 
inhibitors of rhGARFTase (Ki = 210 and 180 nM, respectively, for 10R and 10S) and effective 
inhibitors of cell growth (IC50 = 80 and 50 nM, respectively, against CCRF-CEM cells), which is 
dependent on intracellular polyglutamation by FPGS but not transport by RFC.  
γ-CONH2-10-CF3CO-DDACTHF and γ-tetrazole-10-CF3CO-DDACTHF.A further area 
of examination in these efforts was the glutamic acid portion of 10-CF3CO-DDACTHF. As stated 
previously, folates and many antifolates are polyglutamylated by FPGS after entering cells. Most 
FPGS, including human FPGS, attach additional glutamates to the γ-carboxylic acid of folates and 
antifolates. Polyglutamation of folates and antifolates increases their affinity for some enzymes 
(e.g. TS and GARFTase) and makes them less susceptible to cellular efflux, providing a long-lived 
cellular supply of the molecules. However, this long-term enhanced intracellular accumulation of 
antifolates, due to their polyglutamation, contributes to their cumulative toxicity. Therefore, the 
strategy that preventing polyglutamylation, while maintaining potent enzyme binding, is 
considered a therapeutic asset. γ-CONH2-10-CF3CO-DDACTHF (Table 2) exhibited potent 
inhibitory activity against rhGARFTase (Ki = 56 nM) and purine sensitive cytotoxic activity (IC50 
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= 300 nM, CCRF-CEM),  whereas α-CONH2-10-CF3CO-DDACTHF showed decreased affinity 
(Ki = 4.8 μM) and was inactive in cellular functional assays.155 Another potent 
nonpolyglutamatable inhibitor γ-tetrazole-10-CF3CO-DDACTHF (Table 2) exhibited purine-
sensitive cytotoxic activity (IC50 = 40 nM) and was a selective inhibitor of hGARFTase (Ki = 130 
nM).156 As anticipated, both γ-CONH2-10-CF3CO-DDACTHF and γ-tetrazole-10-CF3CO-
DDACTHF are not dependent on FPGS for acitivty, and hence not susceptible to resistance 
mediated by FPGS. 
4.3. Pyrrolo[2,3-d]pyrimidines and thieno[2,3-d]pyrimidines (Table 3) 
Structure Compound Biological Activity (IC50) Ref. 
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N NH
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H2N
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O COOH
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n = 1-6  
3  n = 3 
 
 
 
4  n = 4 
 
hGARFTase            18 nM 
KB                           1.7 nM 
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hGARFTase            6.8 nM 
KB                           1.9 nM 
IGROV1                  3.6 nM 
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N S
O
H2N
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COOH
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n = 2-8  
5  n = 3 
 
 
6  n = 4 
 
 
hGARFTase          13.8 nM        5 
KB                           23 nM 
IGROV1                  4.7 nM 
 
hGARFTase          13.3 nM     63 
KB                           4.9 nM 
IGROV1                  5.9 nM 
 
7  n = 3 
 
 
 
8  n = 4 
 
hGARFTase          0.69 nM 
KB                         0.26 nM 
IGROV1                0.55 nM 
 
hGARFTase          1.96 nM 
KB                         0.55 nM 
IGROV1                0.97 nM 
1. SAR of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with para substituted benzoyl 
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aromatic rings as side chain in whole cell assay as GARTFase inhibitors with selectivity for FRs 
and/or PCFT over RFC.96 
Table 4. IC50’s (in nM) for 6-Substituted Pyrrrolo[2,3-d]pyrimidine Antifolates 3,4 and classical 
Antifolates in hRFC, hPCFT, and FR-Expressing Cell Lines. (+F (folic acid) = 200 nM, plus/minus 
SEM in parentheses, ND not determined).96  
 
Gangjee and coworkers5,63,95, recently described novel 6-substituted classical pyrrolo[2,3-
d]pyrimidine and thieno[2,3-d]pyrimidine as cytotoxic antifolates with varying lengths of the 
carbon bridge region (Table 3), that are characterized by selective FR and PCFT transport over 
RFC transport. For every series, the three- and four-carbon bridge analogs were the most active 
toward FR-expressing human tumors (KB and IGROV1) and the cytotoxicity was primarily due 
to potent inhibition of GARFTase, although for the thieno[2,3-d]pyrimidine antifolates, a 
secondary target, most likely AICARFTase, was also implied at higher concentration. 
 
Engineered CHO (Chinese Hamster Ovary) Cell Line (IC50S in nM) 
hRFC NIL hFRα hFRβ hPCFT NIL 
PC43-10 R2 RT16 RT16+F D4 D4+F R2/hPCFT4 R2(VC) 
3 304 448 4.1 >1000 5.6 >1000 23 >1000 
4 >1000 >1000 6.3 >1000 10 >1000 213 >1000 
PMX 138(13) 894 (93) 42 (9) 388 (68) 60 (8) 254 (78) 13.2 (2.4) 974.0 (18.1) 
MTX 12 (1.1) 216 (8.7) 114 (31) 461(62) 106 (11) 211 (43) 120.5 (16.8) >1000 
RTX 6.3(1.3) >1000 15(5) >1000 22 (10) 746 (138) 99.5 (11.4) >1000 
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The 6-substituted classical pyrrolo[2,3-d]pyrimidine with a para substituted benzoyl side 
chain compound 3 and 4 were highly potent against  tumor cells (3, IC50s of 1.7 nM for KB and 
2.2 nM IGROV1 and 4, IC50s of 1.9 nM for KB and 3.6 nM IGROV1) . These compounds are 
highly selective towards FRs and PCFT over RFC (Table 4). The selectivity of compound 3 is 
slightly compromised by its RFC transport, however compound 4 has excellent selectivity for FRs 
and PCFT over RFC. These in vitro cytotoxicity results establish that the growth inhibitory effects 
of 3 and 4 are dependent on their cellular accumulation via FRs rather than RFC and that there is 
no apparent difference in the activity of these drugs toward cells that express the FRα isoform from 
cells that express FRβ. 
2. SAR of 2-amino-4-oxo-6-substituted pyrrrolo[2,3-d]pyrimidines with para substituted thieno 
rings as side chain in whole cell assay as GARTFase inhibitors with selectivity for FRs and/or 
PCFT over RFC.5 
The 6-substituted classical thieno[2,3-d]pyrimidines with a para substituted thieno side 
chain 7 and 8 were highly potent against  tumor cells (Table 5) . These compounds showed high 
selective towards FRs over RFC and PCFT (Table 5). These compounds do not use RFC for 
transport into the cell.  
Table 5. IC50’s (in nM) for 6-Substituted pyrrrolo[2,3-d]pyrimidines Antifolates 7, 8 and 
Classical Antifolates in hRFC, hPCFT, and FR-Expressing Cell Lines. (+F (folic acid) = 200 nM, 
plus/minus SEM in parentheses, ND not determined)5   
Table 5. 
 
Engineered CHO (Chinese Hamster Ovary) Cell Line (IC50S in nM) 
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4. Aminoimidazole-4-carboxamide ribonucleotide transformylase (AICARFTase) 
AICARFTase catalyzes the penultimate reaction in the de novo purine biosynthetic 
pathway, producing formyl-AICAR (FAICAR) from AICAR using N10-formyltetrahydrofolate 
(N10-CHOFH4) as the formyl donor. It exists as one domain of a bifunctional enzyme that also 
contains IMP cyclohydrolase (IMP CHase) that catalyzes the final reaction of the pathway (Figure 
4). Because of the large demand for purines by cancer cells, AICARFTase has been targeted by 
antifolate inhibitors in chemotherapy along with GARFTase.160-161 
4.1. Structure of AICARFTase 
AICARFTase is highly conserved from E. coli to human but has no sequence homology 
with other folate-dependent enzymes, such as GARFTase.162 Thus, folate based inhibitors of 
GARFTase do not usually inhibit AICARFTase because of different interactions within the two 
active sites.163 For example, lometrexol potently inhibits GARFTase but not AICARFTase.164 
hRFC NIL hFRα hFRβ hPCFT NIL 
PC43-10 R2 RT16 RT16+F D4 D4+F R2/hPCFT4 R2(VC) 
7 101 273 0.31 >1000 0.17 >1000 3.34 >1000 
8 >1000 >1000 1.82 >1000 0.57 >1000 43.4 >1000 
PMX 138(13) 894 (93) 42 (9) 388 (68) 60 (8) 
254 
(78) 13.2 (2.4) 
974.0 
(18.1) 
MTX 12(1.1) 216 (8.7) 114 (31) 461(62) 
106 
(11) 
211 
(43) 120.5 (16.8) >1000 
RTX 6.3(1.3) >1000 15(5) >1000 22 (10) 
746 
(138) 99.5 (11.4) >1000 
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Wilson and coworkers161,163,165-167have previously reported several crystals 
structures of human and avian ATIC (the bifunctional enzyme, aminoimidazole-4- 
carboxamide ribonucleotide (AICAR) transformylase (AICARFTase)/IMP 
cyclohydrolase (IMPCH)) in both unliganded and complexed forms. The ATIC forms an 
intertwined symmetrical homodimer (each monomer being composed of 393 residues) 
with the IMPCH domain at the N terminus (residues 1–199) and the AICARFTase 
domain at the C terminus (residues 200-593). The IMPCH active sites are contained 
within each monomer of the dimer, but the AICARFTase active site is located at the 
dimer interface with key active-site residues being contributed from both monomers. 
4.2. AICARFTase catalytic mechanism 
The catalytic mechanism of AICARFTase was evaluated with pH dependent kinetics, site-
directed mutagenesis, and quantum chemical calculations.168-170 The results indicated that the 
amide-assisted mechanism is concerted such that the proton transfers from the 5-amino group to 
the formamide are simultaneous with nucleophilic attack by the 5-amino group. Because this 
process does not lead to a kinetically stable intermediate, the intramolecular proton transfer from 
the 5-amino group through the 4-carboxamide to the formamide proceeds via the same transition 
state. Collectively, these experimental and theoretical analyses lead to a proposed mechanism for 
AICARFTase catalysis shown in Figure 14. 
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Figure 14 A proposed mechanism of AICARFTase.170 
In this proposed mechanism, Lys266, with the aid of His267, acts as a general acid catalyst 
to interact with the N3 of the imidazole ring of AICAR. His267 aids Lys266 to be in the right 
position for a hydrogen-bonding interaction. The 4-carboxamide mediates proton shuttling from 
the 5-amino to 4-carboxamide and then to the nitrogen of the leaving group with simultaneous 
nucleophilic attack of the 5-amino group on the formyl group of folate cofactor. The first proton 
transfer is facilitated by the intramolecular hydrogen bond in the ground-state AICAR and the 
protonated 4-carboxamide species is only present transiently. The theoretical results suggest that 
protonation of the nitrogen of the leaving group is critical in the aminolysis reaction between 
AICAR and the formyl group rather than the nucleophilic attack on the carbonyl group. The central 
role assigned to proton transfer compensates for the weak nucleophilicity of the AICAR 5-amino 
group.  
4.3. AICARFTase inhibitors 
Burroughs Wellcome (Research Triangle Park, NC) had designed and synthesized two 
antifolates that are specific inhibitors (nM) for human AICARFTase, as compared with other folate 
dependent enzymes, GARFTase, DHFR, and TS.162 These compounds are both 
sulfamido-bridged 5,8-dideazafolate analogs identified as BW1540U88UD (BW1540) 
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and BW2315U89UC (BW2315) (Fig. 15) that differ only in the disposition of the imido 
and sulfonyl groups within the bridge region. BW1540 and BW2315 have approximate Ki 
values against human ATIC of 8 and 6 nM, respectively, whereas the Ki values against 
GARFTase, DHFR and TS are within the micromolar range, except for BW1540, which 
showed low nanomolar inhibition against DHFR. BW1540 and BW2315 were co-crystallized at 
2.55 and 2.60 Å with human ATIC in the presence of substrate AICAR to elucidate their 
mechanism of inhibition. It was found both of compounds bound to the AICARFTase active site 
of ATIC and the sulfonyl groups dominate inhibitor binding and orientation through 
interaction with the proposed oxyanion hole.  Moreover, interaction of the sulfonyl oxygens with 
the oxyanion hole of the AICARFTase active site suggests that it is the driving force behind the 
high affinity for these sulfonyl-containing antifolates (The Km of 10-f-THF is 100 µM170, whereas 
the Ki values for BW1540 and BW2315 are 8 and 6 nM, respectively).162 Thus, these two 
antifolates bind more strongly to the AICARFTase active site, by at least 1000-fold, than the 
natural co-factor N10-formyltetrahydrofolate. 
 
Figure 15 AICARFTase inhibitors.162 
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Figure 15 AICARFTase inhibitors.162 
b. NSC37173 and NSC30171 
NSC30171 had nanomolar inhibition (Ki = 154 nM, IC50 = 600 nM), and NSC37173 (IC50 
= 4.1 µM) against human AICARFTase.171 The human AICARFTase /BW1540 complex (PDB 
1P4R) was selected as the docking template. NSC30171 was selected via NSC37173 similarity 
search. Docking with and without AICAR substrate in the active site strongly indicates that this 
nonfolate competes with the AICAR substrate for the AICAR binding site. Key interactions with 
the AICARFTase active site residues appear to be the electrostatic and H-bonding interactions 
between its sulfate and the enzyme “oxyanion hole”, and the aromatic stacking of the NSC30171 
naphthalene ring with the Phe590 benzyl ring. 
c. TNP-351 
TNP-351, characterized by a pyrrolo[2,3-d]pyrimidine ring, exhibits potent antitumor 
activities against mammalian solid tumors.172 The mechanism of action of TNP-351 was evaluated 
using methotrexate-resistant CCRF-CEM human lymphoblastic leukemia cell lines as well as 
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partially purified FPGS, AICARFTase, and GARFTase from parent CCRF-CEM cells. TNP-351 
was found to significantly inhibit the growth of L1210 and CCRF-CEM cells in culture, with the 
doses effective against 50% of the cells (ED50 values) being 0.79 and 2.7 nM, respectively. The 
methotrexate-resistant CCRFCEM cell line, which has an impaired methotrexate transport, 
showed less resistance to TNP-351 than to methotrexate. Inhibitory activities of TNP-351 and its 
polyglutamatesGn (n=1–6) for AICARFTase were found to be significantly enhanced with 
increasing glutamyl chain length (inhibition constants (Ki): G1, 52 μM; G6, 0.07 μM). Neither TNP-
351 nor its polyglutamates were very potent AICARFTase inhibitors. 
d. Pemetrexed (PMX, Alimta) 
Pemetrexed (PMX) is currently in widespread clinical use as the first line therapy for 
mesothelioma and non–small cell lung cancer (NSCLC) and is also currently being evaluated for 
the treatment of a variety of other solid tumors in the US.173 Thymidylate synthase (TS) was 
identified originally as the primary intercellular target174 of PMX. However, it is possible start that 
PMX is a multitargeted antifolate that inhibits DHFR, GARFTase and AICARFTase in addition 
to TS.175 However, TS Iis the pricipal target.  
7. Multiple targeted antifolates in combinational anticancer chemotherapy 
It has been of interest not only to design potent antifolates against specific 
enzymes of DHFR, TS, GARFTase and AICARFTase but also to design and synthesize 
 single agents that have potent multiple inhibitory activities against these enzymes.176, 177 
This strategy is particularly promising in anticancer chemotherapy against the multiple 
drug resistant cancers.178 Such a single agent could act at more than one active site and 
provide “combination chemotherapy”. The benefits of single agents are the following: 1) 
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circumvent the pharmacokinetic problems of multiple agents, 2) avoid of drug-drug interactions, 
3) used at lower doses to alleviate toxicity, 4) devoid of overlapping toxicities, and most 
importantly delay or prevent cancer drug resistance.178,179 Other advantages of such single agents 
are cost reduction and patient compliance. In addition, the clinical success of pemetrexed 
provided a good example of multiple targeted antifolates used in combinational anticancer 
chemotherapy.179 
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II. CHEMICAL REVIEW 
 
The chemistry related to the present work is reviewed and includes synthetic approaches to the 
following 5-substituted, 6-substituted pyrrolo[2,3-d]pyrimidines and relevant reactions: 
1. Synthesis of pyrrolo[2,3-d]pyrimidines 
2. Sonogashira coupling in antifolate synthesis 
3. Heck coupling reaction in one-step aldehyde synthesis 
1. Synthesis of pyrrolo[2,3-d]pyrimidine 
A large body of literature exists for the synthesis of pyrrolo[2,3-d] pyrimidines because 
of their application as deazapurine analogs. The synthetic strategies to this ring system have 
three broad classifications for synthesis from:  
1.1 Pyrimidine precursors 
1.2 Pyrrole precursors 
1.3 Furan precursors 
1.1. From pyrimidine precursors 
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Scheme 1 Synthesis of pyrrolo[2,3-d]pyrimidines 11and 13. 
Noell and Robins180 first reported the synthesis of pyrrolo[2,3-d]pyrimidines 11 and 13 by 
the reaction of chloroacetaldehyde 10 with 2-amino-6-alkylamino-4-hydroxypyrimidines 9 and 
6-amino-1,3-dimethyluracil 12 respectively (Scheme 1). 
 
Scheme 2 Synthesis of pyrrolo[2,3-d]pyrimidine 15 
Noell and Robins180 also reported the synthesis of pyrrolo[2,3-d]pyrimidine 15 from 2-
methylthio-6-amino-4-pyrimidone 14 and chloroacetaldehyde 10 (Scheme 2) 
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Scheme 3 Synthesis of pyrrolo[2,3-d] pyrimidines 20 
In 1998, Gibson et al.181 reported a synthetic approach to prepare 2-amino-4-
oxopyrrolo[2,3-d]pyrimidines 20 (Scheme 3). In this method, 2,6-diamino-4-hydroxypyrimidine 
16 was reacted with a biselectrophile, an oxime 17, in the presence of a weak base (sodium 
carbonate, sodium acetate, or triethylamine) to afford the C-5 alkylated pyrimidine derivatives 19. 
No side products resulting from substitution at any other position were isolated. Cyclization of 
pyrimidine derivatives 19 at 120 °C under acid-catalyzed transoximation with benzaldehyde or  
acetaldehyde afforded substituted pyrrolo[2,3-d]pyrimidines 20. 
 
Scheme 4 Synthesis of furo[2,3-d]pyrimidines 22 and pyrrolo[2,3-d]pyrimidines 23. 
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In 1973, Fumio et al.182 reported that the reaction of 6-amino-1,3-dimethyluracil 12 with 
phenacyl bromides 21 in DMF afforded 1,3-dimethyl-6-phenylpyrrolo[2,3-d]pyrimidines 23 in 69-
74% yields (Scheme 4). The reaction of 12 and 21 in acetic acid afforded the isomeric 1,3-
dimethyl-5-phenylfuro[2,3-d]pyrimidine-2,4(1H,3H)-diones 22 as a byproduct in addition to 23. 
 
Scheme 5 Synthesis of pyrrolo[2,3-d] pyrimidines 27. 
Davoll and coworker183 reported the synthesis of various pyrrolo[2,3-d]pyrimidines 27 
(Scheme 5) by an acid mediated cyclization of suitable pyrimidine 5-acetone or acetaldehyde 
side-chains 26 onto the neighboring amino group.  The pyrimidines were in turn obtained from 
the acetals ethyl(2,2-diethoxyethyl)acetate 24, or 2,2-diethoxyethylmalonodinitrile, or their ketal 
derivatives respectively and cyclization with guanidine, urea or thiourea. 
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Scheme 6 Synthesis of pyrrolo[2,3-d]pyrimidines 29 and furo[2,3-d]pyrimidines 30. 
Secrist and Liu184 provided a detailed study of the reaction of 2,6-diamino-4- 
hydroxypyrimidine 16 with various -halo aldehydes and ketones (Scheme 6). They reported that 
the cyclization occurred via two different route to produce either the pyrrolo[2,3-d]pyrimidine 
and/or the furo[2,3-d]pyrimidine. Thus -halo ketones, chloroacetone 10 and 3-bromo-2-butanone 
28, afforded both the furo[2,3-d]pyrimidine 30 and the pyrrolo[2,3-d]pyrimidine 29, whereas 16 
afforded only the pyrrolo[2,3-d]pyrimidine 30 on reaction with 28. It was concluded that a critical 
electron density is necessary at the C5 of the pyrimidine nucleus for it to react with the -carbon 
atom of the -halo aldehydes or ketones to afford exclusively pyrrolo[2,3-d]pyrimidines. 
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Scheme 7 Synthesis of pyrrolo[2,3-d]pyrimidines 34. 
Seela and Luepke185 first reported the synthesis of 6-substituted 2-amino-3,7-
dihydropyrrolo[2,3-d]pyrimidin-4-one 34 from 1,3-dioxolane-2-propanoic acid 33, α-cyano-2-
methyl-ethyl ester 31 and guanidine 32 (Scheme 7).  
 
Gibson et al.186 also reported the synthesis of 5,6-disubstituted-pyrrolo[2,3-d]pyrimidine. 
2-Chloro-2-cyanoethanal 36 was reacted with 35 to afford exclusively the 7-cyano-7-deazaguanine 
37. Substituents at C-5 and C-6 were obtained by brominating the primary deazaguanine 37 with 
N-bromosuccinimide in DMF to afford the 7-cyano-8-bromo derivative 39. These transformations 
establish methods for the synthesis of a wide range of 5,6-disubstituted pyrrolo[2,3-d]pyrimidine. 
Scheme 8. Synthesis of 5,6-disubstituted pyrrolo[2,3-d]pyrimidine 39. 
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Scheme 9 Synthesis of 2-amino-4-methyl pyrrolo[2,3-d]pyrimidine 45. 
In 2000, Gangjee, et al.,187 reported the synthesis of 2-amino-4-methylpyrrolo[2,3- 
d]pyrimidine 45 (Scheme 9) via a novel ring closure method. The synthesis started with 
condensation of 2-acetylbutyrolactone 40 with guanidine carbonate 32 to afford the substituted 
pyrimidine 41. Chlorination with POCl3 provided the dichloro compound 42 which was in turn 
condensed with benzylamine to afford 2-amino-4-methyl-7-(N-benzyl)piperidinyl[2,3-
d]pyrimidine 43. Oxidative aromatization of this compound with MnO2 provided the N7-
benzylated compound 44. Compound 45 was obtained following debenzylation of 44 with metallic 
sodium in ammonia. 
In 2001, Gangjee, et al.,188 reported the synthesis of 2-(2-amino-4-oxo- 4,7-dihydro-1H-
pyrrolo[2,3-d]pyrimidin-6-yl)acetic acid 47 from the condensation of 2,6-diaminopyrimidin-
4(1H)-one 16 with ethyl 4-chloro-3-oxobutanoate 46 in the presence of sodium acetate (Scheme 
10). 
In another report of 2001, Gangjee, et al., also reported the synthesis of 2-amino-4-oxo-
4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 49 (Scheme 11) from the condensation  
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of compound 16 with 2-chloro-3-oxopropanenitrile 48 under basic conditions.189 
 
Scheme 10 Synthesis of 2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d] pyrimidin-6- 
yl)acetic acid 47. 
 
Scheme 11 Synthesis of 2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile 
49. 
In 1991, Miwa and coworkers190 reported a series of 2,4-diamino-5-arylalkyl substituted 
classical pyrrolo[2,3-d]pyrimidine antifolates. In this synthetic approach (Scheme 12), the ring 
system was constructed by the spontaneous lactam formation of the tert-butyl ester of (2,4,6-
triamino-pyrimidin-5-yl)-acetic acid which was in turn generated in situ by the condensation of 
guanidine 32 and the malonodinitrile derivative 51. The resulting lactam 52 was subjected to 
borane reduction to afford the pyrrolo[2,3-d] pyrimidine intermediate 54 along with its 5,6-dihydro 
analog 53, which were separated by flash chromatography in 45% and 46% yields, respectively. 
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Scheme 12 Synthesis of pyrrolo[2,3-d]pyrimidine 54. 
Taylor et al.191reported a novel synthesis of PMX (Scheme 13) which involved the 
spontaneous cyclization of 6-amino-5-pyrimidylacetaldehydes 58 which in turn was generated 
utilizing the Nef reaction with compound 58 onto the adjacent amino group. 2,6-Diamino-4-oxo-
pyrimidine, 16 was known to form Michael adducts at its unsubstituted C-5 position.192-196 The 
synthesis of 58 thus involved a Michael addition reaction between the Michael acceptor 56 and 
compound 16. The Michael acceptor 56 was in turn synthesized in three steps that involved a 
palladium-catalyzed cross-coupling197 between methyl 4-iodobenzoate 56 and allyl alcohol, aldol 
condensation with nitromethane followed by dehydration with methanesulfonyl chloride in the 
presence of triethylamine.198 As expected, the condensation between 56 and 16 afforded the nitro 
derivative 57 in high yield. Compound 58 was converted to 4-[2-(2-amino-4-oxo-7H-pyrrolo[2,3-
d]pyrimidin-5-yl]ethylbenzoic acid 59 by the Nef reaction in a one-pot, five-step procedure. 
Conversion of acid 59 to PMX involved standard peptide coupling with diethyl L-glutamate using 
2-chloro-4,6-dimethoxy-1,3,5-triazine as the coupling agent in presence of N-methylmorpholine 
and final saponification.    
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Scheme 13 Synthesis of pyrrolo[2,3-d]pyrimidine 59 from 6-amino-5-pyrimidylacetalde-hydes 58.
 
Scheme 14 Synthesis of PMX from α-bromo aldehyde 64. 
Barnett and coworkers also reported199 in 1999 a practical synthesis of PMX (Scheme 14) 
which involved the cyclization of 2-bromo-4-arylbutanal 63 with 2,4-diamino-6-oxo-pyrimidine 
16 regioselectively provided 5-substituted pyrrolo[2,3-d]pyrimidine 64 as shown in Scheme 14. 
The key intermediate α-bromo aldehyde 63 was synthesized from aryl bromide 60 and alkyne 61 
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with Sonogashira coupling followed by reduction of the triple bond, oxidation to aldehyde and 
corresponding bromination of the aldehyde 62. 
 
Scheme 15 Synthesis of pyrrolo[2,3-d]pyrimidines 71. 
Legraverend and coworkers200 reported the synthesis of pyrrolo[2,3-d]pyrimidines 71 from 
2-amino-4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine 68 (Scheme 15). Thus, 5-allyl-2-amino-
4,6-dihydroxypyrimidine 65, prepared by the reaction of guanidine hydrochloride with diethyl 
allylmalonate, was converted to the 4,6-dichloro derivative 66 by treatment with POCl3, and 
diethylaniline in the presence of PCl5. The (2-amino-4,6-dichloropyrimidin-5-yl)acetaldehyde 67 
was obtained from 66 by ozonolysis of the allyl group (Scheme 15). The diethylacetal derivative 
69 of 68 was prepared by using standard methods. The acetal 69 was cyclized to 2-amino-4-chloro-
7-alkyl-7H-pyrrolo-[2,3-d]pyrimidine 70 by treatment with dilute aqueous HCl at room 
temperature. Compound 71 was then obtained by hydrolysis of the 4-chloro group of 70 using 1 
N HCl at 100 °C. 
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Kondo et al.201 reported the synthesis of 4-methyl pyrrolo[2,3-d]pyrimidine 74 via a 
palladium(0) catalyzed cross-coupling of terminal acetylenes 73 with N-(5-halo-4-
pyrimidinyl)methane sulfonamides 72 (Scheme 16). 
 
Scheme 16 Synthesis of 4-methyl pyrrolo[2,3-d]pyrimidines 74. 
In the same report, Kondo and coworkers201 also reported the synthesis of 2,4-dimethyl 
pyrrolo[2,3-d]pyrimidine 80 via a photoinduced or thermal cyclization of 4-azidopyrimidines 79 
containing an olefinic functionality at the 5-position (Scheme 17). Intermediates 79 were obtained 
by a palladium catalyzed cross-coupling between the 5-iodopyrimidine 75 and appropriate 
stannanes 76, followed by nucleophilic displacement of the 4-chloro in pyrimidine 78 in the 
presence of sodium azide. 
 
Scheme 17 Synthesis of 2,4-dimethyl pyrrolo[2,3-d]pyrimidines 80 
Sakamoto and coworkers202 reported in 1993 the synthesis of pyrrolo[2,3-d]pyrimidines 84 
by utilizing an intramolecular cyclization of protected 5-acetaldehyde pyrimidines 83 (Scheme 18). 
Compounds 83 were synthesized by palladium (0) catalyzed coupling of the appropriate 2,4-
disubstituted-5-bromo-6-acetamido pyrimidine 81 with (Z)-1-ethoxy-2-(tributylstannyl)ethane 82. 
 - 56 - 
The same methodology was also applicable for the synthesis of pyrrolo[3,2-d]pyrimidines, except 
that, 5-acetylamino-4-iodopyrimidine was used as the starting material. 
 
Scheme 18 Synthesis of pyrrolo[2,3-d]pyrimidines 84. 
Wright, et al.203 reported acid-catalyzed (Fisher indole cyclization) cyclization of 6-
(phenylhydrazino) uracils 86 to 9H-pyrimido[4,5-b]indole-2,4-diones 85. Several authors have 
employed the Fischer indole cyclization of 4-pyrimidinylhydrazones 87 (Scheme 19) to afford the 
pyrrolo[2,3-d]pyrimidine ring system 88.204-208The applicability of the Fischer-indole cyclization 
to the synthesis of pyrrolo[2,3-d]pyrimidines, however is limited by the high reaction temperatures 
and the steric constraints for the [3,3] sigmatropic rearrangement involved in the mechanism.  
 
Scheme 19. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization. 
Gangjee, et al.209 reported the synthesis of 2-amino-4-methylpyrrolo[2,3-d]pyrimidine. 
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Compound 89 (Scheme 20) and guanidine carbonate were refluxed with absolute ethanol in the 
presence of triethylamine or sodium methoxide to afford 90. Compound 90 was converted to 91 
by refluxing with phosphorus oxychloride. Condensation of benzylamine with 91 in the presence 
of triethylamine under reflux in n-BuOH afforded the bicyclic compound 92. Compound 92 was 
oxides to aromatic compound 93 using MnO2. Sodium in liquid ammonium at -78 °C afforded 94. 
 
1.2 From Pyrroles precursors 
in 1965, Taylor, et al.210 reported the synthesis of 4-amino-5-cyano-pyrrolo[2,3-
d]pyrimidine 100 (Scheme 21) starting from the tetracyanoethylene 95 via 2-mercapto-3,4-
dicyano-5-aminopyrrole 97.211 Reaction of 98 with triethylorthoformate followed by ammonia 
results in the formation of a formamidine intermediate which then cyclizes to 99. The mercapto 
group of 99 could be removed by Raney nickel (RaNi) to afford 100. Formamidine acetate 98 also 
condensed with 97 to give 99 but in lower yields. 
Scheme 20. Synthesis of pyrrolo[2,3-d]pyrimidines 94 
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Scheme 21 Synthesis of 4-amino-5-cyanopyrrolo[2,3-d]pyrimidine 100. 
 
Scheme 22 Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 105 
In the same report, Taylor, et al.210 synthesized 4-amino-5-methyl-pyrrolo[2,3-
d]pyrimidine 105 (Scheme 22) from 2-amino-3-cyano-5-substituted pyrroles 104 which in turn 
were obtained from malonodinitrile 103 and the appropriate -aminoketones 101. Treatment of 
pyrrole 104 with triethylorthoformate followed by ammonia resulted in the imidine intermediates 
104 which underwent cyclization with sodium methoxide in pyridine to afford the pyrrolo[2,3-
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d]pyrimidine 105. The fact that pyrroles 103, did not cyclize to pyrrolo[2,3-d]pyrimidine 105 in 
ethanolic ammonia was attributed to the absence of the second nitrile group in the pyrrole 103.    
Tolman and coworkers211 reported the synthesis of pyrrolo[2,3-d]pyrimidine 107 by 
cyclization of 2-amino-5-bromo-3,4-dicyanopyrrole 106 with formamidine acetate (Scheme 23). 
Ramasamy and coworkers212 have also utilized the pyrrole 106 to form the pyrrolo[2,3-
d]pyrimidine ring system for use in nucleoside synthesis. The versatility of the pyrrole 106 
prompted Swayze et al213 to synthesize it in an efficient one-step reaction from tetracyanoethylene 
95. On controlled addition of HBr in acetic acid 95 undergoes an intramolecular self-condensation 
to afford 106.  
 
Scheme 23 Synthesis of 5,6-disubstitutedpyrrolo[2,3-d]pyrimidine 107 
 
Scheme 24 Synthesis of 2,5,6-trimethyl pyrrolo[2,3-d]pyrimidine 111 
Eger and coworkers214,215reported the synthesis of 2,5,6-trimethylpyrrolo[2,3-d]pyrimidine 
111 (Scheme 24) from 1-(1-phenylethyl)-2-amino-3-cyano-4,5-dimethylpyrrole 110 by heating 
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with a mixture of acetonitrile and sodium methoxide. The pyrrole 110 was in turn obtained by 
cyclocondensation of 3-hydroxy-2-butanone 108, 1-phenyl-ethylamine 109 and malonodinitrile 
102. 
Chen, et al.216 reported an efficient synthesis of pyrrolo[2,3-d]pyrimidine 118 (Scheme 25). 
Acetone 112 was condensed with malonodinitrile 102 to afford 113. Bromination of 113 using 
NBS and benzoyl peroxide in chloroform afforded 114. Cyclization of 114 with aryl amine 115 
afforded the substituted pyrrole intermediate 116. Compound 116 was then elaborated to the 
pyrrolo[2,3-d]pyrimidine 118. 
 
Scheme 25 Synthesis of 2,5,-dimethyl-N7-substitutedpyrrolo[2,3-d]pyrimidine 118. 
Barnett, et al.217 reported the synthesis of a 2-amino-4-oxo-5,6-dihydropyrrolo[2,3-
d]pyrimidine 123 via a guanidine cyclization of a preformed 3-carbethoxy-2-thiopyrrolidine 
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intermediate 121 as the key step (Scheme 26). This intermediate was in turn prepared in several 
steps from 4-propionaldehyde benzoic acid tert-butyl ester 120. Compound 122 was oxidized to 
the pyrrolo[2,3-d]pyrimidine intermediate 123, 123 which was then elaborated to PMX in several 
steps. 
 
Scheme 26 Synthesis of pyrrolo[2,3-d]pyrimidine 123. 
Taylor and coworkers218 reported the synthesis of a pyrrolo[2,3-d]pyrimidine analog of 
PMX by a novel route (Scheme 27). A manganic triacetate dihydrate mediated radical cyclization 
of racemic methyl N-crotyl-N-[1-(3,4-phenyl)-eth-1-yl)malonamide 128, afforded a 
diastereomeric mixture of the 3-carbomethoxy-2-pyrrolidinone 129. Compound 128 was in turn 
obtained by alkylation of racemic 1-(3,4-dimethoxy-phenyl)-ethylamine 124 with crotyl bromide 
132 followed by a DMAP catalyzed acylation with methyl malonyl chloride 127. The 
pyrrolidinone 129 was converted to the thiolactam 130 with P2S5 followed by cyclocondensation 
with guanidine to afford the N7-protected 5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine131. 
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Palladium catalyzed cross-coupling with diethyl-4-iodobenzoyl-L-glutamate fortuitously afforded 
the ethano-bridged derivatives, and not the expected vinyl-bridged derivatives, by double bond 
migration. This compound was then elaborated to analogs of PMX. 
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Scheme 27  Synthesis of N7-substituted analogs of PMX 131. 
Pedersen and coworkers219 reported the synthesis of 2,5-dimethyl pyrrolo[2,3-d]pyrimidine 
136 (Scheme 28) from 2-acetylamino-3-cyano-4-methylpyrrole 135 by heating with 85% 
phosphoric acid. The pyrrole 135 was in turn obtained by acetylation of 2-amino-3-cyano-4-
methylpyrrole 134 using acetic anhydride. Cyclocondensation of 132 or 133 with malonodinitrile 
102 using sodium hydroxide afforded the precursor pyrrole 134.220,221 
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Scheme 28 Synthesis of 2,5-dimethylpyrrolo[2,3-d]pyrimidine 136. 
In 2005, Bookser and coworkers222 reported the synthesis of pyrrolo[2,3- 
d]pyrimidine 137 (Scheme 29) via the condensation between substituted pyrrole 138 and 
triethylorthoformate 139 under acidic conditions. 
 
Scheme 29 Synthesis of 5-substituted 2-des-4-oxo-pyrrolo[2,3-d]pyrimidine 139. 
1.3 From Furans precursors 
A general method to 2,5,6-trisubstituted-4-amino-pyrrolo[2,3-d]pyrimidines 143 was 
reported by Taylor and coworkers223 (Scheme 30). Condensation of appropriate -hydroxyketones 
140 with malonodinitrile 102 afforded the corresponding 2-amino-3-cyanofurans 141 which on 
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cyclization with amidines 142 afforded the corresponding pyrrolo[2,3-d]pyrimidines 143 by an 
unexpected ring transformation/ring annulation sequence. 
 
Scheme 30 Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 143. 
2. Sonogashira coupling in antifolate synthesis 
 
Scheme 31 A general transformation of Sonogashira coupling.224, 225 
In 1975, Sonogashira and coworkers226 reported the synthesis of symmetrically substituted 
alkynes via a coupling reaction between acetylene gas and aryl iodides or vinyl bromides in the 
presence of catalytic amounts of Pd(PPh3)Cl2 and CuI under mild conditions (Scheme 31). Thus, 
the copper-palladium catalyzed coupling of terminal alkynes with aryl and vinyl halides to give 
enynes is named the Sonogashira crosscoupling. Typically, two catalysts, a zerovalent palladium 
complex and a halide salt of copper (I), are necessary for the reaction. Copper (I) salts, such as 
copper (I) iodide, react with the terminal alkyne and produce a copper (I) acetylide, which acts as 
an activated species to increase the rate of the coupling reactions.224 However, the copper-free 
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Sonogashira coupling of aryl iodides with terminal acetylenes has been developed recently.227-229 
The Sonogashira coupling reaction also requires a base to neutralize the hydrogen halide produced 
as the byproduct of this coupling reaction. The reactivity order of the aryl and vinyl halides is as: 
I ≈ OTf > Br >> Cl.224, 225 
Sonogashira coupling is believed to involve oxidative addition-reductive 
elimination pathway (Scheme 32), although the mechanism is not clearly understood. 
 
Scheme 32 Mechanism of Sonogashira cross-coupling.230 
Gangjee and coworkers reported231 in 2007 the synthesis of N-(7-benzyl-4-methyl-5- 
(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 146 from N-(7-benzyl-
5-iodo-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 144 and phenyl- 
acetylene 145 via a Sonogashira cross-coupling in the presence of tetrakis (triphenylphosphine) 
palladium(0) and CuI as catalysts in dichloromethane (Scheme 33). 
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Scheme 33 Synthesis of pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 146. 
In 2010, Wang, et al.101 reported the synthesis of classical 2-amino-4- 
oxo-6-substituted-pyrrolo[2,3-d]-pyrimidines 147a-c (Scheme 34) from terminal alkynes 
149a-c and thiophenyl bromide 148 via a Sonogashira cross-coupling in the presence of 
tetrakis(triphenylphosphine)palladium(0) and CuI as catalysts in DMF. 
 
Scheme34 Synthesis of classical 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]-pyrimidines by 
Sonogashira coupling. 
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3. Heck coupling reaction in one-step aldehyde synthesis 
 
Scheme 35 General transformation of Heck coupling 
The Heck coupling reaction (also called the Mizoroki-Heck reaction) is the 
chemical reaction of an aryl or vinyl halide (or triflate) with an alkene and a base and 
palladium catalyst to form a substituted alkene.231,232 Together with the other palladium catalyzed 
cross-coupling reactions, this reaction is of great importance in modern organic 
synthesis as reviewed.233,234 Richard F. Heck was awarded the 2010 Nobel Prize in 
Chemistry for the discovery and development of this reaction. A General transformation 
of Heck coupling is shown in Scheme 35. 
 
Scheme 36  Heck coupling to synthesis aldehyde 152 and 153. 
In 1968, Heck disclosed the formation of 3-aryl aldehydes and ketones by the reaction of 
primary and secondary allylic alcohols  with aryl palladium complexes prepared in situ from 
arylmercuric chlorides or acetates and either an equimolecular amount of a palladium (II) salt, or 
a catalytic amount of this salt with an equimolecular amount of copper (II) chloride to regenerate 
the palladium after each reaction cycle.235 The teams of Heck and Chalk reported in 1976 
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simultaneously, but independently, a strong improvement in these couplings by disclosing that 
such compounds are also obtained using aryl iodides or bromides and, furthermore, with a catalytic 
amount of a palladium catalyst (Scheme 36). 236, As shown in Scheme 36, this reaction was carried 
out with catalytic amount of palladium acetate at 100 C in MeCN for 0.5 hour to afford aldehydes 
152 with good yield (60%) from phenyl iodide 150 and allyl alcohol 151. 236,237 This kind of Heck 
coupling reactions with unsaturated alcohols has been widely used to synthesize aldehydes from 
aryl halides in one step reaction. 
A possible mechanism of this Heck coupling to synthesize aldehydes from phenyl iodide 
and allyl alcohol was proposed in Scheme 37. 
 
Scheme 37 A proposed mechanism of Heck coupling to synthesis aldehyde  
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In 1989, Larock and coworkers239 reported an improved Heck coupling to synthesis 
aldehyde 152 with much better yield (90%) and lower temperature (70 C). (Scheme 38). This 
reaction between phenyl iodide 150 and allyl alcohol 151 is carried out successfully with assistance 
of palladium acetate as the key catalyst, Bu4NCl as the phase transfer catalyst and lithium acetate 
as the base. The easy availability of the reactants and catalysts plused the excellent yield and mild 
condition made this reaction very attractive to synthesize aldehydes as versatile intermediates.239-
241 However, the applications of this condition to heterocycle (such as thiophene and furan) halides 
other than phenyl halides were not reported, which highly limited the application of this reaction. 
239 
 
Scheme 38 Improved Heck coupling to synthesis aldehyde 152 
In 1977 Yoshida and coworkers reported242,243 a improved Heck coupling with thiophenyl 
bromides as shown in Scheme 39. 2-Bromothiophene 154 was alkylated in the 2 position by 
reaction with allylic alcohol 151 in the presence of Pd(OAc)2, NaI, NaHCO3 at 90 C under Ar2 
for 4 h gave 76% 3-(thiophen-2-yl)propanal 155. Although this is a successful example of Heck 
coupling with thiophenyl bromides, the drawbacks of this reaction are obvious: Only thiophenyl 
bromide without any substitutions on the thiophenyl ring was demonstrated; the reaction tolerance 
of different functional groups (e.g. –COOMe, -C=O) on the thiophene ring is not known; the 
reaction condition is pretty hash: high temperature (90 C) and argon protection needed. Due to its 
potential use in synthesis of classical antifolates and analogs such as RTX 
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and PMX,244 the mild conditioned and wide functional group tolerant Heck coupling of thiophenyl 
halides with allyl alcohols to afford aldehydes in one step is highly attractive. 
 
 
Scheme 39 Heck coupling with thiophenyl bromide 155 
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III. STATEMENT OF THE PROBLEM 
 
1. Methylated (S)-2-({5-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-
alkyl]-thiophene-2-carbonyl}-amino)-pentanedioic acids regio-isomers (156 -159) as 
GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC. 
 
Figure 16 The structures of classical 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine 
antifolates (7,8 and 156-159). 
Classical antifolates are all anions at physiologic pH, their ability to cross cell membranes 
by passive diffusion is limited, so specific transporters are required for folates. There are three 
major uptake systems involved in the transport of reduced folates system, all of which are shared 
by antifolates.2-4 Reduced folate carrier is the major transport system for folates in mammalian 
cells and tissues at physiologic pH.2-4 Folate receptor α and Folate receptor β are 
glycosylphosphatidylinositol-anchored proteins that transport folates by receptor-mediated 
endocytosis.5, 6 Finally, proton coupled folate transporter functions optimally at acidic pH.7, 8 
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Classical antifolates continue to serve a key role in the therapy of cancer as well as for 
other diseases.245 Clinically relevant antifolates (Figure 1) such as methotrexate (MTX), 
pemetrexed (PMX), and raltitrexed (RTX) are all substrates for the ubiquitously expressed reduced 
folate carrier (RFC), which is the major folate transport system in tissues and tumors. RFC levels 
and activities are important determinants of drug efficacy, and loss of RFC is a common mode of 
antifolate drug resistance.62 However, RFC is also expressed in normal tissues and it is likely to 
be a determinant of dose-limiting drug toxicity. Along with RFC, other folate membrane 
transporters are recognized as important for physiologic functions in relation to in vivo folate 
homeostasis and likely contribute to assorted clinical manifestations of folate deficiency. For 
instance, FRα is expressed in epithelial tissues such as the renal tubules and cerebral 
microvasculature where it is important in folate reabsorption and folate transport across the 
bloodbrain barrier, respectively.6 A folate-proton symporter, PCFT is expressed in the upper small 
intestine (e.g., jejunum) where it represents the primary mode of dietary folate absorption, and its 
loss is causal in the autosomal recessive folate-deficient condition termed hereditary folate 
malabsorption.4 
Interestingly, these non-RFC transport mechanisms have also attracted attention for their 
potentials in chemotherapy drug targeting, particularly for cancer, since FRs are expressed in a 
subset of malignancies such as ovarian and endometrial cancers,65 and PCFT is present at high 
levels in assorted solid tumors (including lung cancers, ovarian cancer, and hepatomas).246 Further, 
PCFT is maximally active at pHs approximating those attained in the solid tumor 
microenvironment.63 In response to the patterns of expression and function of FRs and PCFT in 
tumors and normal tissues, new cytotoxic agents are being developed, by virtue of their 
specificities for FRs and/or PCFT over RFC for selective tumor targeting.  
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Gangjee et al.101 recently reported 6-substituted classical pyrrolo[2,3-d]pyrimidines with 
varying lengths of the carbon bridge region as cytotoxic tumor-targeted antifolates (Table 3). 
Pyrrolo[2,3-d]pyrimidines and thieno[2,3-d]pyrimidines (Table 3) 
Structure Compound Biological Activity (IC50) Ref. 
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hGARFTase            6.8 nM 
KB                           1.9 nM 
IGROV1                  3.6 nM 
96 
HN
N S
O
H2N
N
H
O COOH
COOH
n
n = 2-8  
5  n = 3 
 
 
6  n = 4 
 
 
hGARFTase          13.8 nM        5 
KB                           23 nM 
IGROV1                  4.7 nM 
 
hGARFTase          13.3 nM     63 
KB                           4.9 nM 
IGROV1                  5.9 nM 
 
7  n = 3 
 
 
 
8  n = 4 
 
hGARFTase          0.69 nM 
KB                         0.26 nM 
IGROV1                0.55 nM 
 
hGARFTase          1.96 nM 
KB                         0.55 nM 
IGROV1                0.97 nM 
 
These compounds were characterized by selective transport via FRα, FRβ and PCFT over 
RFC. Three- and four-carbon bridge analogs were most active toward FR-expressing human 
tumors and cytotoxicity was primarily due to the potent inhibition of GARFTase, the first folate-
dependent reaction in de novo purine nucleotide biosynthesis. The three-carbon pyrrolo[2,3-
d]pyrimidine derivative, 7 was subsequently reported122 to also be a substrate for PCFT, thus 
providing an additional selective means of tumor targeting. Further structural optimization of 
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compounds such as 7, for improved drug efficacy due to selective cellular uptake by non-RFC 
transport mechanisms, and as a sbustrate for folylpolyglutamate synthase for polyglutamylation 
and binding to GARFTase to inhibit purine nucleotide biosynthesis, requires a systematic variation 
of individual structural features. For example, although compound 7 is highly potent, its selective 
tumor-targeting via FRs and PCFT is lower than compound 8 (Table 3). 
Thus, it is of interest to further explore the structure−activity relationships (SAR) for this 
series to determine if absolute selectivity over RFC along with high potency for FRα, FRβ, and/or 
PCFT expressing cells over RFC would be possible.  In this study, we consider the SAR for cellular 
uptake and inhibition of cell proliferation for the pyrrolo[2,3-d]pyrimidine scaffold of 7 and 8 in 
which the thienoyl ring was replaced by methylated thienoyl regioisomers. Our goal was to explore 
the SAR for novel 6-substituted pyrrolo[2,3-d]pyrimidine methylated thienoyl antifolates related 
to 7 and 8 (Figure 16), the most potent compounds of our series for inhibiting proliferation of FRα- 
and PCFT-expressing cells with substantially reduced inhibitory effects toward RFC expressing 
cells. Thus, 6-substituted pyrrolo[2,3-d]pyrimidine classical antifolates with methylated thienoyl 
regioisomers in the side chain 156-159 (Figure 20) were designed and synthesized to evaluate the 
effect of methylation in the side chain on transport by RFC, FR and PCFT and as inhibitors of 
proliferation of human KB tumor cells (IC50) via inhibition of GARFTase. Methylated thienoyl 
regioisomers analogues could provide metabolic stability and perhaps alter the conformation of 
the molecule to allow FRα, FRβ, PCFT, and GARFTase and/or AICARFTase for better binding at 
the required active sites. 
1.1 Molecular Modeling Studies 
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Figure 17. (A) Superimposition of docked poses of 7(red) and 156 (green) in FRα (PDB:  
5IZQ).
12
 
 
 
 
 
 
 
 
 
 
Figure 17. (B) Superimposition of docked poses of 7(green) and 157 (red) in FRα (PDB: 
5IZQ).
12
 Modeled using MOE 2014.08. 
A 
B 
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Figure 18. (A) Superimposition of docked poses of 7 (green) and 156 (red) in GARFTase (PDB: 
4ZZ1).
12
 
 
Figure 18. (B) Superimposition of docked poses of 7 (green) and 157 (red) in GARFTase (PDB: 
4ZZ1).14 Modeled using MOE 2014.08.
13
                                                     
Figures 17 and 18 show the docked poses of methylated thienoyl regioisomers 156 and 157 
in FRα (PDB:  5IZQ) and GARFTase (PDB ID: 4ZZ1), respectively. In FRα and GARFTase, 156 
A 
B 
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maintains the interaction patterns of the bicyclic scaffold and L-glutamate side chain moiety as 7. 
The meta-methyl group in compound 157 decreases the distance (6.94 Å) between the scaffold 
and the L-glutamate side chain moiety, when compareing with that of 7 (8.15 Å), resulting in the 
loss of the interaction pattern of the L-glutamate side chain. In GARFTase, compound 157 with 
the methyl group shifts away from the scaffold binding region, owing to the change in its linker 
conformation (due to the steric clash with the methyl group). This results in a loss of the interaction 
pattern of the bicyclic scaffold, when compared to the parent 7. Though the molecular modeling 
of 157 predicts a lower activity for FRα, modeling in RFC and PCFT is not currently possible due 
to an absence of crystal structures. Thus, it was of interest to determine the effects of methylation 
on the thiophene ring to RFC and PCFT activity.  
Figures 17 and 18 show the docked poses of methylated thienoyl regioisomers 156 and 157 
in FRα (PDB:  5IZQ) and GARFTase (PDB ID: 4ZZ1), respectively. In FRα and GARFTase, 156 
maintains the interaction patterns of the bicyclic scaffold and L-glutamate side chain moiety as 7. 
The meta-methyl group in compound 157 decreases the distance (6.94 Å) between the scaffold 
and the L-glutamate side chain moiety when compared with that of 7 (8.15 Å), resulting in the loss 
of the interaction pattern of the L-glutamate side chain. In GARFTase, compound 157 with the 
methyl group shifts away from the scaffold binding region, owing to the change in its linker 
conformation (due to the steric clash with the methyl group). This results in a loss of the interaction 
pattern of the bicyclic scaffold, when compared to the parent 7. Though the molecular modeling 
of 157 predicts a lower activity for FRα, modeling in RFC and PCFT is not currently possible due 
to an abance of crystal structures. Thus, it was of interest to determine the effects of methylation 
on the thiophene ring to RFC and PCFT activity.  
Figures 19 and 20 show the docked poses of methylated thienoyl regioisomers 158 and 
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159 in FRα (PDB:  5IZQ) and GARFTase (PDB ID: 4ZZ1), respectively. In FRα, 158, 159 retain 
the interaction patterns of the bicyclic scaffold but loss of the interaction patterns of the L-
glutamate side chain moiety as 8. However, in GARFTase, both 158 and 159 overlap with 8 and 
maintain the interaction patterns of the bicyclic scaffold and L-glutamate side chain moiety as 8. 
 
 
 
 
 
 
 
 
 
Figure 19. (A) Superimposition of docked poses of 8 (yellow) and 158 (purple) in FRα (PDB:  
5IZQ).
12
 
 
 
 
 
 
 
Figure 19. (B) Superimposition of docked poses of 8 (yellow) and 159 (blue) in FRα (PDB:  
5IZQ). 
B 
A 
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Figure 20. (A) Superimposition of docked poses of 8 (red) and 158 (green) in GARFTase (PDB: 
4ZZ1).
12
 
  
 
 
 
 
 
 
 
 
Figure 20. (B) Superimposition of docked poses of 8 (red) and 159 (yellow) in GARFTase (PDB: 
4ZZ1).14 Modeled using MOE 2014.08.
13
  
B 
A 
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2. 6-substituted pyrrolo[2,3-d]pyrimidine with three atom chain length having a nitrogen in the 
bridge and fluorinated benzoyl regioisomers as GARTFase inhibitors with selectivity for FRs 
and/or PCFT over RFC. 
 
Figure 21 6-substituted pyrrolo[2,3-d]pyrimidine with three atom chain length having nitrogen 
bridge and fluorinated benzoyl regioisomers compounds design. 
Gangjee et al.96 previously described novel 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl 
antifolates with selective cellular uptake by FRs and/or PCFT over RFC, resulting in potent 
inhibitory activity toward human tumor cells.96  The most active analog of this series, 3 included 
a 3-carbon bridge (Table 3), showed high level activity toward KB human tumors (IC50 = 1.7 nM)  
expressing FRα and PCFT.  Compound 4 has a 4-carbon atom bridge and showed better selectivity 
than 3 for both FR and PCFT over RFC.63 
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The natural substrate for GARFTase, N10-formyl tetrahydrofolate (10-CHOTHF, Figure 3), 
is a 6-substituted pteridine with a –CH2-N-2-atom bridge. The N10 a formyl (CHO) moiety forms 
a hydroxylated, tetrahedral intermediate prior to transfer of the formyl group.129 Thus, replacement 
of the benzylic CH2 of the 6-substituted pyrrolo[2,3-d] pyrimidine 3 (Table 3) with a NH would 
afford “mimics” of the natural substrate side chain with a three-atom rather than two-atom bridge. 
Gangjee et al.247 synthesized the 6-substituted three-atom bridged NH function as potent inhibitors 
of human GARFTase rather than as substrates. The X-ray crystal structures of 161 248with FRα 
and GARFTase showed that the bound conformations of 161 were different and required flexibility 
for attachment to both FRα and GARFTase. Compound 161 showed high potency against FRα and 
GARFTase, but its potency and selective tumor- targeting via PCFT is lower than 3. 
 Recently, Gangjee et al.249report that for 160 (Figure 21), fluorine incorporation on the 
aromatic group adjacent to the L-glutamate amide had better selectivity, as well as potency, toward 
FR- and PCFT-expressing CHO and KB cells than its des-fluorine compound 4 (Figure 21). We 
proposed that fluorine substitution could improve the selectivity in antifolates through electrostatic 
molecular interactions, such as those involving fluorine hydrogen bonding and dipole interactions. 
Thus, it is of interest to further explore the SAR for this series to determine if fluorinated benzoyl 
regioisomers 162 and 163 (Figure 21) could have absolute selectivity along with high potency for 
FRα, FRβ, and/or PCFT over RFC.  
2.1 Molecular Modeling  
The docked poses of 162 (Figure 22A, 23A) in FRα and GARFTase retain the hydrogen 
bonding and hydrophobic interactions seen in the docked pose of the lead compound 161. In 
addition, the fluorine meta to the L-glutamate side chain in 162 facilitated the interaction with the 
polar hydrophobic amino acid Phe 62 and results increased potency toward against FRα-expressing 
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cells. Comparing to the parent 162, fluorine ortho to the L-glutamate side chain in 163 (Figure 22B, 
23B)results in a loss of interaction patterns of the L-glutamate region in FRα and GARFTase, 
which causes a lower inhibitory activity toward cells expressing FRα. Alought the molecular 
modeling predicts lower activity for FRα, modeling in RFC and PCFT is not currently possible 
due to lack of crystal structures. Thus, it was of interest to determine the effects of fluorine on the 
benzyl ring in relation to RFC, FRs and PCFT anti-proliferative activities. 
 
 
        
 
 
 
Figure 22. (A) Superimposition of docked poses of 161 (red) and 162 (green) in FR(PDB:   
5IZQ).
247 
 
 
 
 
 
Figure 22. (B) Superimposition of docked poses of 161 (red) and 163 (green) in FR(PDB: 
5IZQ).
247
 Modeled using MOE 2014.08.
12 
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Figure 23. (A) Superimposition of docked poses of 161 (green) and 162 (red) in GARFTase (PDB: 
4ZZ1).
247
 
 
 
 
 
 
 
 
 
Figure 23. (B) Superimposition of docked poses of AGF161 (green) and 163 (red) in GARFTase 
3. 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2-
fluorobenzoyl)-L-glutamic acid 167 as GARFTase inhibitors with potential selectivity for 
FRs and/or PCFT over RFC 
B 
A 
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Figure 24 5-substituted pyrrolo[2,3-d]pyrimidine antifolates with three bridge carbons and 
fluorinated benzoyl ring compound 167 as antitumor agent.  
As mentioned above, pemetrexed (PMX) is clinically used for the treatment of 
mesothelioma and non–small cell lung cancer (NSCLC) and is currently being evaluated for the 
treatment of a variety of other solid tumors in the US.172 More recently, PMX has been approved 
in combination with cisplatin as a first-line treatment for patients with locally advanced or 
metastatic NSCLC other than squamous cell histology.174 PMX is a multitargeted antifolate that is 
protected to several folate metabolism enzymes: TS, DHFR, AICARFTase and GARFTase.174 
However, its potentional target is TS. PMX suffers from dose-limiting toxicity due to its transport 
by RFC which is ubiquitously expressed in normal cells.248 To determine if altering the length of 
the side chain of PMX would maintain the multitarget attributes of PMX and perhaps provide 
selectivity for FR over RFC, Gangjee et al.249synthesized and evaluated the one to six carbon chain 
homologs of PMX.  Compound 164 and 166 (Figure 24) the 4- and 3- carbon chain homologs of 
PMX, respectively have better KB cell inhibitiory potency than PMX. Compound 164 inhibits KB 
cells at an IC50 of 3.6 nM, about 20-fold greater than PMX. However, 164 and 166 have poor 
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PCFT inhibition potency and poor KB tumor cell inhibitiory potency. Recently, Gangjee et al.247 
reported that for 165 (Figure 24), with a fluorine in the benzene adjacent to the L-glutamate amide 
had better potency for PCFT and FRs, as well as better selectivity, than its des-fluoro 164 (Figure 
24). Based on this result, we designed and synthesized the fluorinated benzoyl analog 167 to 
evaluate the effect of fluorine in the side chain on transport by RFC, FR and PCFT, and as 
inhibitors of human KB tumor cells (IC50). 
4. 5-Substituted pyrrolo[2,3-d]pyrimidine with two- to- four- bridge carbons and  thienoyl 
regioisomers 172-174 in the side chain as GARFTase inhibitors with selectivity for FRs 
and/or PCFT over RFC. 
 
Figure 25 5-substituted pyrrolo[2,3-d]pyrimidine antifolates with two- to- four- bridge carbons 
and  thienoyl regioisomers in the side chain as antitumor agents.  
Gangjee and coworkers101 recently reported a series of 6-substituted pyrrolo[2,3-
d]pyrimidine thienoyl antifolates (Figure 25). The best characterized of this series, compound 8 
included a 4- carbon bridge and was selectively transported into cells by FRs and PCFT (but not 
RFC) whereupon it inhibited de novo purine biosynthesis at the level of GARFTase. Compound 8 
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was highly active toward both KB (IC50 = 3.17 nm) and IGROV1 (IC50 = 176 nm) tumors. In vivo 
in SCID mice with KB tumor xenograft, 8 was highly active against both early and advanced stage 
tumors. Based on the 5-substituted pyrrolo[2,3-d]pyrimidine structure of PMX and our results with 
the 6-substituted compound 8, it was of interest to synthesize 5-substituted pyrrolo[2,3-
d]pyrimidine thienoyl analogs with 2 to 4- carbon atoms in the bridge (169-171) as hybrid 
molecules of PMX and 8. These analogs were expected to afford the multi-targeted attributes of 
PMX, while preserving FRα and/or PCFT specificity of the 6-substituted analogs previously 
reported. However, 171 showed less activity against KB tumor cell, FRs and PCFT than 8. 
Knowing that compound 863 is an excellent lead analog for further structure optimization for 
inhibition of GARFTase and as for transport selectivity by FRs and/or hPCFT over RFC. 
Compound 168 was designed to probe the importance of the regio-positions of the 4-carbon bridge 
and the L-glutamate moiety on the side chain thienoyl ring of 8. The biological result showed that 
168 had 10-fold more FRα activity than 8. Based on this result, compounds 172-174 were designed 
to improve the potency and selectivity of 5-substituted pyrrolo[2,3-d]pyrimidine thienoyl 
antifolates against FRs, PCFT and KB tumor cells.  
 
 
 
 
IV. CHEMICAL DISCUSSION 
 
1. The synthesis of methylated (S)-2-({5-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-
pyrimidin-6-yl)-methyl]-thiophene-2-carbonyl}-amino)-pentanedioic acid isomers 156 and 
157. 
 - 87 - 
S Br
X
b
S
X
MeO
O
MeO
O
OH
S
X
MeO
O
OH
S
X
MeO
O
OH
O
d
S
X
MeO
O
Cl
O
S
X
MeO
O
O N2
S
X
MeO
O
O Br
HN
N NHH2N
O
a
c
e
f g
S
Y
COOR1
HN
N NHH2N
O S
Y O
NH
COOR2
COOR2
189 X = H, Y= CH3, R1 = CH3 (41%) over 4 steps
190 X = CH3, Y = H, R1 = CH3 (30%) over 4 steps
191 X = H, Y= CH3, R1 = H (95%)
192 X = CH3, Y = H, R1 = H (97%)
193 X = H, Y= CH3, R2 = C2H5 (53%)
194 X = CH3, Y = H, R2 = C2H5 (64%)
i
175 X = H, Y= CH3
176 X = CH3, Y = H
Y
177 X = H, Y= CH3 (73%)
178 X = CH3, Y = H (71%)
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179 X = H, Y= CH3 (84%)
180 X = CH3, Y = H (88%)
181 X = H, Y= CH3 (94%)
182 X = CH3, Y = H (83%)
Y Y
183 X = H, Y= CH3
184 X = CH3, Y = H
185 X = H, Y= CH3
186 X = CH3, Y = H
Y
187 X = H, Y= CH3
188 X = CH3, Y = H
Y
X
h
156 X = H, Y= CH3, R2 = H (75%)
157 X = CH3, Y = H, R2 = H (76%)
h
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Scheme 40a Synthesis of classical three carbon atoms side chain methylated thiophene 2-amino-
4-oxo-6-substitutedpyrrolo[2,3-d]pyrimidine isomers 156,157. 
a Conditions: (a) but-3-yn-ol, CuI, PdCl2, PPh3, Et3N, CH3CN, microwave,100 0C,10 min; 
(b)10% Pd/C, H2, 55 psi, MeOH, overnight; (c) H5IO6, pyridinium chlorochromate, 0 0C, 3h; (d) 
oxalyl chloride, CH2Cl2, reflux, 1h; (e) diazomethane, Et2O, RT, 1h; (f) HBr, reflux, 2h; (g) 2,6-
diamino-3H-pyrimidin-4-one, DMF, RT, 3 days; (h) i. 1 N NaOH, RT, overnight; ii. 1 N HCl; (i) 
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N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, RT, overnight. 
The synthesis of target compound 156 and 157 followed a modification of a reported 
procedure101 as shown in Scheme 40. A palladium-catalyzed Sonogashira coupling of 5-bromo-3-
methylthiophene-2-carboxylate 175 and 5-bromo-4-methylthiophene-2-carboxylate 176, with but-
3-yn-1-ol respectively, afforded butynyl alcohols 177, 178 (73%, 71%) respectively, which were 
catalytically hydrogenated to give the saturated alcohols 179, 180 respectively in quantitative yield. 
Subsequent oxidation of 179 and 180 using Jones reagent afforded the carboxylic acids 181, 182 
(94%, 83%) respectively, which were converted to the acid chlorides 183 and 184 and immediately 
reacted with diazomethane followed by 48% HBr to give the desired α-bromomethyl ketones 187 
and 188. Condensation of 2,6-diamino-3H-pyrimidin-4-one, with 187, 188 at room temperature 
for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines 189, 190 (41%, 
30%) respectively. Hydrolysis of 189 and 190 afforded the corresponding free acids 191, 192 (95%, 
97%). Subsequent coupling with L-glutamate diethyl ester using 2-chloro-4,6-dimethoxy-1,3,5-
triazine as the activating agent afforded the diesters 193, 194. Final saponification of the diesters 
gave the desired compounds 156 and157. 
In this study, one of the most important and difficult challenge is to characterize the 
stuructures of these two regioisomers, compound156 and 157. Although the starting materials for 
synthesis 156 and 157 are commercially available, it is still necessary to distinguish between 
regioisomer 5-bromo-3-methylthiophene-2-carboxylate 175 and 5-bromo-4-methylthiophene-2-
carboxylate 176 (Figure 26). 
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Figure 26 Structure of 5-bromo-3-methylthiophene-2-carboxylate 175 and 5-bromo-4-
methylthiophene-2-carboxylate 176 
Compound 175 and 176 have two electongeative founctional group are attached to the same 
position of thiophene ring. These two electron withdrawing groups, bromine and carboxylic ester, 
can affect chemical shift of the adjacent proton to be desheilded. The higher electonegativity 
difference between H and its surrounding atoms results a higher chemical shift. This is because 
the higher the electronegativity difference between H and another atom, the lower the electron 
density is around the H (proton), and thus the more deshielding the proton experiences. In fact, the 
electronegativity of the carboxylic ester is greater than bromine. Therefore, the proton ortho to the 
bromine should have a lower chemical shift than the proton ortho to the carboxylic ester. The 1H 
NMR data showed that the chemical shift of C3-H (δ 6.83 ppm) of 175 is less than the chemical 
shif of the C3-H (δ 7.56 ppm) of 176. The chemical shift of the methyl group of 175 is greater than 
the methyl group of 176. Based on this difference in 1H NMR chemical shifts in the thiophene ring, 
the structure of 175 and 176 can be assigned.  
In this study, the current synthetic method was optimized and simplified via synthetic steps, 
separation procedure, shorte the reaction time and increased yield. Firstly, optimization the 
reaction conditions of the palladium-catalyzed Sonogashira reaction. Without changing the 
reaction regents, a microwave reaction replaced the high temperature reflux reaction (80 0C, 6-8h) 
afforoded alcohols 177, 178 (73%, 71%) respectively. Comparing with the reflux condition, 
microwave reaction shortened the Sonogashira reaction from 8 hours to 10 minutes. Instead of 
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generation multiple spots on TLC, this microwave reaction generated one clear spot. Therefore, 
this microwave reaction significantly simplified the separation step and save cost of separation. In 
addition, the microwave reacrion increased the yield from 54%, 58% to 73%, 71% respectively. 
Since microwave reaction took 10 minutes to complete the Sonogashira coupling, it could be a 
potential methodology for scale-up synthesis.  
In the alcohol oxidation step, different reaction regents were selected to increase the yield 
and shorton the reaction time. Instead of chromium trioxide as the oxidation regents (CrO3, H2SO4, 
24h, rt), periodic acid with pyridinium chlorochromate (H5IO4, PCC, 3h, rt) was used to convert 
the alcohol to the carboxylic acids 181, 182 (94%, 83%) respectively. This optimization shortened 
the reaction time more than 21 hours and doubled the yield. 
For the synthesis of the key intermediate α-bromomethyl ketones 187 and 188 step, fresh 
diazomethane was used to convert acid chlorides 183 and 184 into the haloketones. Comparing 
with the equivalent reagent trimethylsilyldiazomethane, freshly produced diazomethane works 
much faster to generate the desired haloketone.The only limition of diazomethane is that it is 
hazardous on an industrial scale without special precautions. However, it is a popular methylating 
agent in the laboratory. It is universally used as a solution in diethyl ether and kept at lower 
temperature.  
2. The synthesis of methylated (S) -5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)butyl)thiophene-2-carbonyl)-L-glutamic acid isomers 158 and 159.  
 - 91 - 
 
Scheme 41a Synthesis of classical four carbon atoms side chain methylated thiophene2-amino-4-
oxo-6-substituted pyrrolo[2,3-d]pyrimidine isomers 158,159. 
a Conditions: (a) pent-4-yn-ol, CuI, PdCl2, PPh3, Et3N, CH3CN, microwave,100 0C,       
10 min; (b)10%Pd/C, H2, 55psi, MeOH, overnight; (c) H5IO6, pyridinium chlorochromate, 0 0C, 
3h; (d) oxalyl chloride, CH2Cl2, reflux, 1h; (e) diazomethane, Et2O, RT, 1h; (f) HBr, reflux, 2h; 
(g) 2,6-diamino-3H-pyrimidin-4-one, DMF, RT, 3days; (h) i. 1N NaOH, RT, overnight; ii. 1 N 
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HCl; (i) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, RT, overnight. 
The synthesis of target compound 158 and 159 followed a modification of a reported 
procedure101as shown in Scheme 41. A palladium-catalyzed Sonogashira coupling of methyl 5-
bromo-3-methylthiophene-2-carboxylate 175 and methyl 5-bromo-4-methylthiophene-2-
carboxylate 176, with pent-4-yn-ol, afforded butynyl alcohols 195, 196 (72%, 78%) respectively, 
which was catalytically hydrogenated to give the saturated alcohol 197, 198 in quantitative yield. 
Subsequent oxidation of 197 and 198 using Jones reagent afforded the carboxylic acid 199, 200 
(80%, 80%) respectively, which was converted to the acid chloride 201 and 202 and immediately 
reacted with diazomethane followed by 48% HBr to give the desired α-bromomethylketone203 
and 204 respectively. Condensation of 2,6-diamino-3H-pyrimidin-4-one, with 203, 204 at room 
temperature for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines 205, 
206 (38%, 33%) respectively. Hydrolysis of 205, 206 afforded the corresponding free acid 207, 
208 (81%, 87%) respectively. Subsequent coupling with L-glutamate diethyl ester using 2-chloro-
4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the diesters 209, 210 respectively. 
Final saponification of the diesters gave the desired compound 158 and 159. 
 
3 .The synthesis of (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-
fluorobenzoyl)-L-glutamic acid isomers 162 and 163.  
The retro synthetic route A was proposed as shown in Scheme 42. From route A (Scheme 
42), it was anticipatied that nucleophilic substitution of 217 and 218 would afford the ketone 216. 
Ketone 216 could then can be converted to the α-bromoketone compound 215. Sequential 
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condensation with 2,6-diamino-3H-pyrimidin-4-one 214, hydrolysis, L-glutamate peptide 
coupling, and saponification would afford the desired compound 213. 
 
Scheme 42. Retro synthetic route A. 
Synthesis of compounds 225 and 226 were attempted (Scheme 43). Compound 219 and 
220 were reacted with the α, β- unsaturated methyl ketone 217 to afford 221 and 222 respectivly. 
Compound 221, 222 reacted with 33% HBr in acetic acid and bromine afforded the α-bromoketo 
compounds 223, 224 respectivly. Condensation of 223, 224 with compound 214 failed to provide 
compounds 225, 226. TLC of the reaction shows multiple spots at Rf = 0.5 (5:1, Chloroform: 
Methanol), separation of these spot could not be achieved. This could be because of the instability 
of the α-bromomehtyl ketone in the presence of a secondary or tertiary nitrogen. Protection of the 
nitrogen was considered as the next strategy to obtain the target compounds. 
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Scheme 43. Condensation recation between 223, 224 and 214. 
The synthesis of target compound 162 and 163 followed a modification of a reported 
procedure291as shown in Scheme 44. Commercially available methyl 4-amino-3- fluorobenzoate 
219 and methyl 4-amino-2-fluorobenzoate 220 were reacted with methyl vinyl ketone through a 
Michael addition to afford the β-keto amines 221 and 222 respectively. Selective bromination of 
the α-carbon of 221 and 222 under acidic condition using 33% HBr in acetic acid/Br2 afforded the 
α-bromoketone 223 and 224. Trifluroacetic anhydride was converted without protection of the α-
bromoketones 223 and 224. Subsequently, the protected amine was reacted with 2,6-diamino-3H-
pyrimidin-4-one in DMF at room temperature for 3 days to afford the 2-amino-4-oxo-6-
substituted-pyrrolo[2,3-d] pyrimidines 227 and 228. Hydrolysis of 227 and 228 gave the 
corresponding free acids 229 and 230 respectively. Subsequent coupling with L-glutamate di- tert-
butyl ester using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the di-tert-
butyl esters 231 and 232 respectively. Deprotection of di-tert-butyl ester using trifluroacetic acid 
afforded the corresponding final compounds 162 and 163 respectively.   
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Scheme 44a Synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidine with a three atom chain 
length with a  nitrogen atom and fluorinated benzoyl regioisomers 162 and 163. 
a Conditions: (a) but-3-en-2-one, ethanol, reflux, 5 h;  (b) 33% HBr in CH3COOH, Br2, rt, 
2.5 h; (c) (CF3CO)2O, rt, overnight; (d) 2,6-diaminopyrimidin-4(3H)-one, DMF, rt, 3 d; (e) 1N 
NaOH, rt, 10 h; (f) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate 
diethyl ester hydrochloride, DMF, RT, overnight; (g) CF3COOH, CH2Cl2, rt, 2 h 
4. The synthesis of (S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)-2-fluorobenzoyl)-L-glutamic acid 167. 
 - 96 - 
 
Scheme 45.  Synthetic route A of 167. 
The retro synthetic route A was proposed as shown in Scheme 45. The proposed synthesis 
followed a modification of a reported procedure.101A palladium-catalyzed Sonogashira coupling 
of methyl 4-bromo-3-fluorobenzoate 233 with but-3-yn-1-ol 234, afforded alcohol 235, which was 
catalytically hydrogenated to give the saturated alcohol 236. Subsequent oxidation of 236 afforded 
the aldehyde 237. However, over three steps, the total yield of the aldehyde was less than 20%. 
Starting from the Sonogashira coupling to afford aldehyde 237, usually takes three steps and more 
than three days. To improve the yield and simplify the reaction, the synthesis of the aldehyde 237 
was optimized by designing a Heck coupling instead of the Sonogashira coupling. Another 
methodology optimization in the synthesis of 167 is to optimize the synthsis step of the key 
intermediate α-bromoaldehyde 238. Bromine and 1,4-dioxane as a mild brominating agent was 
used to convert the aldehyde 237 into the α-bromoaldehyde 238 (82%). Compared with other 
brominating agents, such as 5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione, this 
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dioxanedibromide shortened the bromination reaction from 36 hours to 3 hours and increased the 
yield from 30% to 82%. 
The synthesis of target compound 167 followed a modidification of a reported 
procedure290as shown in Scheme 46. A palladium-catalyzed Heck coupling reaction of 233 with 
pent-4-en-1-ol 234 in DMF 85 0C afforded the aldehyde 237. Reaction of 237 with bromine in 
dioxane at 0 0C afforded the corresponding α-bromoaldehyde 238. The α-bromoaldehyde 238 
reacted with 2,6-diamino-3H-pyrimidin-4-one in DMF at 45 0C in the presence of sodium acetate 
to afford 5-substituted-pyrrolo[2,3-d]pyrimidine 239. Subsequent hydrolysis of 239 with 1 N 
NaOH followed by coupling with L-glutamate dimethyl ester using N-methyl morpholine and 2,4-
dimethoxy-6-chlorotriazine as the activating agents afforded the diester 241. Final saponification 
of the diester with 1 N NaOH gave the target compound 167. 
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Scheme 46a Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidine antifolates with three 
bridge carbons and fluorinated benzoyl 167. 
a Conditions: (a) pent-4-en-1-ol, Pd(OAc)2, n-Bu4NCl, LiOAc, LiCl, ACN, 85 0C, 4h; (b) 
Br2, Dioxane, 3h, 0C; (c) 2,6-diamino-3H-pyrimidin-4-one, CH3COONa, H2O/MeOH (1:1), 45 
0C, 4h; (d) i. 1N NaOH, RT, overnight; ii. 1 N HCl; (e) N-methylmorpholine, 2-chloro-4,6-
dimethoxy-1,3,5-triazine, L-glutamate diethyl ester hydrochloride, DMF, RT, overnight. (d) i. 1N 
NaOH, RT, overnight; ii. 1 N HCl; 
5. The synthesis of (S)-5-substituted pyrrolo[2,3-d]pyrimidine with two- to- four bridge carbons 
and  thienoyl regioisomers 172-174. 
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Scheme 47a  Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 172-174. 
a Conditions: (a) 3-buten-1-ol, 5-hexen-1-ol, pent-4-en-1-ol, Pd(OAc)2, n-Bu4NCl, LiOAc, 
LiCl, ACN, 85 0C, 4h; (b) 5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione, 2N HCl, 24 h, RT; 
(c) 2,6-diamino-3H-pyrimidin-4-one, CH3COONa, H2O/MeOH (1:1), 45 0C, 4h; (d) i. 1N NaOH, 
RT, overnight; ii. 1 N HCl; (e) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-
glutamate diethyl ester hydrochloride, DMF, RT, overnight. (d) i. 1N NaOH, RT, overnight; ii. 1 
N HCl; 
The synthesis of target compounds 172-174 followed a modidication of a reported 
procedure290 as shown in Scheme 47. A palladium-catalyzed Heck coupling reaction of methyl 4-
bromothiophene-2-carboxylate 242 with 3-buten-1-ol, 5-hexen-1-ol, pent-4-en-1-ol in DMF 85 0C 
afforded the aldehydes 243-245 respectively. Compounds 243-245 reacted with 5,5- dibromo-2,2-
dimethyl-4,6-dioxo-1,3-dioxane at room temperature afforded the corresponding α-bromo 
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aldehydes 246-248. Subsequently, the α-bromoaldehydes 246-248 were eacted with 2,6-diamino-
3H-pyrimidin-4-one in DMF at 45 0C in the presence of sodium acetate to afford 5-substituted-
pyrrolo[2,3-d] pyrimidines 249-251.  Hydrolysis 249-251 with 1 N NaOH followed by coupling 
with L-glutamate dimethyl ester using N-methyl morpholine and 2,4-dimethoxy-6-chlorotriaine as 
the activating agents afforded the diester 255-257. Final saponification of the diester with 1 N 
NaOH gave the target compounds 172-174. 
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V. SUMMARY 
The design and synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidines and 5-
substituted pyrrolo[2,3-d]pyrimidines as potential antifolates have been described. As a part of 
this study, a series of new compounds have been synthesized and characterized. Of these, over 
ten compounds were submitted for biological evaluation. 
The target compounds synthesized as part of this study are as follows: 
1． The synthesis of (S) -(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-
yl)propyl)-3-methylthiophene-2-carbonyl)-L-glutamic acid 156 
2. The synthesis of (S) -(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)propyl)-4-methylthiophene-2-carbonyl)-L-glutamic acid 157 
3. The synthesis of (S) -5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6- 
yl)butyl)-3-methylthiophene-2-carbonyl)-L-glutamic acid 158 
4. The synthesis of (S) -5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6- 
yl)butyl)thiophene-2-carbonyl)-L-glutamic acid 159 
5. The synthesis of (S)- 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethyl)amino)-3-fluorobenzoyl)-L-glutamic acid 162 
6. The synthesis of (S)-4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethyl)amino)-2-fluorobenzoyl)-L-glutamic acid 163 
7. The synthesis of (S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)-2-fluorobenzoyl)-L-glutamic acid 167 
8. The synthesis of (S)- (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)thiophene-2-carbonyl)-L-glutamic acid 172 
9. (S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thiophene-2-carbonyl)-L-glutamic acid 173 
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10. The synthesis of (S)- (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thiophene-2-carbonyl)-L-glutamic acid 174 
During this study, a synthetic procedure for synthesizing 6-substituted pyrrolo[2,3-
d]pyrimidines was successfully exploited. In addition a synthetic method leading to novel 5-
substituted pyrrolo[2,3-d]pyrimidines was accomplished. The classic analog 157 showed excellent 
potent activities for FRα, FRβ and PCFT, and high selectivity for FRα, FRβ and PCFT over RFC. 
Compound 157 further demonstrated potent inhibition of tumor cells in culture (IC50 = 0.3 nM 
toward KB cells).  
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VI . EXPERIMENTAL 
 
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples 
were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P2O5 at 60 °C. Melting 
points were determined on a MEL-TEMP II melting point apparatus with FLUKE 51 K/J 
electronic thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (1H 
NMR) were recorded on Bruker Avance II 400 (400 MHz) and 500 (500 MHz) spectrometer. The 
chemical shift values are expressed in ppm (parts per million) relative to tetramethylsilane as an 
internal standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Thin-
layer chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates with a 
fluorescent indicator, and the spots were visualized under 254 and 366 nm illumination. 
Proportions of solvents used for TLC are by volume. Column chromatography was performed on 
a 230-400 mesh silica gel (Fisher, Somerville, NJ) column. The amount (weight) of silica gel for 
column chromatography was in the range of 50-100 times the amount (weight) of the crude 
compounds being separated. Columns were dry-packed unless specified otherwise. Elemental 
analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are 
within ±0.4% of the calculated values. Fractional moles of water or organic solvents frequently 
found in some analytical samples of antifolates could not be prevented despite 24-48 h of drying 
in vacuo and were confirmed where possible by their presence in the 1H NMR spectra. All solvents 
and chemicals were purchased from Aldrich Chemical Co. and Fisher Scientific and were used as 
received. 
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Methyl 5-(4-hydroxybut-1-yn-1-yl)-3-methylthiophene-2-carboxylate 177. 
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71 
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol), 
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-4-methylthiophene-2-carboxylate 175 (2.35 g, 
10 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, was added but-3-yn-ol (1.05 
g, 10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 10 min. 
Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under reduced 
pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with 
hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and 
evaporated to afford 177 (1.63 g), yield 73% as yellow oil. TLC Rf = 0.37 (hexane/ EtOAc, 1:1); 1 
H NMR (400 MHz, DMSO-d6) δ 2.43 (s, 3H, ArCH3), 2.60-2.62 (t, 2H, CH2CH2OH, J = 6.4 Hz), 
3.57-3.59 (t, 2H, CH2CH2OH, J = 6.4 Hz), 3.79 (s, 3H, OCH3), 4.96-4.98 (t, 1H, OH, exch, J = 
5.6 Hz), 7.16 (s, 1H, Ar). 
Methyl 5-(4-hydroxybut-1-yn-1-yl)-4-methylthiophene-2-carboxylate 178. 
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71 
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol), 
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-4-methylthiophene-2-carboxylate 176 (2.35 g, 
10 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, was added but-3-yn-ol (1.05 
g, 10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 10 min. 
Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under reduced 
pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with 
hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and 
evaporated to afford 178 (1.58 g), yield 71% as yellow oil. TLC Rf = 0.35 (hexane/ EtOAc, 1:1); 1 
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H NMR (400 MHz, DMSO-d6) δ 2.23 (s, 3H, ArCH3), 2.63-2.66 (t, 2H, CH2CH2OH, J = 6.4 Hz), 
3.57-3.60 (t, 2H, CH2CH2OH, J = 6.4 Hz), 3.80 (s, 3H, OCH3), 4.96-4.98 (t, 1H, OH, exch, J = 
5.6 Hz), 7.63 (s, 1H, Ar). 
Methyl 5-(4-hydroxybutyl)-3-methylthiophene-2-carboxylate 179 
To a parr flask was added 177 (1.20 g, 7.14 mmol), 10% palladium on active carbon (50% 
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The 
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under 
reduced pressure to give 179 (1.01 g,) yield 84% as yellow oil. TLC Rf = 0.35 (hexane/ EtOAc, 
1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.44-1.49 (m, 2H, ArCH2CH2), 1.60-1.65 (m, 2H, 
CH2CH2OH), 2.42 (s, 3H, ArCH3), 2.75-2.78 (t, 2H, ArCH2, J = 7.3 Hz), 3.40-3.42 (t, 2H, CH2OH, 
J = 6.0 Hz), 3.75 (s, 3H, OCH3), 4.42-4.43 (t, 1H, OH, exch, J = 4.8 Hz), 6.83 (s, 1H, Ar). 
Methyl 5-(4-hydroxybutyl)-4-methylthiophene-2-carboxylate 180 
To a parr flask was added 178 (2.24 g, 10 mmol), 10% palladium on active carbon (50% 
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The 
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under 
reduced pressure to give 180 (2.0 g,) yield 88% as yellow oil. TLC Rf = 0.35 (hexane/ EtOAc, 1:1); 
1 H NMR (400 MHz, DMSO-d6) δ 1.45-1.50 (m, 2H, ArCH2CH2), 1.59-1.63 (m, 2H, CH2CH2OH), 
2.13 (s, 3H, ArCH3), 2.72-2.76 (t, 2H, ArCH2CH2, J = 7.6 Hz), 3.39-3.42 (t, 2H, CH2OH, J = 6.0 
Hz), 3.77 (s, 3H, OCH3), 4.42-4.44 (t, 1H, OH, exch, J = 5.2 Hz), 7.54 (s, 1H, Ar). 
4-(5-(methoxycarbonyl)-3-methylthiophen-2-yl) butanoic acid 181 
To MeCN (40 mL) was added H5IO6 (2.20 g, 9.65 mmol) and the mixture was stirred 
vigorously at room temperature for 15 min. 179 (1 g, 4.38 mmol) was then added in iced-water 
bath followed by addition of pyridinium chlorochromate (19 mg, 2 mol%) in MeCN (10 mL) and 
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the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc (100 
mL) and washed with brine-water (1:1), sat. aq NaHSO3 solution, and brine, respectively, dried 
over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 181 (1.0 g) yield 94% 
as yellow oil. TLC Rf = 0.56 (hexane/ EtOAc, 1:1).  1 H NMR (400 MHz, DMSO-d6) δ 1.81-1.85 
(m, 2H, ArCH2CH2), 2.25-2.29 (t, 2H, CH2COOH, J = 7.6 Hz), 2.43 (s, 3H, ArCH3), 2.77-2.80 (t, 
2H, ArCH2, J = 7.6 Hz), 3.76 (s, 3H, OCH3), 6.84 (s, 1H, Ar), 12.15 (br, 1H, COOH, exch). 
4-(5-(methoxycarbonyl)-3-methylthiophen-2-yl) butanoic acid 182 
To MeCN (40 mL) was added H5IO6 (1.48 g, 6.49 mmol) and the mixture was stirred 
vigorously at room temperature for 15 min. 180 (673 mg, 2.95 mmol) was then added in iced-
water bath followed by addition of pyridinium chlorochromate (12.7 mg, 2 mol%) in MeCN (10 
mL) and the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc 
(100 mL) and washed with brine-water (1:1), sat. aq NaHSO3 solution, and brine, respectively, 
dried over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 182 (590 mg) 
yield 83% as yellow oil. TLC Rf = 0.55 (hexane/ EtOAc, 1:1). Mp 113.10C.  1 H NMR (400 MHz, 
DMSO-d6) δ 1.79-1.82 (m, 2H, ArCH2CH2), 2.27-2.30 (m, 2H, CH2COOH), 2.13 (s, 3H, ArCH3), 
2.74-2.76 (t, 2H, ArCH2, J = 7.6 Hz), 3.78 (s, 3H, OCH3), 7.55 (s, 1H, Ar), 12.14 (br, 1H, COOH, 
exch). 
Methyl 5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
methylthiophene-2-carboxylate 189 
To 181 (0.65 g, 2.69 mmol) in a 100 mL flask was added oxalyl chloride (2.0 g, 15.9 mmol) 
and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled to the 
room temperature. After evaporating the solvent under reduced pressure, the residue was dissolved 
in 15 mL Et2O. The resulting solution was added dropwise to an ice-cooled diazomethane 
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(generated in stiu from 4.1 g of diazald by using Aldrich Mini Diazald Apparatus) in an ice bath 
for over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an 
additional 1 h. To this solution was added 48% HBr (6 mL). The resulting mixture was refluxed 
for 1.5 h. After cooling to room temperature, the organic layer was separated, and aqueous layer 
extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 solution and 
dried over Na2SO4. To this residue anhydrous DMF (15 mL) was added 2,6-diamino-3H-
pyrimidin-4-one (338 mg, 2.68 mmol). The resulting mixture was stirred under N2 at room 
temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was evaporated under 
reduced pressure. The resulting plug was loaded on to a silica gel column 
(1.5 × 12 cm) and eluted with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired 
fraction (TLC) was collected, and the solvent was evaporated under reduced pressure to 
afford 189 (380 mg) yield 41% as yellow power. TLC Rf = 0.66 (CHCl3/MeOH, 6:1).  Mp 189.3 
0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.90-1.96 (m, 2H, ArCH2CH2CH2Ar), 2.43 (s, 3H, CH3), 
2.53-2.55 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.76-2.79 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 
3.76 (s, 3H, COOCH3),  5.90 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.85 (s, 1H, Ar), 10.16 (s, 
1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch). 
Methyl5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
methylthiophene-2-carboxylate 190 
To 182 (580 mg, 2.4 mmol) in a 100 mL flask was added oxalyl chloride (1.8 g, 14.4 mmol) 
and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled to the 
room temperature. After evaporating the solvent under reduced pressure, the residue was dissolved 
in 15 mL Et2O. The resulting solution was added dropwise to an ice-cooled diazomethane 
(generated in stiu from 10 g of diazald by using Aldrich Mini Diazald Apparatus) in an ice bath 
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for over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an 
additional 1 h. To this solution was added 48% HBr (20 mL). The resulting mixture was refluxed 
for 1.5 h. After cooling to room temperature, the organic layer was separated, and aqueous layer 
extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 solution and 
dried over Na2SO4. To this residue anhydrous DMF (15 mL) was added 2,6-diamino-3H-
pyrimidin-4-one (301 mg, 2.5 mmol). The resulting mixture was stirred under N2 at room 
temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was evaporated under 
reduced pressure. The resulting plug was loaded on to a silica gel column (1.5 × 12 cm) and eluted 
with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired fraction (TLC) was 
collected, and the solvent was evaporated under reduced pressure to afford 190 (250 mg) yield 
30% as yellow power. TLC Rf = 0.63 (CHCl3/MeOH, 6:1).  Mp 181.4 0C.  1 H NMR (400 MHz, 
DMSO-d6) δ 1.88-1.92 (m, 2H, ArCH2CH2CH2Ar), 2.56-2.54 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 
Hz), 2.11 (s, 3H, ArCH3), 2.76-2.74 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 3.78 (s, 3H, OCH3), 
5.90 (s, 1H, C5-CH), 6.00 (s, 2H, 2-NH2, exch), 7.66 (s, 1H, Ar), 10.17 (s, 1H, 3-NH, exch), 10.86 
(s, 1H, 7-NH, exch). 
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
methylthiophene-2-carboxylic acid 191 
To a solution of 189 (370 mg, 1.06 mmol) in MeOH (15 mL) was added 1 N NaOH (10 
mL) and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
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with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 191 (343 mg) yield 
97% as yellow power. Mp 188.40C.  1 H NMR (400 MHz, DMSO-d6) δ 1.90-1.93 (m, 2H, 
ArCH2CH2CH2Ar), 2.40 (s, 3H, ArCH3), 2.55-2.57 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.74-
2.77 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 5.90 (s, 1H, C5-CH), 6.01 (s, 2H, 2-NH2, exch), 6.80 
(s, 1H, Ar), 10.17 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch), 12.74 (br, 1H, COOH, exch). 
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
methylthiophene-2-carboxylic acid 192 
To a solution of 190 (346 mg, 1 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 192 (315 mg) yield 
95% as yellow power. Mp 181.4 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.87-1.90 (m, 2H, 
ArCH2CH2CH2Ar), 2.55-2.57 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.13 (s, 3H, ArCH3), 2.72-
2.75 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 5.90 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 7.46 
(s, 1H, Ar), 10.16 (s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch). 
Diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4-
methylthiophene-2-carbonyl)glutamate 193 
To a solution of 191 (330 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (180 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (314 mg, 1.8 
mmol). The resulting mixtures were stirred at room temperature for 2 h. To this 
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mixture were added N-methylmorpholine (180 mg, 1.8 mmol) and L-glutamate diethyl ester 
hydrochloride (360 mg, 1.5 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 193 (274 mg) yield 53 % as yellow power. 
TLC Rf = 0.42 (CHCl3/ MeOH, 6:1); Mp 143.8 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.10-1.15 
(m, 6H, COOCH2CH3), 1.82-1.84 (m, 2H, β-CH2), 1.87-1.93 (m, 2H, ArCH2CH2CH2Ar), 2.03 (s, 
3H, CH3), 2.35-2.37 (t, 2H, J = 7.2 Hz, γ-CH2), 2.49-2.52 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 
2.68-2.71 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 4.97-4.05 (m, 4H, COOCH2CH3), 4.30-4.34 (m, 
1H, α-CH), 5.90 (s, 1H, C5-CH), 6.02 (s, 2H, 2-NH2, exch), 7.60 (s, 1H, Ar), 8.57-8.56 (d, 1H, J = 
4.0 Hz, CONH, exch), 10.18(s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch). 
Diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4-
methylthiophene-2-carbonyl)glutamate 194 
To a solution of 192 (420 mg, 1.26 mmol) in anhydrous DMF (20 mL) was added N-
methylmorpholine (230 mg, 2.28 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (400mg, 2.28 
mmol). The resulting mixtures were stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (230 mg, 2.28 mmol) and L-glutamate diethyl ester 
hydrochloride (458 mg, 1.9 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 194 (417 mg) yield 64% as yellow power. 
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TLC Rf = 0.42 (CHCl3/ MeOH, 6:1); Mp 143.8 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.10-1.15 
(m, 6H, COOCH2CH3), 1.82-1.84 (m, 2H, β-CH2), 1.87-1.93 (m, 2H, ArCH2CH2CH2Ar), 2.03 (s, 
3H, ArCH3), 2.35-2.37 (t, 2H, γ-CH2, J = 7.2 Hz), 2.40-2.44 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 
2.70-2.74 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 4.04-4.11 (m, 4H, COOCH2CH3), 4.30-4.34 (m, 
1H, α-CH), 5.90 (s, 1H, C5-CH), 5.98 (s, 2H, 2-NH2, exch), 7.60 (s, 1H, Ar), 8.55-8.57 (d, 1H, 
CONH, exch,  J = 4.0 Hz,), 10.15(s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch). 
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4- 
methylthiophene-2-carbonyl)glutamic acid 156 
To a solution of 193 (90 mg, 0.17 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL). 
The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N acetic acid. The resulting suspension was stored in 
a 4-5 0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in 
vacuum using P2O5 to afford 60 mg (76%) of 156 as a yellow powder. Mp 163.5 0C. 1 H NMR 
(400 MHz, DMSO-d6) δ 1.90-2.08 (m, 4H, β-CH2), 2.32-2.34 (t, 2H, J = 7.2 Hz, γ-CH2), 2.36 (s, 
3H, ArCH3), 2.54-2.59 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.71-2.73 (t, 2H, ArCH2CH2CH2Ar, 
J = 7.6 Hz), 4.29-4.33 (m, 1H, α-CH), 5.91 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.74 (s, 1H, 
Ar), 7.98-8.00 (d, 1H, J = 6.6 Hz, CONH, exch), 10.17 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, 
exch). Anal. (C20H23N5O6S. 2.5573 H2O) C, H, N, S. 
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4- 
methylthiophene-2-carbonyl)glutamic acid 157 
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To a solution of 194 (155 mg, 0.3 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL). 
The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 
0C refrigerator and filtered. The residue was washed with  30-40 mL cold water and dried in 
vacuum using P2O5 to afford 105 mg (75%) of 157 as a yellow powder. Mp 167.8 0C. 1 H NMR 
(400 MHz, DMSO-d6) δ 1.89-1.93 (m, 4H, β-CH2), 2.09 (s, 3H, ArCH3), 2.30-2.34 (t, 2H, γ-CH2, 
J = 7.2 Hz), 2.54-2.58 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.71-2.73 (t, 2H, ArCH2CH2CH2Ar, 
J = 7.6 Hz), 4.29-4.32 (m, 1H, α-CH), 5.89 (s, 1H, C5-CH), 5.97 (s, 2H, 2-NH2, exch), 7.58 (s, 1H, 
Ar), 8.41-8.42 (d, 1H, CONH, exch, J = 8.0 Hz), 10.14(s, 1H, 3-NH, exch), 10.84 (s, 1H, 7-NH, 
exch), 12.42 (br, 2H, COOH, exch). Anal. (C20H23N5O6S. 2.5573 H2O) C, H, N, S. 
Methyl 5-(5-hydroxypent-1-yn-1-yl)-3-methylthiophene-2-carboxylate 195 
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71 
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol), 
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-3-methylthiophene-2-carboxylate 175 (2.35 g, 
10 mmol) anhydrous acetonitrile (10 mL). To the stirred mixture, was added pent-4-yn-ol (0.88 g, 
10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 10 min. 
Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under reduced 
pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with 
hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and 
evaporated to afford 195 (1.7 g), yield 71.4 % as yellow oil. TLC Rf = 0.57 (hexane/ EtOAc, 1:1); 
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1 H NMR (400 MHz, DMSO-d6) δ 1.64-1.71 (m, 2H, CH2CH2CH2OH), 2.43 (s, 3H, ArCH3), 2.51-
2.54 (t, 2H, CH2CH2CH2OH, J = 7.1 Hz), 3.47-3.51 (t, 2H, CH2CH2CH2OH, J = 6.2 Hz), 3.78 (s, 
3H, COOCH3), 4.57 (s, 1H, OH, exch), 7.15 (s, 1H, Ar-H). 
Methyl 5-(5-hydroxypent-1-yn-1-yl)-4-methylthiophene-2-carboxylate 196 
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71 
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol), 
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-4-methylthiophene-2-carboxylate 176 (2.35 g, 
10 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, was added pent-4-yn-ol 
(0.88 g, 10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 
10 min. Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under 
reduced pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted 
with hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and 
evaporated to afford 196 (1.87 g), yield 78% as yellow oil. TLC Rf = 0.51 (hexane/ EtOAc, 1:1); 1 
H NMR (400 MHz, DMSO-d6) δ 1.68-1.73 (m, 2H, CH2CH2CH2OH), 2.24 (s, 3H, ArCH3), 2.54-
2.58 (t, 2H, CH2CH2CH2OH, J = 7.2 Hz), 3.50-3.53 (t, 2H, CH2CH2CH2OH, J = 6.2 Hz), 3.80 (s, 
3H, OCH3), 4.58 (Br, 1H, OH, exch), 7.64 (s, 1H, Ar-H). 
Methyl 5-(5-hydroxypentyl)-3-methylthiophene-2-carboxylate 197 
To a parr flask was added 195 (2.4 g, 9.67 mmol), 10% palladium on active carbon (50% 
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The 
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under 
reduced pressure to give 197 g (1.90 g,) yield 82% as green oil. TLC Rf = 0.37 (hexane/ EtOAc, 
1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.31-1.33 (m, 2H, ArCH2CH2CH2), 1.42-1.45 (m, 2H, 
CH2CH2 OH), 1.59-1.63 (m, 2H, ArCH2CH2CH2), 2.42 (s, 3H, ArCH3), 2.74-2.78 (t, 2H, ArCH2, 
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J = 7.5 Hz), 3.35-3.38 (t, 2H, CH2OH, J = 6.0 Hz), 3.75 (s, 3H, OCH3), 4.35-4.37 (t, 1H, OH, exch, 
J = 4.8 Hz), 6.82 (s, 1H, Ar-H). 
Methyl 5-(5-hydroxypentyl)-4-methylthiophene-2-carboxylate 198 
To a parr flask was added 196(600 mg, 2.5 mmol), 10% palladium on active carbon (50% 
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The 
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under 
reduced pressure to give 198 (485 mg,) yield 80% as yellow oil. TLC Rf = 0.53 (hexane/ EtOAc, 
1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.35-1.37 (m, 2H, Ar CH2CH2CH2CH2CH2OH), 1.43-
1.46 (m, 2H, ArCH2CH2CH2CH2CH2OH), 1.57-1.60 (m, 2H, ArCH2CH2CH2CH2CH2OH), 2.12 
(s, 3H, ArCH3), 2.72-2.75 (t, 2H, ArCH2CH2, J = 7.5 Hz), 3.37-3.39 (t, 2H, CH2OH, J = 5.9 Hz), 
3.78 (s, 3H, COOOCH3), 4.37-4.39 (t, 1H, OH, J = 5.0 Hz exch), 7.54 (s, 1H, Ar-H). 
5-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)-pentanoic acid 199 
To MeCN (40 mL) was added H5IO6 (3.94 g, 17.4 mmol) and the mixture was stirred 
vigorously at room temperature for 15 min. 197 (1.90 g, 7.85 mmol) was then added in iced-water 
bath followed by addition of pyridinium chlorochromate (34 mg, 2 mol%) in MeCN (10 mL) and 
the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc (100 
mL) and washed with brine-water (1:1), sat. aq NaHSO3 solution, and brine, respectively, dried 
over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 199 (1.6 g) yield 80% 
as yellow oil. TLC Rf = 0.56 (hexane/ EtOAc, 1:1).  1 H NMR (400 MHz, DMSO-d6) δ 1.51-1.62 
(m, 4H, ArCH2CH2CH2CH2Ar), 2.22-2.26 (t, 2H, CH2COOH, J = 7.2 Hz), 2.42 (s, 3H, ArCH3), 
2.75-2.79 (t, 2H, ArCH2, J = 7.3 Hz), 3.75 (s, 3H, OCH3), 6.83(s, 1H, Ar-H), 12.15 (br, 1H, COOH, 
exch). 
5-(5-(methoxycarbonyl)-3-methylthiophen-2-yl) pentanoic acid 200 
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To MeCN (60 mL) was added H5IO6 (5.18 g, 22.7 mmol) and the mixture was stirred 
vigorously at room temperature for 15 min. 198 (2.5 g, 10.3 mmol) was then added in iced-water 
bath followed by addition of pyridinium chlorochromate (44.7 mg, 2 mol%) in MeCN (10 mL) 
and the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc 
(100 mL) and washed with brine-water (1:1), sat. aq NaHSO3 solution, and brine, respectively, 
dried over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 200 (2.1 g) yield 
80% as yellow oil. TLC Rf = 0.55 (hexane/ EtOAc, 1:1). 1 H NMR (400 MHz, DMSO-d6) δ 1.56-
1.61 (m, 4H, ArCH2CH2CH2CH2COOH), 2.13 (s, 3H, ArCH3), 2.24-2.27 (t, 2H, CH2COOH, J = 
5.9 Hz), 2.74-2.77 (t, 2H, ArCH2, J = 6.9 Hz), 3.78 (s, 3H, COOCH3), 7.55 (s, 1H, Ar-H), 12.05 
(br, 1H, COOH, exch). 
Methyl 5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
methylthiophene-2-carboxylate 207 
To 199 (1.60 g, 6.25 mmol) in a 100 mL flask was added oxalyl chloride (4.85 g, 38.2 
mmol) and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled 
to the room temperature. After evaporating the solvent under reduced pressure, the residue was 
dissolved in 15 of mL Et2O. The resulting solution was added dropwise to an ice-cooled 
diazomethane (generated in stiu from 9.3 g of diazald by using Aldrich Mini Diazald Apparatus) 
in an ice bath for over 10 min. The resulting mixture was allowed to stand for 30 min and then 
stirred for an additional 1 h. To this solution was added 48% HBr (13 mL). The resulting mixture 
was refluxed for 1.5 h. After cooling to room temperature, the organic layer was separated, and 
aqueous layer extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 
solution and dried over Na2SO4. To this residue in anhydrous DMF (15 mL) residue and 2,6-
diamino-3H-pyrimidin-4-one (788 mg, 5.08 mmol) was added The resulting mixture was stirred 
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under N2 at room temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was 
evaporated under reduced pressure. The resulting plug was loaded on to a silica gel column (1.5 × 
12 cm) and eluted with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired 
fraction (TLC) was collected, and the solvent was evaporated under reduced pressure to afford 207 
(855 mg) yield 38% as yellow oil. TLC Rf = 0.50 (CHCl3/MeOH, 6:1).  1 H NMR (400 MHz, 
DMSO-d6) δ 1.58-1.68 (m, 4H, ArCH2CH2CH2CH2Ar), 2.38-2.41 (t, 2H, ArCH2CH2CH2CH2Ar, 
J = 9.3 Hz), 2.41 (s, 3H, ArCH3), 2.76-2.80 (t, 2H, ArCH2CH2CH2CH2Ar, J = 9.3 Hz), 3.75 (s, 
3H, COOCH3),  5.86 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.81 (s, 1H, Ar-H), 10.16 (s, 1H, 
3-NH, exch), 10.82 (s, 1H, 7-NH, exch). 
Methyl 5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4-
methylthiophene-2-carboxylate 208 
To 200 (2.13 g, 8.3 mmol) in a 100 mL flask was added oxalyl chloride (4.7 g, 37.6 mmol) 
and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled to the 
room temperature. After evaporating the solvent under reduced pressure, the residue was dissolved 
in 15 of mL Et2O. The resulting solution was added dropwise to an ice-cooled diazomethane 
(generated in stiu from 10 g of diazald by using Aldrich Mini Diazald Apparatus) in an ice bath 
for over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an 
additional 1 h. To this solution was added 48% HBr (12 mL). The resulting mixture was refluxed 
for 1.5 h. After cooling to room temperature, the organic layer was separated, and aqueous layer 
extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 solution and 
dried over Na2SO4. To this residue in anhydrous DMF (15 mL) was added 2,6-diamino-3H-
pyrimidin-4-one (301 mg, 2.5 mmol). The resulting mixture was stirred under N2 at room 
temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was evaporated under 
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reduced pressure. The resulting plug was loaded on to a silica gel column (1.5 × 12 cm) and eluted 
with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired fraction (TLC) was 
collected, and the solvent was evaporated under reduced pressure to afford 208 (1. 01 g) yield 34% 
as yellow power. TLC Rf = 0.53 (CHCl3/MeOH, 6:1).  1 H NMR (400 MHz, DMSO-d6) δ 1.57-
1.64 (m, 4H, ArCH2CH2 CH2CH2Ar), 2.12 (s, 3H, ArCH3), 2.51-2.54 (t, 2H, ArCH2CH2CH2Ar, J 
= 6.9 Hz), 2.73-2.76 (t, 2H, ArCH2CH2CH2Ar, J = 6.9 Hz), 3.80 (s, 3H, COOCH3), 5.87 (s, 1H, 
C5-CH), 6.06 (s, 2H, 2-NH2, exch), 7.45 (s, 1H, Ar-H), 10.21 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 
7-NH, exch). 
5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-ethylthiophene-
2-carboxylic acid 209 
To a solution of 207 (360 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 209 (280 mg) yield 
81% as yellow oil.  1 H NMR (400 MHz, DMSO-d6) δ 1.53-1.63 (m, 4H, ArCH2CH2CH2CH2Ar), 
2.40 (s, 3H, ArCH3), 2.47-2.51 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 2.74-2.77 (t, 2H, 
ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 5.86 (s, 1H, C5-CH), 6.00 (s, 2H, 2-NH2, exch), 6.77(s, 1H, 
Ar-H), 10.16 (s, 1H, 3-NH, exch), 10.81 (s, 1H, 7-NH, exch), 12.63 (br, 1H, COOH, exch). 
5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4-
methylthiophene-2-carboxylic acid 210 
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To a solution of 208 (400 mg, 1.1 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in vacuum using P2O5 to afford 210 (330 mg) yield 87% as 
yellow power. Mp 179.5 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.57-1.64 (m, 4H, ArCH2CH2 
CH2CH2Ar), 2.12 (s, 3H, ArCH3), 2.51-2.54 (t, 2H, ArCH2CH2CH2Ar, J = 6.9 Hz), 2.73-2.76 (t, 
2H, ArCH2CH2CH2Ar, J = 6.9 Hz), 5.87 (s, 1H, C5-CH), 6.06 (s, 2H, 2-NH2, exch), 7.45 (s, 1H, 
Ar-H), 10.21 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch). 
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
methylthiophene-2-carbonyl)-L-glutamate 211 
To a solution of 209 (340 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (180 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (314 mg, 1.8 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (180 mg, 1.8 mmol) and L-glutamate diethyl ester 
hydrochloride (360 mg, 1.5 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 211 (260 mg) yield 53 % as yellow oil. 
TLC Rf = 0.42 (CHCl3/ MeOH, 6:1).  1 H NMR (400 MHz, DMSO-d6) δ 1.15-1.21(m, 6H, 
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COOCH2CH3), 1.88-1.97 (m, 2H, β-CH2), 1.60-1.65 (m, 2H, ArCH2CH2CH2CH2Ar), 2.34 (s, 3H, 
ArCH3), 2.38-2.42 (t, 2H, J = 7.2 Hz, γ-CH2), 2.49-2.52 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 
2.75-2.78 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 4.06-4.11 (m, 4H, COOCH2CH3), 4.33-4.35 
(m, 1H, α-CH), 5.87 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.70 (s, 1H, Ar-H), 8.13-8.15 (d, 
1H, J = 4.0 Hz, CONH, exch), 10.18(s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch). 
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4-
methylthiophene-2-carbonyl)-L-glutamate 212 
To a solution of 210 (500 mg, 1.45 mmol) in anhydrous DMF (20 mL) was added N-
methylmorpholine (263 mg, 2.61 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (452mg, 
2.61mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (263 mg, 2.61 mmol) and L-glutamate diethyl ester 
hydrochloride (518 mg, 2.15 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 212 (510 mg) yield 66% as yellow power. 
TLC Rf = 0.45 (CHCl3/ MeOH, 6:1); Mp 152.6 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.10-1.15 
(m, 6H, COOCH2CH3), 1.58-1.63 (m, 2H, β-CH2), 1.93-1.98 (m, 4H, ArCH2CH2CH2CH2Ar), 2.15 
(s, 3H, ArCH3), 2.35-2.38 (t, 2H, γ-CH2, J = 7.2 Hz), 2.38-2.43 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 
Hz), 2.70-2.74 (t, 2H, ArCH2CH2 CH2CH2Ar, J = 7.6 Hz), 4.04-4.11 (m, 4H, COOCH2CH3), 4.30-
4.34 (m, 1H, α-CH), 5.86 (s, 1H, C5-CH), 5.97 (s, 2H, 2-NH2, exch), 7.58 (s, 1H, Ar), 8.55-8.57 
(d, 1H, CONH, exch,  J = 4.0 Hz,), 10.14(s, 1H, 3-NH, exch), 10.81 (s, 1H, 7-NH, exch). 
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5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
methylthiophene-2-carbonyl)-L-glutamic acid 158 
To a solution of 211 (200 mg, 0.38 mmol) in MeOH (20 mL) was added 1 N NaOH (10 
mL). The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N acetic acid. The resulting suspension was 
stored in a 4-5 0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and 
dried in vacuum using P2O5 to afford 140 mg (81%) of 158 as a yellow powder.Mp 130.8 0C. 1 H 
NMR (400 MHz, DMSO-d6) δ 1.60-2.62 (m, 4H, ArCH2CH2CH2CH2Ar), 1.88-1.96 (m, 2H, β-
CH2), 2.31-2.34 (t, 2H, J = 7.2 Hz, γ-CH2), 2.35 (s, 3H, ArCH3), 2.51-2.54 (t, 2H, 
ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 2.75-2.78 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 4.28-
4.33 (m, 1H, α-CH), 5.86 (s, 1H, C5-CH), 5.98 (s, 2H, 2-NH2, exch), 6.74 (s, 1H, Ar), 7.97-7.99 
(d, 1H, J = 6.6 Hz, CONH, exch), 10.14 (s, 1H, 3-NH, exch), 10.82 (s, 1H, 7-NH, exch), 12.25 (br, 
2H, COOH, exch). Anal. (C21H25N5O6S. 0.9246 H2O. 0.7945CH3CO2H) C, H, N, S. 
(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4-
methylthiophene-2-carbonyl)-L-glutamic acid 159 
To a solution of 212 (130 mg, 0.24 mmol) in MeOH (20 mL) was added 1 N NaOH (10 
mL). The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
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adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was 
stored in a 4-5 0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and 
dried in vacuum using P2O5 to afford 87 mg (74%) of 159 as a yellow powder. Mp 190.2 0C. 1 H 
NMR (400 MHz, DMSO-d6) δ 1.56-1.65 (m, 4H, ArCH2CH2CH2Ar), 1.87-1.93 (m, 2H, β-CH2), 
1.99-2.09 (m, 2H, CH2), 2.12 (s, 3H, ArCH3), 2.35-2.32 (t, 2H, γ-CH2, J = 7.4 Hz), 2.54-2.71-2.75 
(t, 2H, ArCH2CH2CH2CH2Ar, J = 7.2 Hz), 4.29-4.32 (m, 1H, α-CH), 5.87 (s, 1H, C5-CH), 5.98 (s, 
2H, 2-NH2, exch), 7.58 (s, 1H, Ar-H), 8.43-8.45 (d, 1H, CONH, exch, J = 7.7 Hz), 10.15(s, 1H, 3-
NH, exch), 10.82 (s, 1H, 7-NH, exch), 12.42 (br, 2H, COOH, exch). Anal. (C20H23N5O6S. 1.2735 
H2O. 0.8361 CH3CO2H) C, H, N, S. 
Methyl 3-fluoro-4-((3-oxobutyl) amino) benzoate 221 
To a solution of methyl 4-amino-3-fluorobenzoate 219 (10.14 g, 60 mmol) in in anhydrous 
absolute ethanol (70 mL), methyl vinyl ketone (4.2 g, 60 mmol) was added. The reaction mixture 
was stirred under reflux for 4.5 hours, and the resultant mixture was cooled to 0 °C. The 
precipitated crystalline product was collected and washed with precooled ethanol and dried to 
afford 221, yield 35 % as yellow power; Mp 98 °C; TLC Rf = 0.6 (hexane/ EtOAc, 1:1); 1 H NMR 
(400 MHz, DMSO-d6) δ  2.21 (s, 3H, CH2COCH3), 2.80-2.83(t, 2H, CH2CH2O, J = 6.1 Hz), 3.51-
3.55 (t, 2H, CH2CH2O, J = 6.3 Hz),  3.88 (s, 3H, OCH3), 5.54 (bs, Ar-NH, exch), 6.65-6.70 (t, 1H, 
Ar-CH, J = 8.4 Hz), 7.62-7.65 (d, 1H, Ar-CH, J = 7.0 Hz), 7.74-7.76 (d, 1H, Ar-CH, J = 7.0 Hz). 
Methyl 2-fluoro-4-((3-oxobutyl)amino)benzoate 222 
To a solution of methyl 4-amino-3-fluorobenzoate 220 (9.15 g, 50 mmol) in in anhydrous 
absolute ethanol (10 mL), methyl vinyl ketone (3.4 g, 50 mmol) was added. The reaction mixture 
was stirred under reflux for 4.5 hours, and the resultant mixture was cooled to 0 °C. The 
precipitated crystalline product was collected and washed with precooled ethanol and dried to 
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afford 222 (6.9 g), yield 54 % as yellow power; Mp  86.8 0C. TLC Rf = 0.5 (hexane/ EtOAc, 1:1); 
1 H NMR (400 MHz, DMSO-d6) δ  2.21 (s, 3H, CH2COCH3), 2.78-2.80 (t, 2H, CH2CH2O, 
J = 5.9 Hz), 3.45-3.48 (t, 2H, CH2CH2O, J = 5.9 Hz),  3.88 (s, 3H, OCH3), 5.54 (bs, Ar-NH, exch), 
6.27-6.30 (d, 1H, Ar-CH, J = 13.6 Hz), 6.37-6.39 (d, 1H, Ar-CH, J = 10.7 Hz), 7.78-7.80 (t, 1H, 
Ar-CH, J = 8.5 Hz). 
Methyl 4-((4-bromo-3-oxobutyl)amino)-3-fluorobenzoate 223 
A suspension of 221 (8 g, 33.5 mmol) in 21 mL of 33% hydrogen bromide-glacial acetic 
acid solution was treated with 2.6 mL of bromine in 5.24 mL of glacial acetic acid and stirred for 
2.5 h at 25 °C. Ether (100 mL) was added to the reaction mixture with swirling until separation of 
the syrupy hydrobromide was complete. The ether was decanted, and any ether remaining was 
evaporated from the syrup along with excess hydrogen bromide. After further drying by 
evaporation (bath 35 °C) of a solution in an equal volume of dichloromethane, the syrup 
weighed 8.0 g. The syrup was then stirred with cold water and filtered to afford yellow solid. 
Yellow solid obtained was then washed with water (3 × 20 mL) and dissolved in dichloromethane. 
The solution was dried over sodium sulfate. Removal of solvent under reduced 
pressure at room temperature gave a beige colored semisolid. The crude product was thoroughly 
triturated with precooled ether, and the solid product was collected by filtration to afford 223 (4.2 
g, yield 43%).  223 wasn’t stable. Used directly for the next step without purification. 
Methyl 4-((4-bromo-3-oxobutyl)amino)-2-fluorobenzoate 224 
A suspension of 222 (7 g, 29.0 mmol) in 18 mL of 33% hydrogen bromide-glacial acetic 
acid solution was treated with 2.2 mL of bromine in 4.4 mL of glacial acetic acid and stirred for 
2.5 h at 25 °C. Ether (100 mL) was added to the reaction mixture with swirling until separation of 
the syrupy hydrobromide was complete. The ether was decanted, and any ether remaining was 
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evaporated from the syrup along with excess hydrogen bromide. After further drying by 
evaporation (bath 35 °C) of a solution in an equal volume of dichloromethane, the syrup 
weighed 3.3 g. The syrup was then stirred with cold water and filtered to afford yellow solid. 
Yellow solid obtained was then washed with water (3 × 20 mL) and dissolved in dichloromethane. 
The solution was dried over sodium sulfate. Removal of solvent under reduced 
pressure at room temperature gave a beige colored semisolid. The crude product was thoroughly 
triturated with precooled ether, and the solid product was collected by filtration to afford 224 (2.7 
g) yield 33 % as yellow oil. 224 wasn’t stable. Used directly for the next step without purification. 
Methyl 4-(N-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)-2,2,2-
trifluoroacetamido)-3-fluorobenzoate 227 
A suspension of α-bromoketone 223 (3.15 g, 10 mmol) in trifluoroacetic anhydride (30 mL) 
was stirred for overnight at room temperature and then evaporated to dryness under reduced 
pressure to remove the excess trifluoroacetic anhydride. The residue was dissolved in 
dichloromethane (30 mL). The reaction solution was washed with cold 2% HCl (100 mL), 5% 
NaHCO3 (100 mL) and extraction with cold water (100 mL) and dried over Na2SO4. After 
evaporation of solvent, the residue was dried in vacuo using P2O5 to afford amine protected α-
bromoketone 225 (3.1 g). 225 was then added to a suspension of 2,6-diaminopyrimidin-4-one (1.26 
g, 10 mmol) in anhydrous DMF (25 mL). The resulting mixture was stirred under anhydrous 
condition at room temperature for 3 days. After evaporation of the solvent under reduced pressure, 
methanol (10 mL) was added followed by silica gel (5 g). The resulting plug was loaded on to a 
silica gel column (3.5 cm × 12 cm) and eluted with CHCl3 followed by 5% MeOH in CHCl3 and 
then 8% MeOH in CHCl3. The desired fraction (TLC) were pooled and evaporated to afford 227 
(1.5 g), yield 34% as red power. Mp : 213 0C TLC Rf = 0.23 (CHCl3/ MeOH, 6:1); 1 H NMR (400 
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MHz, DMSO-d6) δ  2.76-2.80 (t, 2H, CH2CH2N, J = 7.3 Hz), 3.89 (s, 3H, OCH3), 4.09-4.12 (t, 2H, 
CH2CH2N, J = 7.3 Hz), 5.96 (s, 2H, 2-NH2, exch), 6.02 (s, 1H, C5-CH), 7.51-7.55 (t, 1H, Ar-CH, 
J = 7.9 Hz), 7.82-7.84 (d, 1H, Ar-CH, J = 8.3 Hz), 7.90-7.93 (d, 1H, Ar-CH, J = 10.2 Hz), 10.18 
(s, 1H, 3-NH, exch), 10.83 (s, 1H, 7-NH, exch). 
Methyl 4-(N-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)-2,2,2-
trifluoroacetamido)-2-fluorobenzoate 228 
A suspension of α-bromoketone 224 (3.0 g, 10 mmol) in trifluoroacetic anhydride (30 mL) 
was stirred for overnight at room temperature and then evaporated to dryness under reduced 
pressure to remove the excess trifluoroacetic anhydride. The residue was dissolved in 
dichloromethane (30 mL). The reaction solution was washed with cold 2% HCI (100 mL), 5% 
NaHCO3 (100 mL) and extraction with cold water (100 mL) and dried over Na2SO4. After 
evaporation of solvent, the residue was dried in vacuo using P2O5 to afford amine protected α-
bromoketone 226 (3.20 g, 10 mmol). 226 was then added to a suspension of 2,6-diaminopyrimidin-
4-one (1.26 g, 10 mmol) in anhydrous DMF (25 mL). The resulting mixture was stirred under 
anhydrous condition at room temperature for 3 days. After evaporation of the solvent under 
reduced pressure, methanol (10 mL) was added followed by silica gel (5 g). The resulting plug 
was loaded on to a silica gel column (3.5 cm × 12 cm) and eluted with CHCl3 followed by 5% 
MeOH in CHCl3 and then 8% MeOH in CHCl3. The desired fraction (TLC) were pooled and 
evaporated to afford 228 (1.59g), yield 43 % as brown power. Mp  178.4 0C. TLC Rf = 0.23 (CHCl3/ 
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ  2.75-2.78 (t, 2H, CH2CH2N, J = 7.3 Hz), 3.89 (s, 
3H, OCH3), 3.97-4.01 (t, 2H, CH2CH2N, J = 7.3 Hz), 5.95 (s, 1H, C5-CH), 6.02 (s, 2H, 2-NH2, 
exch), 7.26-7.28 (d, 1H, Ar-CH, J = 10.1 Hz), 7.34-7.37 (d, 1H, Ar-CH, J = 10.1 Hz), 7.93-7.96 
(t, 1H, Ar-CH, J = 8.1 Hz), 10.20 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch). 
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4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-3-
fluorobenzoic acid 229 
To a solution of 227 (440 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 229 (284 mg) yield 
86 % as yellow power. Mp 204.4 0C.  1 H NMR (400 MHz, DMSO-d6) δ 2.76-2.80 (t, 2H, 
CH2CH2N, J = 7.3 Hz), 3.37-3.40 (t, 2H, CH2CH2N, J = 7.3 Hz), 5.99 (s, 2H, 2-NH2, exch), 6.02 
(s, 1H, C5-CH), 6.34 (s, 1H, NH), 6.82-6.87 (t, 1H, Ar-CH, J = 8.5 Hz), 7.45-7.49 (d, 1H, Ar-CH, 
J = 12.6 Hz), 7.59-7.62 (d, 1H, Ar-CH, J = 8.2 Hz), 10.20 (s, 1H, 3-NH, exch), 10.96 (s, 1H, 7-
NH, exch). 
4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-2-
fluorobenzoic acid 230 
To a solution of 228 (444 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 
mL) and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-
4. The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was 
washed with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 230 (264 
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mg) yield 84 % as brown power. Mp 213.3 0C.  1 H NMR (400 MHz, DMSO-d6) δ 2.74-2.77 (t, 
2H, CH2CH2N, J = 7.2 Hz), 3.30-3.33 (t, 2H, CH2CH2N, J = 7.3 Hz), 6.03 (s, 2H, 1H, C5-CH), 
6.12 (s, 2H, 2-NH2, exch), 6.34 (s, 1H, NH), 6.35-6.40 (d, 1H, Ar-CH, J = 14.5 Hz), 6.45-6.47 
(d, 1H, Ar-CH, J = 10.6 Hz), 7.54-7.62 (t, 1H, Ar-CH, J = 8.8 Hz), 10.69 (s, 1H, 3-NH, exch), 
11.26 (s, 1H, 7-NH, exch). 
Di-tert-butyl (4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethyl)amino)-3-fluorobenzoyl)-L-glutamate 231 
To a solution of 229 (800 mg, 2.4 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (483 mg, 4.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (845 mg, 4.8 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (483 mg, 4.8 mmol) and L-glutamate di-tert-butyl 
hydrochloride (1.04 g, 3.53 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 231 (678 mg) yield 49% as yellow power. 
TLC Rf = 0.63 (CHCl3/ MeOH, 6:1); Mp 202.3 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.39 (s, 9H, 
C(CH3)3), 1.40 (s, 9H, C(CH3)3), 1.87 -2.04 (m, 2H, β-CH2), 2.30-2.34 (t, 2H, γ-CH2, J = 7.5 Hz), 
2.77-2.81 (t, 2H, CH2CH2N, J = 7.5 Hz), 3.36-3.40 (t, 2H, CH2CH2N, J = 7.5 Hz), 4.22-4.31 (m, 
1H, α-CH), 6.00 (s, 1H, NH), 6.02 (s, 2H, 2-NH2, exch), 6.08 (s, 1H, C5-CH), 6.82-6.87 (t, 1H, 
Ar-CH, J = 8.6 Hz), 7.57-7.63(d, 2H, Ar-CH, J = 10.3 Hz), 8.26-8.28 (d, 1H, CONH, exch,  J = 
7.2 Hz), 10.19 (s, 1H, 3-NH, exch), 10.96 (s, 1H, 7-NH, exch). 
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Di-tert-butyl (4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethyl)amino)-2-fluorobenzoyl)-L-glutamate 232 
To a solution of 230 (331 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (182 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (320 mg, 1.8 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (182 mg, 1.8 mmol) and L-glutamate di-tert-butyl 
hydrochloride (442mg, 1.5 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 232 (245 mg) yield 43% as brown power. 
TLC Rf = 0.78 (CHCl3/ MeOH, 6:1); Mp 158.9 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.38 (s, 9H, 
C(CH3)3), 1.40 (s, 9H, C(CH3)3), 1.86 -2.01 (m, 2H, β-CH2), 2.29-2.32 (t, 2H, γ-CH2, J = 7.5 Hz), 
2.73-2.76 (t, 2H, CH2CH2N, J = 7.5 Hz), 3.28-3.30 (t, 2H, CH2CH2N, J = 7.5 Hz), 4.22-4.31 (m, 
1H, α-CH), 5.99 (s, 1H, C5-CH), 6.01 (s, 2H, 2-NH2, exch), 6.39-6.42 (d, 1H, Ar-CH, J = 8.6 Hz),  
6.45-6.49 (d, 1H, Ar-CH, J = 8.6 Hz), 6.61 (s, 1H, NH), 7.44-7.50 (t, 1H, Ar-CH, J = 8.8 Hz), 
7.74-7.78 (t, 1H, CONH, exch,  J = 7.2 Hz), 10.27 (s, 1H, 3-NH, exch), 11.20 (s, 1H, 7-NH, exch). 
4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-3-
fluorobenzoyl)-L-glutamic acid 162 
To a solution of 231 (109 mg, 0.19 mmol) in MeOH (10 mL) was added trifluoroacetic 
acid (2 mL). The mixture was then stirred under N2 at room temperature for 2 h. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
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dissolved in 1 N NaOH, the resulting solution was cooled in an ice bath, and the pH was adjusted 
to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 0C 
refrigerator and filtered. The residue was washed with 10-20 mL cold water and dried in vacuum 
using P2O5 to afford 60 mg (68%) of 162 as a yellow powder. Mp 222.9 0C. 1 H NMR (400 MHz, 
DMSO-d6) δ 1.91 -2.04 (m, 2H, β-CH2), 2.32-2.36 (t, 2H, γ-CH2, J = 7.5 Hz), 2.77-2.82 (t, 2H, 
CH2CH2N, J = 7.5 Hz), 3.36-3.40 (t, 2H, CH2CH2N, J = 7.5 Hz), 4.37-4.34 (m, 1H, α-CH), 6.00 
(s, 1H, NH), 6.02 (s, 1H, C5-CH),  6.19 (s, 2H, 2-NH2, exch), 6.81-6.87 (t, 1H, Ar-CH, J = 8.6 Hz), 
7.57-7.63(d, 2H, Ar-CH, J = 10.3 Hz), 8.29-8.31 (d, 1H, CONH, exch,  J = 7.2 Hz), 10.33 (s, 1H, 
3-NH, exch), 11.04 (s, 1H, 7-NH, exch). Anal. (C20H21FN6O6. 1.40447 H2O. 0.0582CF3COOH) 
C, H, N, F. 
4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-2-
fluorobenzoyl)-L-glutamic acid 163 
To a solution of 232 (100 mg, 0.17 mmol) in MeOH (10 mL) was added trifluoroacetic 
acid (2 mL). The mixture was then stirred under N2 at room temperature for 2 h. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in 1 N NaOH, the resulting solution was cooled in an ice bath, and the pH was adjusted 
to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was 
stored in a 4-5 0C refrigerator and filtered. The residue was washed with 10-20 mL cold water and 
dried in vacuum using P2O5 to afford 60 mg (76%) of 163 as a yellow powder. Mp 187.3 0C. 1 H 
NMR (400 MHz, DMSO-d6) δ1.86 -2.01 (m, 2H, β-CH2), 2.30-2.33 (t, 2H, γ-CH2, J = 7.3 Hz), 
2.72-2.76 (t, 2H, CH2CH2N, J = 7.1 Hz), 3.28-3.32 (t, 2H, CH2CH2N, J = 6.8 Hz), 4.37-4.41 (m, 
1H, α-CH), 6.00 (s, 1H, C5-CH), 6.14 (s, 2H, 2-NH2, exch), 6.38-6.42 (d, 1H, Ar-CH, J = 8.6 Hz),  
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6.48-6.50 (d, 1H, Ar-CH, J = 8.6 Hz), 6.61 (s, 1H, NH), 7.47-7.51 (t, 1H, Ar-CH, J = 8.8 Hz), 
7.74-7.78 (t, 1H, CONH, exch,  J = 7.2 Hz), 10.28 (s, 1H, 3-NH, exch), 11.00 (s, 1H, 7-NH, exch). 
Anal. (C20H21FN6O6. 1.6967 H2O) C, H, N, F. 
Methyl 3-fluoro-4-(5-oxopentyl) benzoate 237 
To a solution of methyl 4-bromo-3-fluorobenzoate 233 (4.66 g, 20 mmol) in 20mL 
anhydrous DMF was added pent-4-en-1-ol (2.06 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc 
(3.4 g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was 
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to 
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5 
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC) 
were pooled and evaporated to afford 237 (2.38 g), yield 50 % as yellow oil. TLC Rf = 0.50 
(hexane/ EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.54-1.59 (m, 4H, ArCH2CH2CH2), 2.44-
2.47 (t, 2H, CH2CHO, J = 7.0 Hz), 2.62-2.65 (t, 2H, ArCH2CH2, J = 7.3 Hz), 3.82 (s, 3H, OCH3), 
7.13-7.19 (t, 2H, Ar, J = 10.9 Hz), 7.77-7.81 (t, 1H, Ar, J = 7.8 Hz), 9.63-9.65 (s, 1H, CHO, J = 
5.6 Hz). 
Methyl 4-(4-bromo-5-oxopentyl)-3-fluorobenzoate 238 
To a solution of aldehyde 237 (2.38 g, 10 mmol) in 10 mL dichloromethane was added the 
Br2(0.66 g, 7.7 mmol), dioxane in dichloromethane solution dropwise and the mixture was stirred 
at ice bath for 3 hours. TLC (hexane/ EtOAc, 1:1) showed the disappearance of the starting material 
(Rf = 0.50) and formation of one major spot at Rf = 0.40 (hexane/ EtOAc, 1:1). The reaction solution 
was washed with 5% NaHCO3 solution and extraction with H2O and dried over Na2SO4. After 
evaporation of solvent the residue was dried in vacuo using P2O5 to afford 238 (3g). 238 wasn’t 
stable. Used directly for the next step without purification.  
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Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2-
fluorobenzoate 239 
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (1.25g, 10 mmol) and sodium 
acetate (1.7 g, 20 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde 
238 (3.17, 10 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.73 (CHCl3/ MeOH, 
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of 
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted 
with CHCl3 followed by 8% MeOH in CHCl3. The desired fraction (TLC) were pooled and 
evaporated to afford 239 (2.01g), yield 61 % as green power. Mp : 171.4 0C TLC Rf = 0.73 (CHCl3/ 
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.91-1.95 (m, 2H, ArCH2CH2CH2), 2.56-2.59 (t, 
2H, ArCH2CH2CH2Ar, J = 7.0 Hz), 2.64-2.68 (t, 2H, ArCH2CH2CH2Ar J = 7.3 Hz), 3.82 (s, 3H, 
OCH3), 6.00 (s, 2H, 2-NH2, exch), 6.38 (s, 1H, C6-CH), 7.15-7.21 (t, 2H, Ar, J = 10.9 Hz), 7.77-
7.81 (t, 1H, Ar, J = 7.8 Hz), 10.14 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch). 
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2-fluorobenzoic 
acid 240 
To a solution of 239 (300 mg, 0.87 mmol) in MeOH (15 mL) was added 1 N NaOH (10 
mL) and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 240 (230 mg) yield 
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81 % as green powder. Mp 202.0 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.91-1.96 (m, 2H, 
ArCH2CH2CH2), 2.54-2.57 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.62-2.65 (t, 2H, 
ArCH2CH2CH2Ar J = 7.4 Hz), 6.00 (s, 2H, 2-NH2, exch), 6.46 (s, 1H, C6-CH), 7.12-7.17 (t, 2H, 
Ar, J = 7.9 Hz), 7.75-7.79 (t, 1H, Ar, J = 8.0 Hz), 10.67 (s, 1H, 3-NH, exch), 10.95 (s, 1H, 7-NH, 
exch), 12.48 (br, 1H, COOH, exch) 
Dimethyl (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2-
fluorobenzoyl)-L-glutamate 241 
To a solution of 240 (200 mg, 0.58 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (105 mg, 1.04 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (185 mg, 1.04 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (105 mg, 1.04 mmol) and L-glutamate diethyl ester 
hydrochloride (209 mg, 0.87 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 241 (131 mg) yield 46 % as yellow powder. 
TLC Rf = 0.5 (CHCl3/ MeOH, 6:1); Mp 192.8 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.91-1.98 
(m, 2H, ArCH2), 2.07-2.14 (m, 2H, β-CH2), 2.44-2.51 (t, 2H, γ-CH2, J = 7.2 Hz), 2.56-2.59 (t, 2H, 
ArCH2CH2CH2Ar, J = 7.6 Hz), 2.64-2.67 (t, 2H, ArCH2CH2CH2Ar J = 7.5 Hz), 3.59 (s, 3H, 
COOCH3, exch), 3.66 (s, 3H, COOCH3, exch), 4.43-4.48 (m, 1H, α-CH), 5.99 (s, 2H, 2-NH2, exch), 
6.38 (s, 1H, C6-CH), 7.12-7.17 (t, 2H, Ar, J = 10.1 Hz), 7.50-7.54 (t, 1H, Ar, J = 8.0 Hz), 8.60-
8.62 (d, 1H, CONH, exch,  J = 7.5 Hz,), 10.13 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch). 
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(S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2-
fluorobenzoyl)-L-glutamic acid 167 
To a solution of 241 (85 mg, 0.17 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL). 
The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 
0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in 
vacuum using P2O5 to afford 60 mg (77%) of 167 as a green powder. Mp 150.6 0C. 1 H NMR (400 
MHz, DMSO-d6) δ 1.87-1.93 (m, 2H, ArCH2), 2.04-2.07 (m, 2H, β-CH2), 2.33-2.37 (t, 2H, γ-CH2, 
J = 7.2 Hz), 2.56-2.59 (t, 2H, ArCH2CH2CH2Ar, J = 7.5 Hz), 2.64-2.67 (t, 2H, ArCH2CH2CH2Ar 
J = 7.6 Hz), 4.37-4.41 (m, 1H, α-CH), 5.98 (s, 2H, 2-NH2, exch), 6.37 (s, 1H, C6-CH), 7.12-7.16 
(t, 2H, Ar, J = 9.9 Hz), 7.51-7.54 (t, 1H, Ar, J = 7.5 Hz), 8.42-8.43 (d, 1H, CONH, exch, J = 6.8 
Hz), 10.13(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.48 (br, 2H, COOH, exch). Anal. 
(C21H22FN5O6. 0.7908 CH3OH. 0.1795 HCl) C, H, N, F,Cl. 
Methyl 4-(4-oxobutyl)thiophene-2-carboxylate 243 
To a solution of methyl 4-bromothiophene-2-carboxylate 242 (4.42 g, 20 mmol) in 20mL 
anhydrous DMF was added 3-buten-1-ol (1.75 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc (3.4 
g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was 
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to 
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5 
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC) 
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were pooled and evaporated to afford 243 (2.35 g), yield 55% as yellow oil. TLC Rf = 0.6 (hexane/ 
EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.82-1.86 (m, 2H, ArCH2CH2CH2CHO), 2.42-
2.45 (t, 2H, ArCH2CH2CHO, J = 3.0 Hz), 2.58-2.60 (t, 2H, ArCH2CH2CH2CHO, J = 3.3 Hz), 3.81 
(s, 3H, OCH3), 7.61 (s, 1H, Ar), 7.70 (s, 1H, Ar), 9.64-9.66 (t, 1H, CHO, J = 1.5 Hz). 
Methyl 4-(5-oxopentyl)thiophene-2-carboxylate 244 
To a solution of methyl 4-bromothiophene-2-carboxylate 242 (4.42 g, 20 mmol) in 20mL 
anhydrous DMF was added 4-penten-1-ol (2.06 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc 
(3.4 g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was 
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to 
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5 
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC) 
were pooled and evaporated to afford 244 (1.60 g), yield 35 % as yellow oil. TLC Rf = 0.6 (hexane/ 
EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.50-1.60 (m, 4H, ArCH2CH2CH2CH2CHO), 
2.46-2.48 (t, 2H, ArCH2CH2CH2CH2CHO, J = 3.0 Hz), 2.58-2.60 (t, 2H, ArCH2CH2CH2CH2CHO, 
J = 7.2 Hz), 3.80 (s, 3H, OCH3), 7.58 (s, 1H, Ar), 7.68 (s, 1H, Ar), 9.64-9.66 (t, 1H, CHO, J = 1.5 
Hz). 
Methyl 4-(6-oxohexyl)thiophene-2-carboxylate 245 
To a solution of methyl 4-bromothiophene-2-carboxylate 242 (4.42 g, 20 mmol) in 20mL 
anhydrous DMF was added 5-hexen-1-ol (2.4 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc (3.4 
g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was 
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to 
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5 
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC) 
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were pooled and evaporated to afford 245 (2.16 g), yield 45 % as yellow oil. TLC Rf = 0.5 (hexane/ 
EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.25-1.28 (m, 2H, ArCH2CH2CH2 CH2CH2CHO), 
1.50-1.61 (m, 4H, ArCH2CH2CH2CH2CH2CHO), 2.41-2.45 (t, 2H, ArCH2CH2CH2CH2CH2CHO, 
J = 7.4 Hz), 2.57-2.60 (t, 2H, ArCH2CH2, J = 7.6 Hz), 3.80 (s, 3H, OCH3), 7.58 (s, 1H, Ar), 7.68 
(s, 1H, Ar), 9.65-9.66 (t, 1H, CHO, J = 1.6 Hz). 
Methyl 4-(3-bromo-4-oxobutyl)thiophene-2-carboxylate 246 
To a solution of aldehyde 243 (1.0 g, 4.72 mmol) in 10 mL of anhydrous Et2O was added 
5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (0.71 g, 2.36 mmol) and 2N HCl (245 µL, 0.23 
mmol) in Et2O solution and the mixture was stirred at room temperature for 24 hours. TLC 
(hexane/ EtOAc, 1:1) showed the disappearance of the starting material (Rf = 0.60) and formation 
of one major spot at Rf = 0.8 (hexane/ EtOAc, 1:1). The reaction solution was washed with 5% 
NaHCO3 solution and extraction with H2O and dried over Na2SO4. After evaporation of solvent 
the residue was dried in vacuo using P2O5 to afford 246 (1.26 g). Yield 91% as yellow oil. 246 
wasn’t stable. Used directly for the next step without purification. 1 H NMR (400 MHz, DMSO-
d6) δ 2.72-2.74 (t, 2H, ArCH2CH2, J = 3.3 Hz), 2.79-2.81 (t, 2H, ArCH2CH2CHBr, J = 3.0 Hz), 
3.81 (s, 3H, OCH3), 4.64-4.66 (m, 1H, CHBr), 7.67 (s, 1H, Ar), 7.74 (s, 1H, Ar), 9.42 (s, 1H, 
CHO). 
Methyl 4-(4-bromo-5-oxopentyl) thiophene-2-carboxylate 247 
To a solution of aldehyde 244 (726 mg, 3.37 mmol) in 10 mL of anhydrous Et2O was added 
5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (505 mg, 1.68 mmol) and 2N HCl (174 µL, 0.17 
mmol) in Et2O solution and the mixture was stirred at room temperature for 24 hours. TLC 
(hexane/ EtOAc, 1:1) showed the disappearance of the starting material (Rf = 0.50) and formation 
of one major spot at Rf = 0.5 (hexane/ EtOAc, 1:1). The reaction solution was washed with 5% 
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NaHCO3 solution and extraction with H2O and dried over Na2SO4. After evaporation of solvent 
the residue was dried in vacuo using P2O5 to afford 247 (700 mg). 247 wasn’t stable. Used directly 
for the next step without purification. 1 H NMR (400 MHz, DMSO-d6) δ1.50-1.60 (m, 2H, 
ArCH2CH2), 2.72-2.74 (t, 2H, ArCH2CH2, J = 3.3 Hz), 2.79-2.81 (t, 2H, ArCH2CH2CH2CHBr, J 
= 3.0 Hz), 3.81 (s, 3H, OCH3), 4.73-4.76 (m, 1H, CHBr), 7.61 (d, 1H, Ar), 7.69 (s, 1H, Ar), 9.42 
(s, 1H, CHO). 
Methyl 4-(5-bromo-6-oxohexyl)thiophene-2-carboxylate 248 
To a solution of aldehyde 245 (2.4 g, 1.0 mmol) in 10 mL of anhydrous Et2O was added 
5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (600 mg, 2 mmol) and 2N HCl (210 µL, 0.2 
mmol) in Et2O solution and the mixture was stirred at room temperature for 24 hours. TLC 
(hexane/ EtOAc, 1:1) showed the disappearance of the starting material (Rf = 0.50) and formation 
of one major spot at Rf = 0.4 (hexane/ EtOAc, 1:1). The reaction solution was washed with 5% 
NaHCO3 solution and extraction with H2O and dried over Na2SO4. After evaporation of solvent 
the residue was dried in vacuo using P2O5 to afford 248 (700 mg) yield 25 % as yellow oil. 248 
wasn’t stable. Used directly for the next step without purification.  
Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)thiophene-
2-carboxylate 249 
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (534 mg, 4.3 mmol) and sodium 
acetate (740 mg, 9.0 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde 
246 (1.26, 4.3 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.5 (CHCl3/ MeOH, 
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of 
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted 
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with CHCl3 followed by 10 % MeOH in CHCl3. The desired fraction (TLC) were pooled and 
evaporated to afford 249 (861mg), yield 63% as red power. Mp: 124.1 0C.  TLC Rf = 0.5 (CHCl3/ 
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ  2.84-2.87 (t, 2H, ArCH2CH2Ar, J = 8.2 Hz), 
2.92-2.95 (t, 2H, ArCH2CH2Ar, J = 8.2 Hz), 3.80 (s, 3H, OCH3), 6.00 (s, 2H, 2-NH2, exch), 6.33 
(s, 1H, C6-CH), 7.54 (s, 1H, Ar), 7.65 (s, 1H, Ar), 10.15 (s, 1H, 3-NH, exch), 10.64 (s, 1H, 7-NH, 
exch). 
Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-l)propyl)thiophene-
2-carboxylate 250 
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (1.03 g, 8.2 mmol) and sodium 
acetate (1.4 g, 17.0 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde 
247 (2.6 g, 8.5 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.53 (CHCl3/ MeOH, 
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of 
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted 
with CHCl3 followed by 10% MeOH in CHCl3. The desired fraction (TLC) were pooled and 
evaporated to afford 250 (861mg), yield 63% as red power. Mp : 186.2 0C TLC Rf = 0.73 (CHCl3/ 
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ  1.92-1.95(m, 2H, ArCH2 CH2CH2Ar), 2.56-2.63 
(m, 4H, ArCH2), 3.80 (s, 3H, OCH3), 6.00 (s, 2H, 2-NH2, exch), 6.37 (s, 1H, C6-CH), 7.60 (s, 1H, 
Ar), 7.67 (s, 1H, Ar), 10.11 (s, 1H, 3-NH, exch), 10.64 (s, 1H, 7-NH, exch). 
Methyl 4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)thiophene-
2-carboxylate 251 
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (1.15 g, 8.8 mmol) and sodium 
acetate (1.56 g, 18.3 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde 
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248 (2.9 g, 9.14 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf = 0.53 (CHCl3/ MeOH, 
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of 
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted 
with CHCl3 followed by 10 % MeOH in CHCl3. The desired fraction (TLC) were pooled and 
evaporated to afford 251 (2.12 g), yield 67% as red power. Mp 164.4 0C. TLC Rf = 0.5 (CHCl3/ 
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ  1.58-1.59(m, 4H, ArCH2CH2 CH2CH2Ar), 2.51-
2.61 (m, 4H, ArCH2), 3.80 (s, 3H, OCH3), 5.98 (s, 2H, 2-NH2, exch), 6.33 (s, 1H, C6-CH), 7.56 (s, 
1H, Ar), 7.65 (s, 1H, Ar), 10.12 (s, 1H, 3-NH, exch), 10.62 (s, 1H, 7-NH, exch). 
4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)thiophene-2-
carboxylic acid 252 
To a solution of 249 (318mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flited. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 252 (256 mg) yield 
84% as red power. Mp 183.9 0C.  1 H NMR (400 MHz, DMSO-d6) δ 2.73-2.91 (m, 4H, 
ArCH2CH2Ar), 6.00 (s, 2H, 2-NH2, exch), 6.34 (s, 1H, C6-CH), 7.43 (s, 1H, Ar), 7.56 (s, 1H, Ar), 
10.11(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.88 (br, 1H, COOH, exch) 
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-2-
carboxylic acid 253 
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To a solution of 257 (332 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 253 (287 mg) yield 
92 % as blue powder. Mp 167.9 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.89-1.92 (m, 2H, ArCH2 
CH2CH2Ar), 2.57-2.65 (m, 4H, ArCH2), 5.99 (s, 2H, 2-NH2, exch), 6.36 (s, 1H, C6-CH), 7.45 (s, 
1H, Ar), 7.65 (s, 1H, Ar), 10.11(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.88 (br, 1H, 
COOH, exch). 
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-2-
carboxylic acid 254 
To a solution of 251 (692 mg, 2.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL) 
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The 
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4. 
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed 
with 20-40 mL cold water and dried in dried in vacuum using P2O5 to afford 254 (577 mg) yield 
87% as red powder. Mp 153.2 0C.  1 H NMR (400 MHz, DMSO-d6) δ 1.52-1.64 (m, 4H, ArCH2 
CH2CH2Ar), 2.55-2.64 (m, 4H, ArCH2), 6.13 (s, 2H, 2-NH2, exch), 6.35 (s, 1H, C6-CH), 7.49 (s, 
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1H, Ar), 7.56 (s, 1H, Ar), 10.23 (s, 1H, 3-NH, exch), 10.67 (s, 1H, 7-NH, exch), 12.88 (br, 1H, 
COOH, exch). 
Dimethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl) 
thiophene-2-carbonyl)glutamate 255 
To a solution of 252 (230 mg, 0.75 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (137 mg, 1.35 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (241mg, 1.35 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (137 mg, 1.35 mmol) and L-glutamate diethyl ester 
hydrochloride (272 mg, 1.13 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 255 (172 mg) yield 50% as red powder. 
TLC Rf = 0.78 (CHCl3/ MeOH, 6:1); Mp 189.3 0C.  1 H NMR (400 MHz, DMSO-d6) δ 2.07-2.13 
(m, 2H, β-CH2), 2.44-2.47 (t, 2H, γ-CH2, J = 7.2 Hz), 2.85-2.90 (m, 4H, ArCH2CH2Ar), 3.59 (s, 
3H, COOCH3, exch), 3.65 (s, 3H, COOCH3, exch), 4.39-4.47 (m, 1H, α-CH), 6.06 (s, 2H, 2-NH2, 
exch), 6.37 (s, 1H, C6-CH), 7.39 (s, 1H, Ar), 7.80 (s, 1H, Ar), 8.74-8.76 (d, 1H, CONH, exch,  J = 
7.5 Hz,), 10.21 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch). 
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-2-
carboxylic acid 257 
To a solution of 253 (318 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (182 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (320 mg, 1.8 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
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mixture were added N-methylmorpholine (182 mg, 1.8 mmol) and L-glutamate diethyl ester 
hydrochloride (361 mg, 1.5 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 256 (320 mg) yield 64 % as red power. 256  
is not very pure.  
4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)thiophene-2-
carboxylic acid 257 
To a solution of 254 (508 mg, 1.47 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (267 mg, 2.6 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (469 mg, 2.6 
mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture were added N-methylmorpholine (267 mg, 2.6 mmol) and L-glutamate diethyl ester 
hydrochloride (530 mg, 2.2 mmol). The reaction mixture was stirred for overnight at room 
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in 
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 × 
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were 
pooled, and the solvent evaporated to dryness to afford 257 (320 mg) yield 63% as red powder. 
(S)- (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)thiophene-2-
carbonyl)glutamic acid 172 
To a solution of 255 (240 mg, 0.5 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL). 
The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
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reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 
0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in 
vacuum using P2O5 to afford 172 82 mg yield 84% as red powder. Mp 169.0 0C. 1 H NMR (400 
MHz, DMSO-d6) δ 1.84-2.16 (m, 2H, β-CH2), 2.28-2.34 (t, 2H, γ-CH2, J = 8.2 Hz), 2.83-2.95 (m, 
4H, ArCH2CH2Ar), 4.29-4.41 (m, 1H, α-CH), 6.00 (s, 2H, 2-NH2, exch), 6.37 (s, 1H, C6-CH), 7.37 
(s, 1H, Ar), 7.81 (s, 1H, Ar), 8.62-8.59 (d, 1H, CONH, exch, J = 10.8 Hz), 10.14 (s, 1H, 3-NH, 
exch), 10.65 (s, 1H, 7-NH, exch), 12.48 (br, 2H, COOH, exch). Anal. (C18H19N5O6S. 0.596 
CH3OH. 0.6232 HCl) C, H, N, S. 
(S)- 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-
2-carbonyl)-L-glutamic acid 173 
To a solution of 256 (100 mg, 0.21 mmol) in MeOH (20 mL) was added 1 N NaOH (10 
mL). The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 
0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in 
vacuum using P2O5 to afford 184 mg (83%) of 173 as a red powder. Mp 239.8 0C. 1 H NMR (400 
MHz, DMSO-d6) δ 1.88 -1.94 (m, 2H, ArCH2CH2CH2), 2.04 -2.11 (m, 2H, β-CH2), 2.28-2.39 (t, 
2H, γ-CH2, J = 8.2 Hz), 2.59-2.63 (m, 4H, ArCH2), 4.30-4.37 (m, 1H, α-CH), 5.99 (s, 2H, 2-NH2, 
exch), 6.38 (s, 1H, C6-CH), 7.42 (s, 1H, Ar), 7.76 (s, 1H, Ar), 8.56-8.60 (d, 1H, CONH, exch, J = 
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10.8 Hz), 10.12 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch), 12.62 (br, 2H, COOH, exch). 
Anal. (C19H21N5O6S. 2.2443 H2O) C, H, N, S. 
(S)- 4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)thiophene-2-
carbonyl)-L-glutamic acid 174 
To a solution of 257 (250 mg, 0.5 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL). 
The mixture was then stirred under N2 at room temperature overnight. TLC showed the 
disappearance of the starting material and one major spot at the origin (CHCl3/ MeOH, 6:1). The 
reaction mixture was then evaporated to dryness under reduced pressure. The residue was 
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was 
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 
0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in 
vacuum using P2O5 to afford 190 mg (80%) of 174 as a green powder. Mp 146.1 0C. 1 H NMR 
(400 MHz, DMSO-d6) δ 1.53 -1.59 (m, 2H, ArCH2CH2CH2), 1.88 -1.93 (m, 2H, ArCH2CH2CH2), 
2.02 -2.07 (m, 2H, β-CH2), 2.30-2.35 (t, 2H, γ-CH2, J = 8.2 Hz), 2.56-2.65 (m, 4H, ArCH2), 4.30-
4.35 (m, 1H, α-CH), 5.98 (s, 2H, 2-NH2, exch), 6.38 (s, 1H, C6-CH), 7.39 (s, 1H, Ar), 7.75 (s, 1H, 
Ar), 8.55-8.56 (d, 1H, CONH, exch, J = 10.8 Hz), 10.12 (s, 1H, 3-NH, exch), 10.62 (s, 1H, 7-NH, 
exch), 12.62 (br, 2H, COOH, exch). Anal. (C20H23N5O6S. 0.333 CHCl3) C, H, N, S. 
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APPENDIX 1 
The biological evaluations of the analogs listed in the following tables were performed by 
Dr. Larry H. Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos Cancer 
Institute and the Cancer Biology Program and Department of Pharmacology, Wayne State 
University School of Medicine) against GARFTase, RFC-expressing PC43-10 cells, FRα-
expressing RT16 cells, FRβ-expressing D4 cells and hPCFT-expressing R2/hPCFT4 cells. 
 - 178 - 
Cell Lines and Assays of Antitumor Drug Activities. RFC- and FRR-null 
MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne Flintoff (University of Western 
Ontario) and were cultured in R-minimal essential medium (MEM) supplemented with 10% 
bovine calf serum (Invitrogen, Carlsbad, CA), penicillin- streptomycin solution and L-glutamine 
at 37 °C with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC. RT16 cells are R2 cells 
transfected with human FRα, and D4 cells are R2 cells transfected with human FRβ. R2/hPCFT4 
cells were prepared by transfection of R2 cells with a hPCFT cDNA, epitope tagged at the C-
terminus with Myc-His6 (hPCFTMyc-His6) and cloned in pCDNA3.1. All the R2 transfected cells 
(PC43- 10, RT16, D4, R2/hPCFT4) were routinely cultured in R-MEM plus 1.5 mg/mL G418. 
Prior to the cytotoxicity assays (see below), RT16 and D4 cells were cultured in complete folate-
free RPMI1640 (without added folate) for 3 days. KB human cervical cancer cells were purchased 
from the American Type Culture Collection (Manassas, VA), whereas IGROV1 ovarian carcinoma 
cells were a gift of Dr. Manohar Ratnam (Medical University of Ohio). Cells were routinely 
cultured in folate-free RPMI1640 medium, supplemented with 10% fetal bovine serum, penicillin-
streptomycin solution, and 2 mM L-glutamine at 37 °C with 5% CO2. For growth inhibition assays, 
cells (CHO, KB, or IGROV1) were plated in 96 well dishes (∼2500-5000 cells/well, total volume 
of 200 µL medium) with a broad range of antifolate concentrations. The medium was RPMI1640 
(contains 2.3 µM folic acid) with 10% dialyzed serum and antibiotics for experiments with R2 and 
PC43-10 cells. For RT16, D4, KB, and IGROV1 cells, the cells were cultured in folate-free RPMI 
media with 10% dialyzed fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 nM 
LCV. The requirement for FR mediated drug uptake in these assays was established in a parallel 
incubation including 200 nM folic acid. For R2/hPCFT4 cells, the medium was folate-free 
RPMI1640 (pH 7.2) containing 25 nM LCV, supplemented with 10% dialyzed fetal bovine serum 
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(Invitrogen) and antibiotics. Cells were routinely incubated for up to 96 h, and metabolically active 
cells (a measure of cell viability) were assayed with Cell Titer-blue cell viability assay (Promega, 
Madison, WI), with fluorescence measured (590 nm emission, 560 nm excitation) using a 
fluorescence plate reader. Raw data were exported from Softmax Pro software to an Excel 
spreadsheet for analysis and determinations of IC50s, corresponding to the drug concentrations that 
result in 50% loss of cell growth. For some of the in vitro growth inhibition studies, the inhibitory 
effects of the antifolate inhibitors on de novo thymidylate biosynthesis (i.e., TS) and de novo purine 
biosynthesis (GARFTase and AICARFTase) were tested by coincubations with thymidine (10 µM) 
and adenosine (60 µM), respectively. For de novo purine biosynthesis, additional protection 
experiments used AICA (320 µM) as a means of distinguishing inhibitory effects at GARFTase 
from those at AICARFTase. For assays of colony formation in the presence of the antifolate drugs, 
KB cells were harvested and diluted. 200 cells were plated into 60mmdishes in folate-free 
RPMI1640 medium supplemented with 2 nM LCV, 10% dialyzed fetal bovine serum, penicillin-
streptomycin, and 2 mM L-glutamine in the presence of antifolate drugs. The dishes were 
incubated at 37 °C with 5% CO2 for 10-14 days. At the end of the incubations, the dishes were 
rinsed with Dulbecco’s phosphate-buffered saline (DPBS), 5%trichloroacetic acid, and borate 
buffer (10 mM, pH 8.8), followed by 30 min incubation in 1% methylene blue in the borate buffer. 
The dishes were rinsed with the borate buffer, and colonies were counted for calculating percent 
colony-forming efficiency normalized to control.  
FR Binding Assay. [3H]Folic acid binding was used to assess levels of surface FRs. Briefly, 
cells (e.g., RT16 or D4; ∼1.6 × 106) were rinsed twice with Dulbecco’s phosphate-buffered saline 
(DPBS) followed by two washes in acidic buffer (10 mM sodium acetate, 150 mM NaCl, pH 3.5) 
to remove FR-bound folates. Cells were washed twice with ice-cold HEPES-buffered saline (20 
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mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM glucose, pH 7.4; HBS), then 
incubated in HBS with [3H]folic acid (50 nM, specific activity 0.5 Ci/mmol) in the presence and 
absence of a range of concentrations of unlabeled folic acid or antifolate for 15 min at 0 °C. The 
dishes were rinsed three times with ice-cold HBS, after which the cells were solubilized with 0.5 
N sodium hydroxide and aliquots measured for radioactivity and protein contents. Protein 
concentrations were measured with Folin phenol reagent. Bound [3H]folic acid was calculated as 
pmol/mg protein. Relative binding affinities for assorted folate/antifolate substrates were 
calculated as the inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding 
by 50%. By definition, the relative affinity of folic acid is 1.  
Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) CHO cells 
grown as monolayers were used to seed spinner flasks. For experiments to determine the 
inhibitions of transport by antifolate substrates, cells were collected and washed with DPBS and 
resuspended in 2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC43-10 cells and 
in HBS adjusted to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)-buffered saline (20 
mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) adjusted to pH 6.5, 6.0, 
or 5.5 for R2/hPCFT4 cells. In either case, uptakes of [3H]MTX (0.5 µM) were measured over 2 
min at 37 °C in the presence and absence of unlabeled antifolates (10 µM). Uptakes of [3H]MTX 
were quenched with ice-cold DPBS. Cells were washed with icecold DPBS (3×) and solubilized 
with 0.5 N NaOH. Levels of intracellular radioactivity were expressed as pmol/mg protein, 
calculated from direct measurements of radioactivity and protein contents of cell homogenates. 
Protein concentrations were measured with Folin phenol reagent. Percent MTX transport 
inhibition was calculated by comparing level of [3H]MTX uptake in the presence and absence of 
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the inhibitors. Kinetic constants (Kt, Vmax) and Kis were calculated from Lineweaver-Burke and 
Dixon plots, respectively.  
In Vitro GARFTase Enzyme Inhibition Assay. Purified recombinant mouse GARFTase 
enzyme was a gift from Dr. Richard Moran (Virginia Commonwealth University, Richmond, VA). 
Briefly, enzyme activity was assayed spectrophotometrically at 37 °C using GARFTase (0.75 nM), 
α,β-GAR (11 µM), and coenzyme 10-formyl-5,8-dideazafolic acid (10 µM) in HEPES buffer (75 
mM, pH 7.5) with or without antifolate inhibitor (10-30 000 nM). The absorbance of the reaction 
product, 5,8-dideazafolic acid, was monitored at 295 nM over the first minute as a measure of the 
initial rate of enzyme activity. IC50s were calculated as the concentrations of inhibitors that resulted 
in a 50% decrease in the initial velocity of the GARFTase reaction.  
In Situ GARFT Enzyme Inhibition Assay. Incorporation of [14C]glycine into [14C]FGAR, 
as an in situ measure of endogenous GARFTase activity, was described by Beardsley et al. and 
modified by Deng et al. For these experiments, KB cells were seeded in 4 mL of complete folate-
free RPMI1640 plus 2 nM LCVin 60 mm dishes at a density of 2 × 106 cells per dish. On the next 
day, the medium was replaced with 2 mL of fresh complete folate-free RPMI1640 plus 2 nM LCV 
(without supplementing glutamine). Azaserine (4 µM final concentration) was added in the 
presence and absence of the antifolate inhibitors (0.1, 1, 10, 100, or 1000 nM). After 30 min, L-
glutamine (final concentration, 2 mM) and [14C]glycine (tracer amounts; final specific activity 0.1 
mCi/L) were added. Incubations were at 37 °C for 15 h, at which time cells were washed (one-
time) with ice-cold folate-free RPMI1640 plus serum. Cell pellets were dissolved in 2mL of 5% 
trichloroacetic acid at 0 °C. Cell debris was removed by centrifugation (the cell protein contents 
in the pellets were measured), and the supernatants were extracted twice with 2 mL of ice-cold 
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ether. The aqueous layer was passed through a 1 cm column of AG1 × 8 (chloride form), 100-200 
mesh (Bio-Rad), washed with 10 mL of 0.5 N formic acid and then 10 mL of 4 N formic acid, and 
finally eluted with 8 mL of 1 N HCl. The elutants were collected and determined for radioactivity. 
The accumulation of radioactive FGAR was calculated as pmol per mg protein over a range of 
inhibitor concentrations. IC50s were calculated as the concentrations of inhibitors that resulted in 
a 50% decrease in FGAR synthesis.
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Table 1.  IC50s (in nM) for 6-substituted pyrrolo[2,3-d]pyrimidine antifolates and classical antifolates in RFC-, PCFT-, and FR-
expressing cell lines.  Growth inhibition assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRα 
(RT16), FRβ (D4), or PCFT (R2/PCFT4), for comparison with transporter-null [R2, R2(VC)] CHO cells and for the KB human tumor 
subline (expresses RFC, FRα, and PCFT), as described in the Experimental Section. For the FR experiments, growth inhibition assays 
were performed in the presence and the absence of 200 nM folic acid (FA). The data shown are mean values from 3-10 experiments 
(plus/minus SEM in parentheses). Results are presented as IC50 values, corresponding to the concentrations that inhibit growth by 50% 
relative to cells incubated without drug.  
 
 
 
 
 
 
Comp  
RFC FRα FRβ PCFT RFC/FRα/PCFT 
PC43-10 R2 RT16 
RT16 
(+FA) D4 
D4 
(+FA) R2/PCFT4 R2(VC) KB 
KB 
(+FA) 
7 101.0(16.6) 273.5(49.1) 0.31(0.14) >1000 0.17(0.03 >1000 3.34(0.26) 288(12) 
0.26 
(0.03) >1000 
8 >1000 >1000 1.82(0.28) >1000 0.57(0.09 >1000 43.4(4.1) >1000 0.55(0.10) >1000 
163 88.2 >1000 0.68 >1000 0.19 >1000 2.07 >1000 0.3 >1000 
164 101.7 >1000 2.16 >1000 0.95 >1000 35.7 >1000 1.38 >1000 
165 >1000 >1000 2.99 >1000 2.98 >1000 132 >1000 0.98 >1000 
166 >1000 >1000 9.81 >1000 3.81 >1000 140 >1000 5.32 >1000 
MTX 12(1.1) 216(8.7) 114(31) 461(62) 106(11) 211(43) 120.5(16.8) >1000 6.0(0.6) 20(2.4) 
PMX 138(13) 894(93) 42(9) 388(68) 60(8) 254(78) 13.2(2.4) 974.0(18.1) 68(12) 
327(103
) 
RTX 6.3(1.3) >1000 15(5) >1000 22(10) 746(138) 99.5(11.4) >1000 5.9(2.2) 22(5) 
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Table 2. IC50s (in nM) for 6-substituted pyrrrolo[2,3-d]pyrimidine benzoyl antifolates with heteroatom replacements, and 
classical antifolates in RFC-, PCFT- and FR-expressing cell lines. Proliferation assays were performed for CHO sublines engineered 
to express human RFC (PC43-10), FRα (RT16), FRβ (D4) or PCFT (R2/PCFT4), transporter-null [R2, R2(VC)] CHO cells,29, 46-48 and 
KB human tumor cells (express RFC, FRα, and PCFT). For the experiments measuring FR-mediated effects, assays were performed in 
the presence or absence of 200 nM folic acid (FA) (results are shown only for KB cells). Results are presented as IC50 values, 
corresponding to the concentrations that inhibit growth by 50% relative to cells incubated without drug. The data are mean values from 
5-16 experiments (+/- standard errors in parentheses). Results are also summarized for KB cells for the protective effects of adenosine 
(60 µM), thymidine (10 µM), or 5-aminoimidazole-4-carboxamide (320 µM). Methods are summarized in the Experimental Section. 
Undefined abbreviations: Ade, adenosine; AICA, 5-aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined;  
 
 
 
 
 
 
 
Com 
 
RFC FRα FRβ PCFT RFC/FRα/PCFT 
PC43-10 R2 RT16 D4 R2/PCFT4 R2(VC) KB KB (+FA) 
KB + 
Ade/Thd/AIC
A 
4 >1000 >1000 6.3 (1.6) >1000 213 (28) >1000 1.9 (0.7) >1000 Ade/AICA 
160 62(12) 140(27) 1.12 (0.37) 3.87 (0.14) 3.82 (0.27) ND ND ND ND 
161 510(90) >1000 3.04 (0.71) 0.62 (0.20) 87.4(9.9) >1000 0.32(0.05) 666(46) Ade/AICA 
162 >1000 >1000 1.3 (0.8) 0.1 (0.02) 245 (102) >1000 0.21(0.04) ND ND 
173 808 (81) >1000 4.1(1.4) 0.62 (0.04) 125 (15) >1000 3.81(0.92) ND ND 
MTX 12(1.1) 114(31) 114 (31) 106 (11) 121(17) >1000 6.00(0.60) 20(2.4) Thd/Ade 
PMX 138(13) 42(9) 42 (9) 60 (8) 13.2(2.4) 974 (18) 68(12) 327(103) Thd/Ade 
RTX 6.3(1.3) 15(5) 15 (5) 22 (10) 99.5(11.4) >1000 5.90(2.20) 22(5) Thd 
LMTX 12(2.3) 12(8) 12 (8) 2.6 (1.0) 38.0(5.3) >1000 1.20(0.60) 31(7) Ade/ AICA 
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Table 3. IC50s (in nM) for 5-substituted pyrrrolo[2,3-d]pyrimidine, and classical antifolates in RFC-, PCFT- and FR-expressing 
cell lines. Proliferation assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRα (RT16), FRβ (D4) 
or PCFT (R2/PCFT4), transporter-null [R2, R2(VC)] CHO cells,29, 46-48 and KB human tumor cells (express RFC, FRα, and PCFT). For 
the experiments measuring FR-mediated effects, assays were performed in the presence or absence of 200 nM folic acid (FA) (results 
are shown only for KB cells). Results are presented as IC50 values, corresponding to the concentrations that inhibit growth by 50% 
relative to cells incubated without drug. The data are mean values from 5-16 experiments (+/- standard errors in parentheses). Results 
are also summarized for KB cells for the protective effects of adenosine (60 µM), thymidine (10 µM), or 5-aminoimidazole-4-
carboxamide (320 µM). Methods are summarized in the Experimental Section. Undefined abbreviations: Ade, adenosine; AICA, 5-
aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined;  
 
 
 
 
 
 
 
 
Com 
 
RFC FRα  PCFT RFC/FRα/PCFT 
PC43-10 R2 RT16 RT16 (+FA) R2/PCFT4 R2(VC) KB KB (+FA) 
KB + 
Ade/Thd/AI
CA 
164 56.6(5.8) >1000 8.6 (2.1) >1000 840(90) >1000 12.7 (5.4) ND Ade 
165 >1000 >1000 0.58 >1000 75.4 ND 0.59 ND ND 
166 68.8 (21.2) >1000 72.0 (27.1) >1000 329 (61) >1000 49.5 (13.2) 533(233) Ade 
167 151 >1000 228 >1000 59 >1000 32.5 ND ND 
MTX 12(1.1) 114(31) 114 (31) 106 (11) 121 (17) >1000 6.00(0.60) 20(2.4) Thd/Ade 
PMX 138(13) 42(9) 42 (9) 60 (8) 13.2(2.4) 974(18) 68(12) 327(103) Thd/Ade 
RTX 6.3(1.3) 15(5) 15 (5) 22 (10) 99.5(11.4) >1000 5.90(2.20) 22(5) Thd 
LMTX 12(2.3) 12(8) 12 (8) 2.6 (1.0) 38.0(5.3) >1000 1.20(0.60) 31(7) Ade/ AICA 
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Table 4. IC50s (in nM) for 5-substituted pyrrrolo[2,3-d]pyrimidine, and classical antifolates in RFC-, PCFT- and FR-expressing 
cell lines. Proliferation assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRα (RT16), FRβ (D4) 
or PCFT (R2/PCFT4), transporter-null [R2, R2(VC)] CHO cells,29, 46-48 and KB human tumor cells (express RFC, FRα, and PCFT). For 
the experiments measuring FR-mediated effects, assays were performed in the presence or absence of 200 nM folic acid (FA) (results 
are shown only for KB cells). Results are presented as IC50 values, corresponding to the concentrations that inhibit growth by 50% 
relative to cells incubated without drug. The data are mean values from 5-16 experiments (+/- standard errors in parentheses). Results 
are also summarized for KB cells for the protective effects of adenosine (60 µM), thymidine (10 µM), or 5-aminoimidazole-4-
carboxamide (320 µM). Methods are summarized in the Experimental Section. Undefined abbreviations: Ade, adenosine; AICA, 5-
aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined;  
 
Comp  
RFC FRα FRβ PCFT RFC/FRα/PCFT 
PC43-10 R2 RT16 
RT16 
(+FA) D4 
D4 
(+FA) R2/PCFT4 R2(VC) KB 
KB 
(+FA) 
8 >1000 >1000 1.82(0.28) >1000 0.57(0.09 >1000 43.4(4.1) >1000 0.55(0.10) >1000 
168 >1000 >1000 2.54(0.52) >1000 ND ND 41.6 (13.1) >1000 0.17(0.02) >1000 
169 59.8(11.1) >1000 550 (50) ND ND ND 80.2(5.5) >1000 875 (125) ND 
170 
116.0(22.5
) >1000 109 (44) 
ND ND 
ND 312 (90) >1000 211 (58) 
>1000 
171 38.3(6.6) >1000 49.3(11.5) ND ND ND 141(40) >1000 66.0(14.4) >1000 
172 ND ND ND ND ND ND ND ND ND ND 
173 >1000 >1000 >1000 ND ND ND >1000 >1000 320 ND 
174 >1000 >1000 >1000 ND ND ND 125 >1000 260 ND 
MTX 12(1.1) 216(8.7) 114(31) 
461(62
) 106(11) 211(43) 120.5(16.8) >1000 6.0(0.6) 20(2.4) 
PMX 138(13) 894(93) 42(9) 
388(68
) 60(8) 254(78) 13.2(2.4) 974.0(18.1) 68(12) 
327(103
) 
RTX 6.3(1.3) >1000 15(5) >1000 22(10) 746(138) 99.5(11.4) >1000 5.9(2.2) 22(5) 
